Genetically modified non-human animals with humanized immunoglobulins and MHC loci

By genetically modifying animals, their endogenous immunoglobulin loci include humanized genes and expressing humanized MHC protein complexes, solving the problem of difficult to generate diverse peptide-MHC complex antibodies in the prior art. The production and applicability of diverse antibodies and therapeutic uses is achieved.

CN118946265APending Publication Date: 2024-11-12BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO LTD

Patent Information

Application Number
CN202380027634.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-21
Filing Date
2023-03-21
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to generate antibodies that can identify diverse peptide-MHC complexes for therapeutic purposes, especially human or humanized antibodies, and the MHC protein complexes have polymorphisms between different species, resulting in limitations on antigen presentation. sex.

Method used

By genetically modifying animals, their endogenous heavy and light chain immunoglobulin loci include humanized IGHV, IGHD, IGHJ genes, and express human or chimeric MHC protein complexes to produce diverse immunoglobulins Variable domains for the generation of diverse antibodies.

Benefits of technology

The generation of diverse humanized antibodies is achieved, which enhances the diversity and affinity of antigen presentation, is suitable for various therapeutic uses, and reduces the risk of immunogenicity in the human body.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946265A_ABST
    Figure CN118946265A_ABST
Patent Text Reader

Abstract

The present disclosure relates to genetically modified animals and cells having a humanized light chain immunoglobulin locus and / or a humanized heavy chain immunoglobulin locus. These animals and cells may also express human or chimeric (e.g., humanized) major histocompatibility complex (MHC) protein complexes.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority declaration

[0002] This application claims the benefit of PCT Application No. PCT / CN2022 / 081924, filed on March 21, 2022. The entire contents of the foregoing application are incorporated herein by reference. Technical Field

[0003] The present disclosure relates to genetically modified animals and cells having humanized heavy chain immunoglobulin loci and / or humanized light chain immunoglobulin loci. These animals and cells may also express human or chimeric major histocompatibility complex (MHC) protein complexes. Background Art

[0004] Major histocompatibility complex (MHC) class I and class II proteins play a key role in the adaptive branch of the immune system. Both classes of proteins have the task of presenting peptides on the cell surface for T cell recognition. Immunogenic peptide-MHC class I (pMHCI) complexes are present on nucleated cells and are recognized by cytotoxic CD8+ T cells. In contrast, presentation of pMHCII by antigen-presenting cells (e.g., dendritic cells (DC), macrophages, or B cells) activates CD4+ T cells, thereby coordinating and regulating effector cells.

[0005] Human MHC protein complexes are highly polymorphic and differ from animal MHC. It is desirable to generate antibodies, particularly human or humanized antibodies, that can recognize peptide-MHC complexes for a variety of therapeutic uses. Summary of the invention

[0006] The present disclosure relates to genetically modified animals and cells with humanized heavy and light chain immunoglobulin loci. In some embodiments, these animals and cells may also express human or chimeric (e.g., humanized) major histocompatibility complex (MHC) protein complexes. In some embodiments, these genetically modified animals have a limited set of human IGKV genes and IGKJ genes at endogenous light chain immunoglobulin loci. In one aspect, genetically modified animals as described herein may produce immunoglobulin light chain variable domains that may be paired with a fairly diverse family of heavy chain variable domains, including, for example, affinity-matured or somatically mutated variable domains.

[0007] In one aspect, the present disclosure relates to a genetically modified non-human animal comprising one or more human IGHV genes, one or more human IGHD genes, and one or more human IGHJ genes at an endogenous heavy chain immunoglobulin locus, in some embodiments, these human IGHV genes, human IGHD genes, and human IGHJ genes are operably linked and can undergo VDJ rearrangement, in some embodiments, the animal expresses a fusion protein comprising β2 microglobulin (B2M) and a human or humanized major histocompatibility complex (MHC) α chain.

[0008] In some embodiments, the animal comprises at least 150 human IGHV genes selected from Table 1, at least 20 human IGHD genes selected from Table 2, and at least 5 human IGHJ genes selected from Table 3. In some embodiments, the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes in the endogenous heavy chain immunoglobulin locus of human chromosome 14 of a human subject. In some embodiments, the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes in the endogenous heavy chain immunoglobulin locus of human chromosome 14 of a human cell. In some embodiments, the animal comprises a disruption of the endogenous heavy chain immunoglobulin locus of the animal. In some embodiments, the animal is a mouse, and the disruption of the endogenous heavy chain immunoglobulin locus of the animal comprises a deletion of one or more mouse IGHV genes in Table 4, one or more mouse IGHD genes in Table 5, and / or one or more mouse IGHJ genes in Table 6. In some embodiments, the animal is a mouse, and the destruction of the endogenous heavy chain immunoglobulin locus of the animal includes the deletion of a continuous sequence starting from the mouse IGHV1-85 gene to the mouse IGHJ4 gene. In some embodiments, the animal comprises one or more endogenous IGHM genes, IGHδ genes, IGHG3 genes, IGHG1 genes, IGHG2b genes, IGHG2a genes, IGHE genes, and IGHA genes. In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus, and in some embodiments, the unmodified human sequence is at least 800kb. In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus starting from human IGHV (III) -82 to human IGHV1-2. In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus starting from human IGHV (III) -82 to human IGHV6-1. In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus starting from human IGHD1-1 to human IGHJ6. In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus starting from human IGHV (III) -82 to human IGHJ6. In some embodiments, the animal is homozygous for the heavy chain immunoglobulin locus. In some embodiments, the animal is heterozygous for the heavy chain immunoglobulin locus. In some embodiments, the animal also comprises one or more human IGKV genes and one or more human IGKJ genes at the endogenous light chain immunoglobulin locus. In some embodiments, the animal is included in the destruction of the endogenous λ light chain immunoglobulin locus of the animal. In some embodiments, the animal is a rodent (e.g., mouse).

[0009] In one aspect, the present disclosure relates to a genetically modified non-human animal comprising one or more human IGKV genes and one or more human IGKJ genes at an endogenous light chain immunoglobulin locus, in some embodiments, the animal expresses a fusion protein comprising a β2 microglobulin (B2M) and a human or humanized major histocompatibility complex (MHC) α chain. In some embodiments, the animal comprises all human IGKV genes in Table 7 and all human IGKJ genes in Table 8. In some embodiments, the animal comprises an unmodified sequence derived from a human light chain immunoglobulin locus starting from human IGKV3D-7 to human IGKJ5. In some embodiments, the animal comprises a disruption of the endogenous light chain immunoglobulin locus of the animal. In some embodiments, the animal is a mouse, and the disruption of the endogenous light chain immunoglobulin locus of the animal comprises the deletion of one or more mouse IGKV genes in Table 9 and one or more mouse IGKJ genes in Table 10. In some embodiments, the animal is a mouse, and the destruction of the endogenous light chain immunoglobulin locus of the animal includes the deletion of the sequence starting from mouse IGKV2-137 to mouse IGKJ5. In some embodiments, the animal comprises endogenous IGKC. In some embodiments, the animal is homozygous for the light chain immunoglobulin locus. In some embodiments, the animal is heterozygous for the light chain immunoglobulin locus. In some embodiments, the animal also comprises one or more human IGHV genes, one or more human IGHD genes, and one or more human IGHJ genes in the endogenous heavy chain immunoglobulin locus. In some embodiments, the animal is included in the destruction of the endogenous λ light chain immunoglobulin locus of the animal. In some embodiments, the animal is a rodent (e.g., mouse).

[0010] In one aspect, the present disclosure relates to a genetically modified non-human animal comprising an exogenous light chain variable region gene sequence at an endogenous light chain immunoglobulin locus, in some embodiments, the exogenous light chain variable region gene sequence comprises no more than three human IGKV genes and no more than two human IGKJ genes, in some embodiments, the no more than three human IGKV genes and the no more than two human IGKJ genes are operably linked to an endogenous light chain constant domain gene, in some embodiments, the animal expresses a fusion protein comprising a β2 microglobulin (B2M) and a human or humanized major histocompatibility complex (MHC) α chain. In some embodiments, the no more than three human IGKV genes are selected from Table 7, and the no more than two human IGKJ genes are selected from Table 8. In some embodiments, the exogenous light chain variable region gene sequence comprises a human IGKV gene and a human IGKJ gene. In some embodiments, the exogenous light chain variable region gene sequence also comprises a human IGKJ 3'-UTR sequence. In some embodiments, the exogenous light chain variable region gene in one or more cells of the animal may undergo somatic hypermutation. In some embodiments, the somatic hypermutation may result in changes of up to one, two or three amino acids in the light chain variable region in one or more cells of the animal. In some embodiments, the exogenous light chain variable region gene sequence comprises a human IGKV gene and a human IGKJ gene, in some embodiments, the human IGKV gene is selected from IGKV3-20, IGKV3-11 and IGKV1-39, and in some embodiments, the human IGKV gene and the human IGKJ gene are operably connected. In some embodiments, the human IGKV gene is IGVK3-11. In some embodiments, the human IGKJ gene is selected from IGKJ1 and IGKJ4. In some embodiments, the human IGKV gene is IGKV1-39, and the human IGKJ gene is IGKJ4. In some embodiments, the human IGKV gene is IGKV3-11, and the human IGKJ gene is IGKJ1. In some embodiments, the human IGKV gene is IGKV3-20 and the human IGKJ gene is IGKJ1. In some embodiments, the animal further comprises a promoter sequence operably linked to the human IGKV gene, in some embodiments, the promoter sequence is within 2500bp or 3000bp of the human IGKV gene. In some embodiments, the promoter is an IGKV3-20 promoter, an IGKV3-11 promoter, or an IGKV1-39 promoter. In some embodiments, the animal comprises a disruption of the endogenous light chain immunoglobulin locus of the animal.In some embodiments, the animal is a mouse, and the destruction of the endogenous light chain immunoglobulin locus of the animal includes the deletion of one or more mouse IGKV genes in Table 9 and one or more mouse IGKJ genes in Table 10. In some embodiments, the animal is a mouse, and the destruction of the endogenous light chain immunoglobulin locus of the animal includes the deletion of the sequence starting from mouse IGKV2-137 to mouse IGKJ5. In some embodiments, the animal comprises an endogenous IGKC. In some embodiments, the animal also comprises a κ intron enhancer 5' and / or κ3' enhancer relative to the endogenous IGKC. In some embodiments, the human light chain variable region is a rearranged sequence. In some embodiments, the animal is homozygous for the light chain immunoglobulin locus. In some embodiments, the animal is heterozygous for the light chain immunoglobulin locus. In some embodiments, the animal is included in the destruction of the endogenous λ light chain immunoglobulin locus of the animal. In some embodiments, the animal is a rodent (e.g., mouse). In some embodiments, the animal further comprises one or more human IGHV genes, one or more human IGHD genes, and one or more human IGHKJ genes at the endogenous heavy chain immunoglobulin locus, and in some embodiments, these human IGHV genes, human IGHD genes, and human IGHJ genes are operably linked and can undergo VDJ rearrangement. In some embodiments, the animal comprises at least 150 human IGHV genes selected from Table 1, at least 20 human IGHD genes selected from Table 2, and at least 5 human IGHJ genes selected from Table 3. In some embodiments, the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes in the endogenous heavy chain immunoglobulin locus of human chromosome 14 of a human subject. In some embodiments, the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes in the endogenous heavy chain immunoglobulin locus of human chromosome 14 of a human cell. In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus, and in some embodiments, the unmodified human sequence is at least 800 kb. In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus starting from human IGHV (III) -82 to human IGHV1-2. In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus starting from human IGHV (III) -82 to human IGHV6-1. In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus starting from human IGHD1-1 to human IGHJ6. In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus starting from human IGHV (III) -82 to human IGHJ6.

[0011] In some embodiments, the animal lacks an endogenous immunoglobulin heavy chain variable region locus that can rearrange and form a nucleic acid sequence encoding an endogenous heavy chain variable domain (e.g., a mouse heavy chain variable domain). In some embodiments, the animal lacks an endogenous immunoglobulin light chain variable region locus that can rearrange and form a nucleic acid sequence encoding an endogenous light chain variable domain (e.g., a mouse light chain variable domain). In some embodiments, the animal can produce humanized antibodies.

[0012] In some embodiments, the genome of the animal comprises at least one chromosome, and the at least one chromosome comprises a sequence encoding a fusion protein. In some embodiments, the fusion protein includes human or humanized B2M protein. In some embodiments, the MHC α chain is an MHC class I α chain. In some embodiments, the MHC α chain is a chimeric MHC α chain. In some embodiments, the MHC α chain is a human HLA protein (e.g., HLA-A, HLA-B or HLA-C). In some embodiments, the MHC α chain is a human HLA / mouse H-2 chimeric molecule, in some embodiments, the human HLA is selected from HLA-A, HLA-B, HLA-C, and in some embodiments, the mouse H-2 is selected from H-2K, H-2D and H-2L. In some embodiments, the MHC α chain is a human HLA / mouse H2-D1 chimeric molecule. In some embodiments, the fusion protein includes human B2M protein and a chimeric MHC α chain comprising human HLA α1 and α2 domains. In some embodiments, the chimeric MHC alpha chain further comprises a mouse H2-D1 alpha 3 domain.In some embodiments, the sequence encoding the fusion protein is operably linked to an endogenous regulatory element (eg, a promoter) at an endogenous β2 microglobulin (B2M) locus in at least one chromosome. In some embodiments, the human HLA is human HLA-A*0101, HLA-A*0201, HLA-A*0301, HLA-A*0302, HLA-A*1101, HLA-A*2402, HLA-A*2901, HLA-A*3101, HLA-A*32 01. HLA-A*3301, HLA-A*3303, HLA-B*4402, HLA-B*0702, HLA-C*0702, HLA-C*0102, HLA-C*0701, HLA-C*0401, HLA-C*0801 or HLA-C*0802.

[0013] In some embodiments, the fusion protein includes (a) human B2M; and (b) human HLA (e.g., HLA-A, HLA-B or HLA-C). In some embodiments, the human B2M and the human HLA are connected by a linker peptide sequence. In some embodiments, the fusion protein includes (a) human B2M; and (b) a chimeric MHC α chain. In some embodiments, the human B2M and the chimeric MHC α chain are connected by a linker peptide sequence. In some embodiments, the chimeric MHC α chain comprises human HLA α1 and α2 domains. In some embodiments, the chimeric MHC α chain also comprises a human HLA α3 domain. In some embodiments, the chimeric MHC α chain also comprises an endogenous MHC α3 domain of the animal and / or an endogenous MHC cytoplasmic region of the animal. In some embodiments, the chimeric MHC α chain comprises an α3 domain, a connecting peptide, a transmembrane region, and a cytoplasmic region of an endogenous MHC. In some embodiments, the animal is a mouse, and the chimeric MHC α chain comprises the α3 domain, connecting peptide, transmembrane region, and cytoplasmic region of mouse H2-D1. In some embodiments, the fusion protein further comprises a signal peptide of the human HLA (e.g., at the N-terminus of the fusion protein). In some embodiments, the animal is heterozygous for the sequence encoding the fusion protein. In some embodiments, the animal is homozygous for the sequence encoding the fusion protein.

[0014] In one aspect, the disclosure relates to cells obtained from animals as described herein. In some embodiments, the cell is a B cell expressing a chimeric immunoglobulin heavy chain, the chimeric immunoglobulin heavy chain comprising a rearranged immunoglobulin heavy chain variable domain derived from one or more human IGHV genes, one or more human IGHD genes, and one or more human IGHJ genes, in some embodiments, the immunoglobulin heavy chain variable domain is operably connected to a non-human heavy chain constant region. In some embodiments, the cell is a B cell expressing a chimeric immunoglobulin light chain, the chimeric immunoglobulin light chain comprising a rearranged immunoglobulin light chain variable domain derived from one or more human IGKV genes and one or more human IGKJ genes, and in some embodiments, the immunoglobulin light chain variable domain is operably connected to a non-human light chain constant region. In some embodiments, the cell is an embryonic stem (ES) cell.

[0015] In one aspect, the present disclosure relates to a method for preparing an antibody that specifically binds to an antigenic peptide-MHC complex, the method comprising exposing an animal as described herein to the antigenic peptide-MHC complex comprising an antigenic peptide. In some embodiments, the method further comprises producing a hybridoma from cells collected from the animal; and collecting or analyzing antibodies produced by the hybridoma. In some embodiments, the method further comprises sequencing the genome of the hybridoma. In some embodiments, the antigenic peptide is an intracellular antigenic peptide (e.g., any of the antigenic peptides listed in Table 16).

[0016] In one aspect, the present disclosure relates to a method for obtaining a nucleic acid encoding an antibody binding domain that specifically binds to an antigenic peptide-MHC complex, the method comprising: exposing an animal as described herein to the antigenic peptide-MHC complex comprising an antigenic peptide; and sequencing a nucleic acid encoding human heavy chain and light chain immunoglobulin variable regions in a cell, the cell expressing a hybrid antibody that specifically binds to the antigenic peptide-MHC complex.

[0017] In one aspect, the present disclosure relates to a method of obtaining a sample, the method comprising: exposing an animal as described herein to an antigenic peptide-MHC complex; and collecting the sample from the animal. In some embodiments, the sample is spleen tissue, lymphoid tissue, splenocytes, or B cells.

[0018] In one aspect, the present disclosure relates to a method for screening antibodies that specifically bind to an antigenic peptide-MHC complex, the method comprising exposing an animal as described herein to the antigenic peptide-MHC complex comprising an antigenic peptide of interest; producing a hybridoma from cells collected from the animal; collecting or analyzing antibodies produced by the hybridoma; incubating the antibody with cells presenting the antigenic peptide of interest, cells presenting a control antigenic peptide, and / or cells that do not present any antigenic peptide; and determining that the antibody can specifically bind to cells presenting the antigenic peptide of interest, and optionally determining that the antibody does not bind to cells presenting the control antigenic peptide or cells that do not present any antigenic peptide. In some embodiments, flow cytometry is used to determine whether the antibody can specifically bind to cells presenting the antigenic peptide of interest.

[0019] In one aspect, the present disclosure relates to a method for screening antibodies that specifically bind to an antigenic peptide-MHC complex, the method comprising: exposing an animal as described herein to the antigenic peptide-MHC complex comprising an antigenic peptide of interest; and sequencing nucleic acids encoding human heavy chain and light chain immunoglobulin variable regions in cells, the cells expressing antibodies that specifically bind to the antigenic peptide-MHC complex. In some embodiments, the methods described herein further comprise (a) expressing antibodies comprising the encoded human heavy chain and light chain immunoglobulin variable regions; (b) incubating the antibodies with cells presenting the antigenic peptide of interest; and (c) determining that the antibodies can specifically bind to cells presenting the antigenic peptide of interest. In some embodiments, the methods described herein further comprise (a) incubating the antibodies with cells presenting a control antigenic peptide and / or cells that do not present any antigenic peptide; and (b) determining that the antibodies do not bind to cells presenting the control antigenic peptide or cells that do not present any antigenic peptide.

[0020] In some embodiments, the genetically modified non-human animal is heterozygous for the modified B2M locus. In some embodiments, the genetically modified non-human animal is homozygous for the modified B2M locus.

[0021] In some embodiments, the genetically modified non-human animal is heterozygous for the modified MHC locus. In some embodiments, the genetically modified non-human animal is homozygous for the modified MHC locus.

[0022] In some aspects, the present disclosure relates to a genetically modified non-human animal comprising one or more human IGHV genes, one or more human IGHD genes, and one or more human IGHJ genes at an endogenous heavy chain immunoglobulin locus. In some embodiments, these human IGHV genes, human IGHD genes, and human IGHJ genes are operably linked and can undergo VDJ rearrangement.

[0023] In some embodiments, the animal comprises about or at least 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, or 161 human IGHV genes selected from Table 1, about or at least 20, 21, 22, 23, 24, 25, 26, or 27 human IGHD genes selected from Table 2, and about or at least 5, 6, 7, 8, or 9 human IGHJ genes selected from Table 3. In some embodiments, the animal comprises all human IGHV genes in Table 1 except IGHV2-10, IGHV3-9, and IGHV1-8, all human IGHD genes in Table 2, and all human IGHJ genes in Table 3. In some embodiments, the animal comprises all human IGHV genes in Table 1 except IGHV5-10-1 and IGHV3-64D, all human IGHD genes in Table 2, and all human IGHJ genes in Table 3. In some embodiments, the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes in the endogenous heavy chain immunoglobulin locus of human chromosome 14 of a human subject. In some embodiments, the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes in the endogenous heavy chain immunoglobulin locus of human chromosome 14 of a human cell (e.g., a somatic cell, a cultured cell, a non-immune cell, a cell without any V(D)J rearrangement).

[0024] In some embodiments, the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus. In some embodiments, the unmodified human sequence is about or at least 10 kb, 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb, 100 kb, 200 kb, 300 kb, 400 kb, 500 kb, 600 kb, 700 kb, 800 kb, 900 kb or 1000 kb.

[0025] In some aspects, the present disclosure relates to a genetically modified animal comprising a first sequence, a second sequence, and a third sequence at an endogenous heavy chain immunoglobulin locus, the first sequence comprising one or more human IGHV genes, the second sequence comprising an endogenous sequence, the third sequence comprising one or more human IGHD genes and one or more human IGHJ genes, wherein the first sequence, the second sequence, and the third sequence are operably linked.

[0026] In some embodiments, the first sequence comprises about or at least 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, or 161 human IGHV genes selected from Table 1. In some embodiments, the first sequence comprises about or at least 20, 21, 22, 23, 24, 25, 26, or 27 human IGHD genes selected from Table 2.

[0027] In some embodiments, the first sequence is an unmodified sequence derived from a human heavy chain immunoglobulin locus. In some embodiments, the first sequence is about or at least 10 kb, 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb, 100 kb, 200 kb, 300 kb, 400 kb, 500 kb, 600 kb, 700 kb, 800 kb, 900 kb or 1000 kb.

[0028] In some embodiments, the second sequence comprises an endogenous sequence that is about or at least 1 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 7 kb, 8 kb, 9 kb, 10 kb, 11 kb, 12 kb, 13 kb, 14 kb, 15 kb, 16 kb, 17 kb, 18 kb, 19 kb, or 20 kb.

[0029] In some embodiments, the third sequence comprises about or at least 20, 21, 22, 23, 24, 25, 26, or 27 human IGHD genes selected from Table 2. In some embodiments, the third sequence comprises about or at least 5, 6, 7, 8, or 9 human IGHJ genes selected from Table 3. In some embodiments, the third sequence comprises all human IGHD genes in Table 2 and all human IGHJ genes in Table 3.

[0030] In some embodiments, the third sequence is an unmodified sequence derived from a human heavy chain immunoglobulin locus. In some embodiments, the third sequence is about or at least 10 kb, 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb or 100 kb.

[0031] In some embodiments, the animal comprises a disruption of an endogenous heavy chain immunoglobulin locus in the animal.

[0032] In some embodiments, the animal is a mouse, and the disruption of the animal's endogenous heavy chain immunoglobulin locus comprises a deletion of one or more mouse IGHV genes in Table 4, one or more mouse IGHD genes in Table 5, and one or more mouse IGHJ genes in Table 6.

[0033] In some embodiments, the animal is a mouse, and the disruption of the animal's endogenous heavy chain immunoglobulin locus comprises a deletion of sequence beginning with mouse IGHV1-85 to mouse IGHJ4.

[0034] In some embodiments, the animal comprises one or more endogenous genes selected from the group consisting of an IGHM gene, an IGHδ gene, an IGHG3 gene, an IGHG1 gene, an IGHG2b gene, an IGHG2a gene, an IGHE gene, and an IGHA gene.

[0035] In some embodiments, the animal is homozygous for the heavy chain immunoglobulin locus. In some embodiments, the animal is heterozygous for the heavy chain immunoglobulin locus.

[0036] In some aspects, the disclosure relates to a genetically modified non-human animal comprising one or more human IGKV genes and one or more human IGKJ genes at an endogenous light chain immunoglobulin locus.

[0037] In some embodiments, the animal comprises about or at least 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 or 76 of the human IGKV genes in Table 7 and / or comprises about or at least 1, 2, 3, 4 or 5 of the human IGKJ genes in Table 8.

[0038] In some embodiments, the animal comprises an unmodified sequence derived from the human light chain immunoglobulin locus starting from human IGKV3D-7 to human IGKJ5.

[0039] In some embodiments, the animal comprises a disruption of an endogenous light chain immunoglobulin locus in the animal.

[0040] In some embodiments, the animal comprises all human IGKV genes and all human IGKJ genes at the endogenous kappa chain immunoglobulin locus of human chromosome 2 of a human subject. In some embodiments, the animal comprises all human IGKV genes and all human IGKJ genes in the endogenous heavy chain immunoglobulin locus of human chromosome 2 of a human cell (e.g., a somatic cell, a cultured cell, a non-immune cell, a cell without any V(D)J rearrangement).

[0041] In some aspects, the present disclosure relates to a genetically modified non-human animal whose genome comprises an endogenous heavy chain immunoglobulin locus comprising: a replacement of one or more endogenous IGHV genes, endogenous IGHD genes, and endogenous IGHJ genes by one or more human IGHV genes, human IGHD genes, and human IGHJ genes. In some embodiments, the human IGHV genes, human IGHD genes, and human IGHJ genes are operably linked to one or more of the endogenous genes selected from the group consisting of an IGHM gene, an IGHδ gene, an IGHG gene, an IGHE gene, and an IGHA gene.

[0042] In some embodiments, one or more endogenous IGHV genes, endogenous IGHD genes, and endogenous IGHJ genes are replaced by about or at least 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, or 161 human IGHV genes from Table 1, about or at least 20, 21, 22, 23, 24, 25, 26, or 27 human IGHD genes from Table 2, and about or at least 5, 6, 7, 8, or 9 human IGHJ genes from Table 3.

[0043] In some embodiments, the animal is a mouse, and about or at least 180 of the mouse IGHV genes in Table 4, all of the mouse IGHD genes in Table 5, and all of the mouse IGHJ genes in Table 6 are replaced.

[0044] In some aspects, the present disclosure relates to a genetically modified non-human animal whose genome comprises an endogenous light chain immunoglobulin locus comprising: a replacement of one or more endogenous IGKV genes and endogenous IGKJ genes by one or more human IGKV genes and human IGKJ genes. In some embodiments, the human IGKV gene and the human IGKJ gene are operably linked to an endogenous IGKC gene.

[0045] In some embodiments, one or more endogenous IGKV genes and endogenous IGKJ genes are replaced by about or at least 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 or 76 human IGKV genes in Table 7, and about or at least 1, 2, 3, 4 or 5 human IGKJ genes in Table 8.

[0046] In some embodiments, the animal is a mouse, and all of the mouse IGKV genes in Table 9 and all of the mouse IGKJ genes in Table 10 are replaced.

[0047] In some aspects, the present disclosure relates to a method for modifying the genome of a cell, the method comprising modifying a human chromosome; introducing the modified human chromosome into a cell of an animal; and inducing recombination between the modified human chromosome and an endogenous chromosome, thereby replacing one or more endogenous genes with one or more human genes.

[0048] In some embodiments, the modified human chromosome comprises two or more exogenous recombination sites.

[0049] In some embodiments, the endogenous chromosome comprises two or more exogenous recombination sites.

[0050] In some embodiments, about or at least 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, or 161 human IGHV genes selected from Table 1, about or at least 20, 21, 22, 23, 24, 25, 26, or 27 human IGHD genes selected from Table 2, and about or at least 5, 6, 7, 8, or 9 human IGHJ genes selected from Table 3 are integrated into an endogenous chromosome by recombination.

[0051] In some embodiments, about or at least 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, or 76 of the human IGKV genes in Table 7, and about or at least 1, 2, 3, 4, or 5 of the human IGKJ genes in Table 8 are integrated into the endogenous chromosome by recombination.

[0052] In some embodiments, the human sequence is integrated into an endogenous chromosome by recombination and the human sequence is about or at least 10 kb, 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb, 100 kb, 200 kb, 300 kb, 400 kb, 500 kb, 600 kb, 700 kb, 800 kb, 900 kb or 1000 kb.

[0053] In one aspect, the present disclosure provides a method for preparing an antibody that specifically binds to an antigen. The method includes: obtaining a nucleic acid sequence encoding a human heavy chain and light chain immunoglobulin variable region in a cell expressing a hybrid antibody that specifically binds to the antigen, wherein the cell is obtained by exposing an animal as described herein to an antigen-MHC complex containing the antigen; operably linking a nucleic acid encoding the human heavy chain immunoglobulin variable region to a nucleic acid encoding a human heavy chain immunoglobulin constant region, and a nucleic acid encoding the human light chain immunoglobulin variable region to a nucleic acid encoding a human light chain immunoglobulin constant region; and expressing the nucleic acid in a cell to obtain the antibody.

[0054] In one aspect, the present disclosure provides a method for preparing an antibody that specifically binds to an antigen. The method includes: exposing an animal as described herein to an antigen-MHC complex comprising the antigen; obtaining (e.g., by sequencing) the sequence of a nucleic acid encoding a human heavy chain and light chain immunoglobulin variable region in a cell expressing a hybrid antibody that specifically binds to the antigen; and operably linking in a cell a nucleic acid encoding the human heavy chain immunoglobulin variable region and a nucleic acid encoding a human heavy chain immunoglobulin constant region, and a nucleic acid encoding the human light chain immunoglobulin variable region and a nucleic acid encoding a human light chain immunoglobulin constant region.

[0055] In one aspect, the present disclosure provides a genetically modified non-human animal comprising an exogenous light chain variable region gene sequence at an endogenous light chain immunoglobulin locus. In some embodiments, the exogenous light chain variable region gene sequence comprises no more than three human IGKV genes and no more than two human IGKJ genes. In some embodiments, the no more than three human IGKV genes and the no more than two human IGKJ genes are operably linked to an endogenous light chain constant domain gene.

[0056] In some embodiments, the animal comprises IGHV(III)-82, IGHV7-81, IGHV4-80, IGHV3-79, IGHV(II)-78-1, IGHV5-78, IGHV7-77, IGHV(III)-76-1, IGHV3-76, IGHV3-75, and IGHV(II)-74-1. In some embodiments, the animal comprises IGHV5-10-1 and IGHV3-64D.

[0057] In some embodiments, the animal further comprises a first sequence at an endogenous heavy chain immunoglobulin locus comprising one or more human IGHV genes;

[0058] A second sequence comprising an endogenous sequence; and a third sequence comprising one or more human IGHD genes and one or more human IGHJ genes. In some embodiments, the first sequence, the second sequence, and the third sequence are operably linked.

[0059] In some embodiments, the first sequence comprises at least 150 human IGHV genes selected from Table 1. In some embodiments, the first sequence comprises at least 20 human IGHD genes selected from Table 2. In some embodiments, the first sequence is an unmodified sequence derived from a human heavy chain immunoglobulin locus. In some embodiments, the first sequence is at least 800 kb. In some embodiments, the second sequence comprises at least 3 kb of endogenous sequence. In some embodiments, the third sequence comprises at least 20 human IGHD genes selected from Table 2 and at least 5 human IGHJ genes selected from Table 3.

[0060] In some embodiments, the third sequence comprises all of the human IGHD genes in Table 2 and all of the human IGHJ genes in Table 3. In some embodiments, the third sequence is an unmodified sequence derived from a human heavy chain immunoglobulin locus. In some embodiments, the third sequence is at least 50 kb. In some embodiments, the animal comprises a disruption of an endogenous heavy chain immunoglobulin locus in the animal.

[0061] In some embodiments, the animal is a mouse, and the disruption of the animal's endogenous heavy chain immunoglobulin locus comprises a deletion of one or more mouse IGHV genes in Table 4, one or more mouse IGHD genes in Table 5, and one or more mouse IGHJ genes in Table 6. In some embodiments, the animal is a mouse, and the disruption of the animal's endogenous heavy chain immunoglobulin locus comprises a deletion of the sequence starting from mouse IGHV1-85 to mouse IGHJ4. In some embodiments, the animal comprises one or more endogenous IGHM genes, IGHδ genes, IGHG3 genes, IGHG1 genes, IGHG2b genes, IGHG2a genes, IGHE genes, and IGHA genes.

[0062] In some embodiments, the animal is homozygous for the heavy chain immunoglobulin locus. In some embodiments, the animal is heterozygous for the heavy chain immunoglobulin locus.

[0063] In one aspect, the present disclosure provides a genetically modified non-human animal whose genome comprises an endogenous light chain immunoglobulin locus comprising: a replacement of one or more endogenous IGKV genes by one or more human IGKV genes selected from Table 7; and a replacement of one or more endogenous IGKJ genes by one or more human IGKJ genes selected from Table 8. In some embodiments, the human IGKV gene and the human IGKJ gene are operably linked to an endogenous IGKC gene.

[0064] In some embodiments, the one or more human IGKV genes are selected from IGKV3-20, IGKV3-11, and IGKV1-39. In some embodiments, the human IGKV gene is IGKV3-11. In some embodiments, the one or more human IGKJ genes are selected from IGKJ1 and IGKJ4. In some embodiments, the animal further comprises an insertion of a human IGKJ 3'-UTR sequence. In some embodiments, the human IGKV gene is IGKV1-39, and the human IGKJ gene is IGKJ4. In some embodiments, the human IGKV gene is IGKV3-11, and the human IGKJ gene is IGKJ1. In some embodiments, the human IGKV gene is IGKV3-20, and the human IGKJ gene is IGKJ1. In some embodiments, all endogenous IGKV genes are replaced by the one or more human IGKV genes. In some embodiments, all endogenous IGKJ genes are replaced by the one or more human IGKJ genes.

[0065] In some embodiments, the animal further comprises a promoter sequence preceding the human IGKV gene. In some embodiments, the promoter sequence is within 3000 bp of the human IGKV gene. In some embodiments, the animal further comprises a kappa intronic enhancer at 5' of the endogenous IGKC. In some embodiments, the animal further comprises a kappa 3' enhancer.

[0066] In some embodiments, the genome of the animal further comprises an endogenous heavy chain immunoglobulin locus, which comprises: one or more human IGHV genes, human IGHD genes, and human IGHJ genes replace one or more endogenous IGHV genes, endogenous IGHD genes, and endogenous IGHJ genes. In some embodiments, the one or more human IGHV genes, human IGHD genes, and human IGHJ genes are operably linked to one or more of the endogenous IGHM genes, IGHδ genes, IGHG genes, IGHE genes, and IGHA genes. In some embodiments, the one or more endogenous IGHV genes, endogenous IGHD genes, and endogenous IGHJ genes are replaced by at least 150 human IGHV genes in Table 1, at least 20 human IGHD genes in Table 2, and at least 5 human IGHJ genes in Table 3.

[0067] In some embodiments, the animal is a mouse, and at least 180 of the mouse IGHV genes in Table 4, all of the mouse IGHD genes in Table 5, and all of the mouse IGHJ genes in Table 6 are replaced.

[0068] In some embodiments, the animal lacks an endogenous immunoglobulin heavy chain variable region locus that can rearrange and form a nucleic acid sequence encoding an endogenous heavy chain variable domain (e.g., a mouse heavy chain variable domain). In some embodiments, the animal lacks an endogenous immunoglobulin light chain variable region locus that can rearrange and form a nucleic acid sequence encoding an endogenous light chain variable domain (e.g., a mouse light chain variable domain).

[0069] In some embodiments, the animal can produce a humanized antibody. In some embodiments, the antibody comprises a light chain variable region encoded by an IGKV gene and an IGKJ gene.

[0070] In one aspect, the disclosure provides a cell obtained from an animal as described herein. In some embodiments, the cell is a B cell expressing a chimeric immunoglobulin light chain comprising an immunoglobulin light chain variable domain encoded by a human IGKV gene selected from IGKV3-20, IGKV3-11, and IGKV1-39 and a human IGKJ gene selected from IGKJ1 and IGKJ4. In some embodiments, the immunoglobulin light chain variable domain is operably linked to a non-human light chain constant region.

[0071] In some embodiments, a B cell expressing a chimeric immunoglobulin heavy chain comprises a rearranged immunoglobulin heavy chain variable domain derived from one or more human IGHV genes, one or more human IGHD genes, and one or more human IGHJ genes. In some embodiments, the immunoglobulin heavy chain variable domain is operably linked to a non-human heavy chain constant region.

[0072] In some embodiments, the cell is an embryonic stem (ES) cell.

[0073] In one aspect, the present disclosure provides a method for preparing an antibody that specifically binds to an antigen, the method comprising: exposing an animal as described herein to an antigen-MHC complex comprising the antigen; sequencing nucleic acids encoding human heavy chain and light chain immunoglobulin variable regions in a cell, the cell expressing a hybrid antibody that specifically binds to the antigen; and operably linking in the cell a nucleic acid encoding the human heavy chain immunoglobulin variable region with a nucleic acid encoding a human heavy chain immunoglobulin constant region, and a nucleic acid encoding the human light chain immunoglobulin variable region with a nucleic acid encoding a human light chain immunoglobulin constant region.

[0074] In one aspect, the present disclosure provides a method for preparing an antibody that specifically binds to a protein of interest, the method comprising: exposing an animal as described herein to a protein of interest, such as a peptide-MHC complex; and sequencing nucleic acids encoding human heavy chain and light chain immunoglobulin variable regions in cells expressing antibodies that specifically bind to the protein of interest.

[0075] In some embodiments, a gene encoding an endogenous protein is disrupted in an animal. In some embodiments, a gene encoding an endogenous protein is knocked out.

[0076] In some embodiments, the endogenous protein is at least 80%, 90%, 95% homologous to the protein of interest. In some embodiments, the endogenous protein is at least 80%, 90% or 95% identical to the protein of interest.

[0077] The present disclosure also relates to offspring of non-human mammals.

[0078] In some embodiments, the non-human mammal is a rodent. In some embodiments, the non-human mammal is a mouse.

[0079] The present disclosure also provides cells comprising a targeting vector as described herein.

[0080] The present disclosure also relates to cells (e.g., stem cells, embryonic stem cells, immune cells, B cells, T cells or hybridomas) or cell lines derived from non-human mammals or their progeny, or primary cell cultures thereof. The present disclosure also relates to tissues, organs or cultures thereof derived from non-human mammals or their progeny.

[0081] The present disclosure also relates to the use of non-human mammals or their progeny, animal models generated by the methods described herein, in developing products related to immune processes, preparing human antibodies, or as model systems for pharmacology, immunology, microbiology, and medical research.

[0082] Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Methods and materials for use in the present invention are described herein; other suitable methods and materials known in the art may also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated herein by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail.

[0083] Other features and advantages of the invention will be apparent from the following detailed description and drawings, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0084] Figure 1 is a schematic diagram showing the unrestricted MHC humanization strategy.

[0085] Figure 2A Schematic diagram showing the humanized mouse B2M locus. The mouse B2M gene coding region is replaced by a nucleic acid sequence encoding a human HLA-A signal peptide, a human B2M protein, a portion of a human HLA-A protein, and a portion of a mouse H2-D1 protein.

[0086] Figure 2B A schematic diagram of the targeting strategy at the mouse B2M locus is shown.

[0087] Figure 3A Schematic diagram showing the humanized mouse B2M locus. The mouse B2M gene coding region is replaced by nucleic acid sequences encoding the human HLA-A signal peptide, human B2M protein, and human HLA-A protein without a signal peptide.

[0088] Figure 3B A schematic diagram of the targeting strategy at the mouse B2M locus is shown.

[0089] Figure 4A to Figure 4B The results of PCR detection of F1 generation mice using primers WT-F / WT-R or WT-F / Mut-R are shown. M is a marker. H2O is a water control. WT is a wild-type control. PC is a positive control. F1-01 to F1-16 are mouse numbers.

[0090] Figure 5 The results of Southern blot analysis of F1 generation mice by 5' probe and 3' probe are shown. WT is wild type control. F1-01, F1-02, F1-03, F1-04, F1-05, F1-06, F1-07, F1-08, F1-17, F1-18, F1-19 and F1-20 are mouse numbers.

[0091] 6A to 6F The serum titer curve of antigen-specific antibodies after three immunizations of MHC-I VH / VL mice with antigen-MHC complexes including antigen peptide A, peptide B, peptide C, peptide D, peptide E and peptide F, respectively, is shown. H / + hVH / hVL、HLA-A*0201 H / + hVH / hcVL) or HLA homozygous mice (HLA-A*0201 H / H hVH / hVL).

[0092] Figure 7KD values ​​for 115 antigen-specific antibodies against peptide A-MHC complexes are shown.

[0093] Figure 8 The length distribution of the VH CDR3 sequences of 16 peptide A-specific antibodies is shown.

[0094] FIG. 9A to FIG. 9B Results of germline IGHV and IGKV gene application for 16 peptide A-specific antibodies are shown.

[0095] Fig.10 Shown is the length distribution of the VH CDR3 sequences of 19 peptide B-specific antibodies.

[0096] FIG. 11A to FIG. 11B Results of the use of germline IGHV and IGKV genes for 19 peptide B-specific antibodies are shown.

[0097] Fig.12 The length distribution of VH CDR3 sequences of 18 peptide C-specific antibodies is shown.

[0098] FIG. 13A to FIG. 13B Results of the use of germline IGHV and IGKV genes for 18 peptide C-specific antibodies are shown.

[0099] Fig.14 is a schematic diagram showing the human immunoglobulin heavy chain (IGH) locus on chromosome 14 (14q32.33).

[0100] Fig.15 is a schematic diagram showing the mouse (Mus musculus) IGH locus (strain C57BL / 6) on chromosome 12 (12F2).

[0101] Fig.16 is a schematic diagram showing the human immunoglobulin kappa chain (IGK) locus on chromosome 2 (2p11.2).

[0102] Fig.17 is a schematic diagram showing the mouse (Mus musculus) IGK locus on chromosome 6 (6C1).

[0103] Fig.18 Immunization of HLA-A*0201hVH / hcVL heterozygous mice (HLA-A*0201) with peptide F-MHC complexes is shown. H / + Serum titer curve of antigen-specific antibodies after hVH / hcVL v2).

[0104] Fig.19 Shown by immunization with HLA-A*0201 H / +KD values ​​of 30 antigen-specific antibodies to peptide F-MHC complexes produced by hVH / hcVL v2 mice.

[0105] Fig. 20 Shown by immunization with HLA-A*0201 H / + Results of germline IGHV gene application for 29 peptide-F-specific antibodies generated by hVH / hcVL v2 mice.

[0106] Fig.21 The results show that in HLA-A*0302hVH / hVL heterozygous mice (HLA-A*0302) immunized with peptide G-MHC complexes H / + hVH / hVL) and HLA-A*0302hVH / hVL homozygous mice (HLA-A*0302 H / H hVH / hVL) after the serum titer curve of antigen-specific antibodies.

[0107] Fig. 22 The results show that in HLA-A*1101hVH / hVL heterozygous mice (HLA-A*1101) immunized with peptide G-MHC complexes H / + hVH / hVL) and HLA-A*1101hVH / hVL homozygous mice (HLA-A*1101 H / H hVH / hVL) after the serum titer curve of antigen-specific antibodies.

[0108] Fig.23 Shown are the KD values ​​of 24 antigen-specific antibodies after immunization of HLA-A*1101hVH / hVL mice.

[0109] Fig.24 The results show that in HLA-A*2402hVH / hVL heterozygous mice (HLA-A*2402) were immunized with peptide H-MHC complexes. H / + hVH / hVL) after the serum titer curve of antigen-specific antibodies.

[0110] Fig.25 Sequences discussed in this disclosure are listed. DETAILED DESCRIPTION

[0111] The present disclosure relates to genetically modified animals and cells having humanized heavy chain immunoglobulin loci and / or humanized light chain immunoglobulin loci (e.g., κ chain loci). In some embodiments, these animals and cells may also express human or chimeric (e.g., humanized) major histocompatibility complex (MHC) protein complexes.

[0112] Genetically modified animals can express humanized antibodies or chimeric antibodies. For example, in some cases, the genetically modified animals described herein have a complete human antibody library. In some cases, the humanized light chain immunoglobulin locus has a limited set of IGKV genes and IGKJ genes. Because endogenous IGHV genes, IGHD genes, IGHJ genes, IGKV genes, and IGKJ genes have been effectively deleted, the antibodies produced by the antibody library are less likely to be immunogenic in humans. Therefore, these antibodies are more suitable for use as human therapeutics. Therefore, genetically modified animals provide a favorable platform for the production of humanized antibodies. RenMab TM Mice and RenLite TM A detailed description of mice can be found in, for example, PCT / CN2020 / 075698 and PCT / CN2021 / 097652, each of which is incorporated herein by reference in its entirety.

[0113] These animals and cells may also express human or chimeric (e.g., humanized) major histocompatibility complex (MHC) protein complexes. It is well established that T cells recognize antigens associated with self-MHC proteins, but not with foreign MHC proteins: that is, T cells exhibit MHC restriction. This restriction is due to a positive selection process during T cell development in the thymus. In this process, those immature T cells that are able to recognize foreign peptides presented by self-MHC proteins are selected to survive, while the remaining T cells that are useless to the animal undergo apoptosis. Thus, MHC restriction is an acquired property of the immune system that occurs as T cells develop in the thymus.

[0114] Here, nucleotide sequences encoding human or chimeric MHC protein complexes are introduced into RenMab TM Mice and RenLite TM Mice are used to obtain genetically modified non-human animals (MHC-IVH / VL background) that can express and tolerate human MHC protein molecules in vivo. Such animals can be immunized with antigen peptide-MHC complexes to produce TCR-like antibodies with high diversity and high affinity. The VH and VL sequences of the antibodies produced can also be used to prepare chimeric antigen receptors (CARs) or T cell receptors that can target specific cancer antigens.

[0115] As used herein, the term "antibody" refers to an immunoglobulin molecule comprising four polypeptide chains (two heavy (H) chains and two light (L) chains) interconnected by disulfide bonds. Each heavy chain comprises a heavy chain variable (VH) domain and a heavy chain constant region (CH). Each light chain comprises a light chain variable (VL) domain and a light chain constant region (CL). The VH domain and the VL domain can be further subdivided into hypervariable regions, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). Each VH and VL comprises three CDRs and four FRs, which are arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (heavy chain CDRs may be abbreviated as HCDR1, HCDR2, and HCDR3; light chain CDRs may be abbreviated as LCDR1, LCDR2, and LCDR3). The term "high affinity" antibody refers to an antibody having about 10 CDRs relative to the target epitope of the antibody. -9 M or less (e.g., about or less than 1×10 -9 M, 1×10 -10 M, 1×10 -11 M or 1×10 -12 M) K D In some embodiments, K D Surface plasmon resonance (Biacore TM or ELISA) to measure.

[0116] As used herein, the term "antigen binding fragment" refers to a portion of a full-length antibody, wherein the portion of the antibody is capable of specifically binding to an antigen. In some embodiments, the antigen binding fragment contains at least one variable domain (e.g., a heavy chain variable domain or a light chain variable domain). Non-limiting examples of antibody fragments include, for example, Fab, Fab', F(ab')2, and Fv fragments.

[0117] As used herein, the term "human antibody" refers to an antibody encoded by a nucleic acid present in a human (e.g., a rearranged human immunoglobulin heavy chain or light chain locus). In some embodiments, human antibodies are collected from humans or produced in human cell cultures (e.g., human hybridoma cells). In some embodiments, human antibodies are produced in non-human cells (e.g., mouse or hamster cell lines). In some embodiments, human antibodies are produced in bacteria or yeast cells. In some embodiments, human antibodies are produced in transgenic non-human animals (e.g., mice) containing human immunoglobulin loci (e.g., heavy or light chain human immunoglobulin loci) that are not rearranged or rearranged.

[0118] As used herein, the term "chimeric antibody" refers to an antibody containing sequences present in at least two different antibodies (e.g., antibodies from two different mammalian species, such as human and mouse antibodies). A non-limiting example of a chimeric antibody is an antibody containing a variable domain sequence of a human antibody (e.g., all or part of a light chain and / or heavy chain variable domain sequence) and a constant domain of a non-human antibody. Other examples of chimeric antibodies are described herein and are known in the art.

[0119] As used herein, the term "humanized antibody" refers to a non-human antibody which contains sequences derived from non-human (eg, mouse) immunoglobulin and sequences derived from human immunoglobulin.

[0120] As used herein, the term "single-chain antibody" refers to a single polypeptide containing at least two immunoglobulin variable domains (eg, variable domains of a mammalian immunoglobulin heavy or light chain) capable of specific binding to an antigen.

[0121] As used herein, the terms "subject" and "patient" are used interchangeably throughout the specification and describe animals (human or non-human). The present disclosure contemplates veterinary and non-veterinary applications. Human patients can be adults or adolescents (e.g., people under 18 years of age). In addition to humans, patients include, but are not limited to, mice, rats, hamsters, guinea pigs, rabbits, ferrets, cats, dogs, and primates. Including, for example, non-human primates (e.g., monkeys, chimpanzees, gorillas, etc.), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), lagomorphs, pigs (e.g., pigs, miniature pigs), horses, dogs, cats, cattle and other domestic animals, farm animals, and zoo animals.

[0122] As used herein, the phrase "specific binding" when referring to an antibody means that the antibody interacts with its target molecule preferentially over other molecules because the interaction depends on the presence of a specific structure (i.e., antigenic determinant or epitope) on the target molecule; in other words, the agent recognizes and binds to molecules that include a specific structure, rather than all molecules in general. An antibody that specifically binds to a target molecule can be referred to as a target-specific antibody.

[0123] As used herein, the terms "polypeptide," "peptide," and "protein" are used interchangeably to refer to amino acid polymers of any length of at least two amino acids.

[0124] As used herein, the terms "polynucleotide," "nucleic acid molecule," and "nucleic acid sequence" are used interchangeably herein to refer to nucleotide polymers of any length of at least two nucleotides, and include but are not limited to DNA, RNA, DNA / RNA hybrids, and modifications thereof.

[0125] As used herein, the term "unmodified human sequence" refers to a sequence derived from a human subject, a human cell, a cultured human cell, or a human cell line, wherein the sequence is identical to a gene sequence of the human subject, the human cell, the cultured human cell, or the human cell line.

[0126] Genetically modified heavy chain immunoglobulin locus

[0127] The heavy chain immunoglobulin locus (also called IGH or immunoglobulin heavy chain locus) is the region on a chromosome (e.g., human chromosome 14) that contains human antibody (or immunoglobulin) heavy chain genes.

[0128] This region represents the germline organization of the heavy chain locus. The locus includes V (variable), D (diversity), J (joining) and C (constant) segments. The genes in the V region form the V gene cluster (also referred to as the IGHV gene cluster). The genes in the D region form the D gene cluster (also referred to as the IGHD gene cluster). The genes in the J region form the J gene cluster (also referred to as the IGHJ gene cluster).

[0129] During B cell development, recombination events at the DNA level join a single D segment (also called the IGHD gene) to a J segment (also called the IGHJ gene); the fused DJ exons of this partially rearranged DJ region are then joined to a V segment (also called the IGHV gene). The rearranged VDJ region containing the fused VDJ exons is then transcribed at the RNA level and fused to the IGHM constant region; this transcript encodes the mu heavy chain. Later in development, B cells produce VDJ-Cmu-Cdelta pre-messenger RNA, which is alternatively spliced ​​to encode the mu or delta heavy chain. Mature B cells in the lymph nodes undergo switch recombination, so that the fused VDJ gene segment is close to one of the IGHG, IGHA, or IGHE gene segments, and each cell expresses a gamma, alpha, or epsilon heavy chain. The potential recombination of many different IGHV genes with several IGHJ genes provides a wide range of antigen recognition. Additional diversity is obtained through junctional diversity generated by random addition of nucleotides by terminal deoxynucleotidyl transferase and somatic hypermutation that occurs during B cell maturation in the spleen and lymph nodes. Several V segments, D segments, J segments, and C segments are known to be unable to encode proteins and are considered to be pseudogene segments (often simply referred to as pseudogenes).

[0130] The human heavy chain immunoglobulin locus is located on human chromosome 14. Table 1 lists the IGHV genes in this locus and their relative order.

[0131] Table 1. List of IGHV genes on human chromosome 14

[0132]

[0133]

[0134]

[0135] RPS8P1, ADAM6 and KIAA0125 are also located in this locus. The relative order of RPS8P1 is 160, the relative order of ADAM6 is 161, and the relative order of KIAA0125 is 164. Table 2 lists all IGHD genes on human chromosome 14 and their relative order. Table 3 lists all IGHJ genes on human chromosome 14 and their relative order. The genes of immunoglobulin constant domains are located after the IGHV genes, IGHD genes and IGHJ genes. These genes include (as shown in the following order): immunoglobulin weight constant mu (IGHM), immunoglobulin weight constant delta (IGHδ), immunoglobulin weight constant gamma 3 (IGHG3), immunoglobulin weight constant gamma 1 (IGHG1), immunoglobulin weight constant epsilon P1 (pseudogene) (IGHEP1), immunoglobulin weight constant alpha 1 (IGHA1), immunoglobulin weight constant gamma P (non-functional) (IGHGP), immunoglobulin weight constant gamma 2 (IGHG2), immunoglobulin weight constant gamma 4 (IGHG4), immunoglobulin weight constant epsilon (IGHE), and immunoglobulin weight constant alpha 2 (IGHA2). These genes and the order of these genes are also shown in Fig.14 middle.

[0136] Table 2. List of IGHD genes on human chromosome 14

[0137] Gene name order Gene name order Gene name order Gene name order IGHD1-1 165 IGHD2-8 172 IGHD2-15 179 IGHD3-22 186 IGHD2-2 166 IGHD3-9 173 IGHD3-16 180 IGHD4-23 187 IGHD3-3 167 IGHD3-10 174 IGHD4-17 181 IGHD5-24 188 IGHD4-4 168 IGHD4-11 175 IGHD5-18 182 IGHD6-25 189 IGHD5-5 169 IGHD5-12 176 IGHD6-19 183 IGHD1-26 190 IGHD6-6 170 IGHD6-13 177 IGHD1-20 184 * IGHD1-7 171 IGHD1-14 178 IGHD2-21 185 IGHD7-27 192

[0138] Table 3. List of IGHJ genes on human chromosome 14

[0139] Gene name order Gene name order IGHJ1P 191 IGHJ4 197 IGHJ1 193 IGHJ5 198 IGHJ2 194 IGHJ3P 199 IGHJ2P 195 IGHJ6 200 IGHJ3 196

[0140] The mouse heavy chain immunoglobulin locus is located on mouse chromosome 12. Table 4 lists the IGHV genes in this locus and their relative order.

[0141] Table 4. List of IGHV genes on mouse chromosome 12

[0142]

[0143]

[0144] Table 5 lists all the IGHD genes on mouse chromosome 12 and their relative order. Table 6 lists all the IGHJ genes on mouse chromosome 12 and their relative order. The genes for the immunoglobulin constant domains are after the IGHV genes, IGHD genes, and IGHJ genes. These genes include (as shown in the following order): immunoglobulin weight constant mu (IGHM), immunoglobulin weight constant delta (IGHδ), immunoglobulin weight constant gamma 3 (IGHG3), immunoglobulin weight constant gamma 1 (IGHG1), immunoglobulin weight constant gamma 2b (IGHG2b), immunoglobulin weight constant gamma 2a (IGHG2a), immunoglobulin weight constant epsilon (IGHE), and immunoglobulin weight constant alpha (IGHA) genes. These genes and the order of these genes are also shown in Fig.15 middle.

[0145] Table 5. List of IGHD genes on mouse chromosome 12

[0146] Gene name order Gene name order Gene name order IGHD5-1 183 IGHD2-5 191 IGHD5-5 198 IGHD3-1 184 IGHD5-3 192 IGHD2-8 199 IGHD1-1 185 IGHD5-7 193 IGHD5-6 200 IGHD6-1 186 IGHD2-6 194 IGHD3-2 201 IGHD2-3 187 IGHD5-4 195 IGHD4-1 202 IGHD6-2 188 IGHD5-8 196 IGHD2-4 189 IGHD2-7 197

[0147] Table 6. List of IGHJ genes on mouse chromosome 12

[0148]

[0149]

[0150] The present disclosure provides a genetically modified non-human animal comprising one or more human IGHV genes, one or more human IGHD genes and / or one or more human IGHJ genes. In some embodiments, these human IGHV genes, human IGHD genes and human IGHJ genes are operably linked together and can undergo VDJ rearrangement. In some embodiments, these human IGHV genes, human IGHD genes and human IGHJ genes are located at an endogenous heavy chain immunoglobulin locus.

[0151] In some embodiments, the animal comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, or 161 human IGHV genes (e.g., as shown in Table 1).

[0152] In some embodiments, the animal comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 genes selected from IGHV(III)-82, IGHV7-81, IGHV4-80, IGHV3-79, IGHV(II)-78-1, IGHV5-78, IGHV7-77, IGHV(III)-76-1, IGHV3-76 and IGHV3-75.

[0153] In some embodiments, the animal comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 genes selected from IGHV(III)-5-2, IGHV(III)-5-1, IGHV2-5, IGHV7-4-1, IGHV4-4, IGHV1-3, IGHV(III)-2-1, IGHV1-2, IGHV(II)-1-1 and IGHV6-1.

[0154] In some embodiments, the animal comprises an unmodified human sequence comprising a sequence starting with a gene selected from the group consisting of IGHV(III)-82, IGHV7-81, IGHV4-80, IGHV3-79, IGHV(II)-78-1, IGHV5-78, IGHV7-77, IGHV(III)-76-1, IGHV3-76, and IGHV3-75, and ending at a gene selected from the group consisting of IGHV(III)-5-2, IGHV(III)-5-1, IGHV2-5, IGHV7-4-1, IGHV4-4, IGHV1-3, IGHV(III)-2-1, IGHV1-2, IGHV(II)-1-1, and IGHV6-1. In some embodiments, the unmodified human sequence is derived from the human heavy chain immunoglobulin locus starting from human IGHV (III) -82 to human IGHV1-2. In some embodiments, the unmodified human sequence is derived from the human heavy chain immunoglobulin locus starting from human IGHV (III) -82 to human IGHV (II) -1-1. In some embodiments, the unmodified human sequence is derived from the human heavy chain immunoglobulin locus starting from human IGHV (III) -82 to human IGHV-6-1.

[0155] In some embodiments, the animal comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 human IGHD genes (e.g., as shown in Table 2). In some embodiments, the animal comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 genes selected from IGHD1-1, IGHD2-2, IGHD3-3, IGHD4-4, IGHD5-5, IGHD4-23, IGHD5-24, IGHD6-25, IGHD1-26, and IGHD7-27.

[0156] In some embodiments, the animal comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, or 9 human IGHJ genes (e.g., genes as shown in Table 3). In some embodiments, the animal comprises 1, 2, 3, 4, 5, 6, 7, 8, or 9 human IGHJ genes selected from IGHJ1P, IGHJ1, IGHJ2, IGHJ2P, IGHJ3, IGHJ4, IGHJ5, IGHJ3P, and IGHJ6.

[0157] In some embodiments, the animal comprises an unmodified human sequence comprising a sequence starting from a gene selected from the group consisting of IGHD1-1, IGHD2-2, IGHD3-3, IGHD4-4, IGHD5-5, IGHD4-23, IGHD5-24, IGHD6-25, IGHD1-26, and IGHD7-27, and ending at a gene selected from the group consisting of IGHJ1P, IGHJ1, IGHJ2, IGHJ2P, IGHJ3, IGHJ4, IGHJ5, IGHJ3P, and IGHJ6. In some embodiments, the unmodified human sequence is derived from a human heavy chain immunoglobulin locus starting from human IGHD1-1 to human IGHJ6.

[0158] In some embodiments, the unmodified human sequence is derived from the human heavy chain immunoglobulin locus starting from human IGHD1-1 to human IGHD7-27.

[0159] In some embodiments, the unmodified human sequence is derived from the human heavy chain immunoglobulin locus starting from human IGHJ1P to human IGHJ6. In some embodiments, the unmodified human sequence is derived from the human heavy chain immunoglobulin locus starting from human IGHJ1 to human IGHJ6.

[0160] In some embodiments, the unmodified human sequence is derived from the human heavy chain immunoglobulin locus starting from human IGHV(III)-82 to human IGHJ6.

[0161] In some embodiments, the unmodified human sequence is derived from the human heavy chain immunoglobulin locus starting from human IGHV1-2 to human IGHJ6. In some embodiments, the unmodified human sequence is derived from the human heavy chain immunoglobulin locus starting from human IGHV(II)-1-1 to human IGHJ6. In some embodiments, the unmodified human sequence is derived from the human heavy chain immunoglobulin locus starting from human IGHV6-1 to human IGHJ6.

[0162] In some embodiments, the animal may have one, two, three, four, five, six, seven, eight, nine, or ten unmodified human sequences. In some embodiments, the unmodified human sequence has a length of about or at least 10 kb, 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb, 100 kb, 200 kb, 300 kb, 400 kb, 500 kb, 600 kb, 700 kb, 800 kb, 900 kb, or 1000 kb.

[0163] In some embodiments, the animal comprises one or more endogenous genes selected from the group consisting of immunoglobulin weight constant mu (IGHM), immunoglobulin weight constant delta (IGHδ), immunoglobulin weight constant gamma 3 (IGHG3), immunoglobulin weight constant gamma 1 (IGHG1), immunoglobulin weight constant gamma 2b (IGHG2b), immunoglobulin weight constant gamma 2a (IGHG2a), immunoglobulin weight constant epsilon (IGHE), and immunoglobulin weight constant alpha (IGHA) genes. In some embodiments, these endogenous genes are operably linked together. In some embodiments, these endogenous genes have the same order as in wild-type animals. In some embodiments, isotype switching (immunoglobulin class switching) can occur in animals.

[0164] In some embodiments, IGHV genes, IGHD genes and / or IGHJ genes are operably linked together. VDJ recombination can occur in these genes and produce functional antibodies. In some embodiments, these genes are arranged in an order similar to the order in the human heavy chain immunoglobulin locus. This arrangement provides a variety of advantages. For example, the arrangement of these genes allows the production of heavy chain variable domains with a diversity that is very similar to the diversity of heavy chain variable domains in humans. Since some random sequences may be inserted into the sequence during VDJ recombination, in some embodiments, a complete human antibody library with no or only minimal modifications can reduce the possibility of inserting non-human sequences during VDJ recombination.

[0165] In some embodiments, the IGHV gene, IGHD gene and / or IGHJ gene are operably linked to one or more genes (e.g., all genes) selected from the group consisting of an IGHM gene, an IGHδ gene, an IGHG3 gene, an IGHG1 gene, an IGHG2b gene, an IGHG2a gene, an IGHE gene, and an IGHA gene.

[0166] In some embodiments, the animal comprises a disruption of an endogenous heavy chain immunoglobulin locus of the animal. In some embodiments, the disruption of the endogenous heavy chain immunoglobulin locus of the animal comprises a deletion of one or more endogenous IGHV genes, one or more endogenous IGHD genes, and one or more endogenous IGHJ genes.

[0167] In some embodiments, the animal is a mouse. The disruption of the animal's endogenous heavy chain immunoglobulin locus comprises a deletion of at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, or 182 mouse IGHV genes (e.g., genes shown in Table 4). In some embodiments, the disruption comprises a deletion of about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mouse IGHV genes selected from IGHV1-86, IGHV1-85, IGHV1-84, IGHV1-83, IGHV1-82, IGHV1-81, IGHV1-80, IGHV1-79, IGHV1-78, and IGHV1-77. In some embodiments, the mouse further comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mouse IGHV genes selected from IGHV1-86, IGHV1-85, IGHV1-84, IGHV1-83, IGHV1-82, IGHV1-81, IGHV1-80, IGHV1-79, IGHV1-78 and IGHV1-77 (e.g., IGHV1-86).

[0168] In some embodiments, the disruption comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 deletions of mouse IGHV genes selected from IGHV5-6, IGHV5-5, IGHV2-3, IGHV6-1, IGHV5-4, IGHV5-3, IGHV2-2, IGHV5-2, IGHV2-1 and IGHV5-1. In some embodiments, the mouse further comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 deletions of mouse IGHV genes selected from IGHV5-6, IGHV5-5, IGHV2-3, IGHV6-1, IGHV5-4, IGHV5-3, IGHV2-2, IGHV5-2, IGHV2-1 and IGHV5-1.

[0169] In some embodiments, the disruption of the animal's endogenous heavy chain immunoglobulin locus comprises a deletion of at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mouse IGHD genes (e.g., as shown in Table 5). In some embodiments, the disruption comprises a deletion of about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mouse IGHD genes selected from IGHD5-1, IGHD3-1, IGHD1-1, IGHD6-1, IGHD2-3, IGHD2-7, IGHD2-8, IGHD5-6, IGHD3-2, and IGHD4-1. In some embodiments, the mouse further comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mouse IGHD genes selected from IGHD5-1, IGHD3-1, IGHD1-1, IGHD6-1, IGHD2-3, IGHD2-7, IGHD2-8, IGHD5-6, IGHD3-2, and IGHD4-1.

[0170] In some embodiments, the disruption comprises a deletion of about or at least 1, 2, 3, or 4 mouse IGHJ genes selected from IGHJ1, IGHJ2, IGHJ3, and IGHJ4. In some embodiments, the mouse further comprises about or at least 1, 2, 3, or 4 mouse IGHJ genes selected from IGHJ1, IGHJ2, IGHJ3, and IGHJ4.

[0171] In some embodiments, the disruption of the animal's endogenous heavy chain immunoglobulin locus comprises a deletion of about or at least 500 kb, 600 kb, 700 kb, 800 kb, 900 kb, 1000 kb, 1500 kb, 2000 kb, 2500 kb, or 3000 kb of endogenous sequence.

[0172] In some embodiments, the deleted sequence starts from IGHV1-86 to IGHJ4, starts from IGHV1-85 to IGHJ4, starts from IGHV1-84 to IGHJ4, starts from IGHV1-83 to IGHJ4, or starts from IGHV1-82 to IGHJ4 (e.g., starts from IGHV1-85 to IGHJ4).

[0173] In some embodiments, the animal comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to sequences in a human heavy chain immunoglobulin locus. In some embodiments, the sequence has a length of about or at least 10 kb, 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb, 100 kb, 200 kb, 300 kb, 400 kb, 500 kb, 600 kb, 700 kb, 800 kb, 900 kb, 1000 kb, 1500 kb, 2000 kb, 2500 kb, 3000 kb or 3500 kb. In some embodiments, the sequence starts from human IGHV (III) -82 to IGHV1-2. In some embodiments, the sequence starts from human IGHV7-81 to IGHV1-2. In some embodiments, the sequence starts from human IGHV (II) -1-1 to IGHVJ6. In some embodiments, the sequence starts from human IGHV6-1 to IGHVJ6.

[0174] These human IGHV genes, human IGHD genes and human IGHJ genes are operably linked together and can undergo VDJ rearrangement. In some embodiments, the modified mouse has a complete human IGHV, IGHD and IGHJ gene library (e.g., including all non-pseudo-human IGHV genes, IGHD genes and IGHJ genes). Therefore, the modified mouse can produce a complete human antibody library. In some embodiments, after VDJ recombination, an IGHV gene (e.g., IGHV3-21 or IGHV3-74) constitutes a sequence encoding an antibody heavy chain variable region. An IGHD gene constitutes a sequence encoding an antibody heavy chain variable region. And an IGHJ gene constitutes a sequence encoding an antibody heavy chain variable region. In some embodiments, the IGHV gene is IGHV3-21 or IGHV3-74.

[0175] Furthermore, in some cases, the entire mouse IGHV gene, IGHD gene, and IGHJ gene (e.g., including all non-pseudogenes) are knocked out, and the heavy chain variable region will not have any sequence encoded by a sequence derived from the mouse, thereby minimizing immunogenicity in humans.

[0176] Genetically modified kappa light chain immunoglobulin locus

[0177] The kappa chain immunoglobulin locus (also referred to as IGK or immunoglobulin kappa locus) is a region of a chromosome (e.g., human chromosome 2) containing human antibody (or immunoglobulin) light chain genes. Similarly, immunoglobulin light chain genes can also undergo a series of rearrangements, resulting in the production of mature immunoglobulin light chain nucleic acids (e.g., kappa chains).

[0178] The connection of the V segment (also called IGKV gene) and the J segment (also called IGKJ gene) produces a continuous exon encoding the entire light chain variable domain. In unrearranged DNA, the V gene segment (or IGKV gene cluster) is located relatively far away from the C region. The J gene segment (or IGKJ gene cluster) is located close to the C region. The connection of the V segment to the J gene segment also brings the V gene close to the C region sequence. The J gene segment of the rearranged V region is separated from the C region sequence only by introns. In order to prepare a complete immunoglobulin light chain messenger RNA, the V region exons are connected to the C region sequence by RNA splicing after transcription.

[0179] The human light chain immunoglobulin locus is located on human chromosome 2. Table 7 lists the IGKV genes in this locus and their relative order. There are several different groups of human IGKV genes, including IGKV1 genes (including all IGKV genes starting with IGKV1, also known as VκI), IGKV2 genes (including all IGKV genes starting with IGKV2, also known as VκII), IGKV3 genes (including all IGKV genes starting with IGKV3, also known as VκIII), IGKV4 genes (including all IGKV genes starting with IGKV4, also known as VκIV), IGKV5 genes (including all IGKV genes starting with IGKV5, also known as VκV), IGKV6 genes (including all IGKV genes starting with IGKV6, also known as VκVI) and IGKV7 genes (including all IGKV genes starting with IGKV7, also known as VκVII).

[0180] These IGKV genes in human chromosome 2 also form two clusters, the proximal Vκ cluster and the distal Vκ cluster. The sequences in the two clusters are similar but not identical. Large segmental duplications of this sequence have occurred since the human lineage diverged from its most recent common ancestor with other great apes.

[0181] Table 7. List of IGKV genes on human chromosome 2

[0182] Gene name order Gene name order Gene name order Gene name order IGKV3D-7 1 IGKV3D-25 21 IGKV2-36 41 IGKV1-16 61 IGKV1D-8 2 IGKV2D-26 22 IGKV1-35 42 IGKV3-15 62 IGKV1D-43 3 IGKV1D-27 23 IGKV3-34 43 IGKV2-14 63 IGKV1D-42 4 IGKV2D-28 24 IGKV1-33 44 IGKV1-13 64 IGKV2D-10 5 IGKV2D-29 25 IGKV1-32 45 IGKV1-12 65 IGKV3D-11 6 IGKV2D-30 26 IGKV3-31 46 IGKV3-11 66 IGKV1D-12 7 IGKV3D-31 27 IGKV2-30 47 IGKV2-10 67 IGKV1D-13 8 IGKV1D-32 28 IGKV2-29 48 IGKV1-9 68 IGKV2D-14 9 IGKV1D-33 29 IGKV2-28 49 IGKV1-8 69 IGKV3D-15 10 IGKV3D-34 30 IGKV1-27 50 IGKV3-7 70 IGKV1D-16 11 IGKV1D-35 31 IGKV2-26 51 IGKV1-6 71 IGKV1D-17 12 IGKV2D-36 32 IGKV3-25 52 IGKV1-5 72 IGKV6D-41 13 IGKV1D-37 33 IGKV2-24 53 IGKV2-4 73 IGKV2D-18 14 IGKV2D-38 34 IGKV2-23 54 IGKV7-3 74 IGKV2D-19 15 IGKV1D-39 35 IGKV1-22 55 IGKV5-2 75 IGKV3D-20 16 IGKV2D-40 36 IGKV6-21 56 IGKV4-1 76 IGKV6D-21 17 IGKV2-40 37 IGKV3-20 57 IGKV1D-22 18 IGKV1-39 38 IGKV2-19 58 IGKV2D-23 19 IGKV2-38 39 IGKV2-18 59 IGKV2D-24 20 IGKV1-37 40 IGKV1-17 60

[0183] Table 8 lists all IGKJ genes on human chromosome 2 and their relative order. The immunoglobulin kappa constant (IGKC) gene encoding the light chain immunoglobulin constant domain is located after the IGKV gene and the IGKJ gene. These genes and the order of these genes are also shown in Fig.16 middle.

[0184] Table 8. List of IGKJ genes on human chromosome 2

[0185] Gene name order Gene name order IGKJ1 77 IGKJ4 80 IGKJ2 78 IGKJ5 81 IGKJ3 79

[0186] The mouse light chain immunoglobulin locus is located on mouse chromosome 6. Table 9 lists the IGKV genes in this locus and their relative order.

[0187] Table 9. List of IGKV genes on mouse chromosome 6

[0188]

[0189]

[0190] Gm9728 and Amd-ps2 are also located in this locus. The relative order of Gm9728 is 4, and the relative order of Amd-ps2 is 134. Table 10 lists all IGKJ genes on mouse chromosome 6 and their relative order. The IGKC gene encoding the constant domain of light chain immunoglobulins is located after the IGKV gene and the IGKJ gene. These genes and the order of these genes are also shown in Fig.17 middle.

[0191] Table 10. List of IGKJ genes on mouse chromosome 6

[0192] Gene name order Gene name order IGKJ1 166 IGKJ4 169 IGKJ2 167 IGKJ5 170 IGKJ3 168

[0193] The present disclosure provides a genetically modified non-human animal comprising one or more human IGKV genes and / or one or more human IGKJ genes. In some embodiments, the human IGKV gene and the human IGKJ gene are operably linked together and can undergo VJ rearrangement. In some embodiments, the human IGKV gene and the human IGKJ gene are located at an endogenous light chain immunoglobulin locus.

[0194] In some embodiments, the animal comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, or 76 human IGKV genes (e.g., as shown in Table 7).

[0195] In some embodiments, the animal comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 genes selected from IGKV3D-7, IGKV1D-8, IGKV1D-43, IGKV1D-42, IGKV2D-10, IGKV3D-11, IGKV1D-12, IGKV1D-13, IGKV2D-14, and IGKV3D-15.

[0196] In some embodiments, the animal comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 genes selected from IGKV2-10, IGKV1-9, IGKV1-8, IGKV3-7, IGKV1-6, IGKV1-5, IGKV2-4, IGKV7-3, IGKV5-2, and IGKV4-1.

[0197] In some embodiments, the animal comprises about or at least 1, 2, 3, 4, or 5 human IGKJ genes (e.g., genes shown in Table 3). In some embodiments, the animal comprises 1, 2, 3, 4, or 5 human IGKJ genes selected from IGKJ1, IGKJ2, IGKJ3, IGKJ4, and IGKJ5.

[0198] In some embodiments, the animal comprises endogenous IGKC. In some embodiments, IGKV gene and / or IGKJ gene are operably linked together. VJ recombination can occur in these genes and produce functional antibodies. In some embodiments, these genes are arranged in an order similar to the order in the human light chain immunoglobulin locus. This arrangement provides multiple advantages, for example, the arrangement of these genes allows the production of light chain variable domains with a diversity very similar to the diversity of light chain variable domains in humans.

[0199] In some embodiments, an IGKV gene and / or an IGKJ gene is operably linked to an IGKC gene (eg, an endogenous IGKC gene).

[0200] In some embodiments, the animal comprises a disruption of an endogenous light chain immunoglobulin locus in the animal. In some embodiments, the disruption of the endogenous light chain immunoglobulin locus in the animal comprises a deletion of one or more endogenous IGKV genes and one or more endogenous IGKJ genes.

[0201] In some embodiments, the animal is a mouse. The disruption of the animal's endogenous heavy chain immunoglobulin locus comprises a deletion of at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, or 163 mouse IGKV genes (e.g., genes shown in Table 9). In some embodiments, the disruption comprises a deletion of about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mouse IGKV genes selected from IGKV2-137, IGKV1-136, IGKV1-135, IGKV14-134-1, IGKV17-134, IGKV1-133, IGKV1-132, IGKV1-131, IGKV14-130, and IGKV9-129. In some embodiments, the mouse further comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mouse IGKV genes selected from IGKV2-137, IGKV1-136, IGKV1-135, IGKV14-134-1, IGKV17-134, IGKV1-133, IGKV1-132, IGKV1-131, IGKV14-130 and IGKV9-129.

[0202] In some embodiments, the disruption comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 deletions of mouse IGKV genes selected from IGKV3-10, IGKV3-9, IGKV3-8, IGKV3-7, IGKV3-6, IGKV3-5, IGKV3-4, IGKV3-3, IGKV3-2 and IGKV3-1. In some embodiments, the mouse further comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 deletions of mouse IGKV genes selected from IGKV3-10, IGKV3-9, IGKV3-8, IGKV3-7, IGKV3-6, IGKV3-5, IGKV3-4, IGKV3-3, IGKV3-2 and IGKV3-1.

[0203] In some embodiments, the disruption comprises a deletion of about or at least 1, 2, 3, 4, or 5 mouse IGKJ genes selected from IGKJ1, IGKJ2, IGKJ3, IGKJ4, and IGKJ5. In some embodiments, the mouse further comprises about or at least 1, 2, 3, 4, or 5 mouse IGKJ genes selected from IGKJ1, IGKJ2, IGKJ3, IGKJ4, and IGKJ5 (e.g., IGKJ5).

[0204] In some embodiments, the disruption of the animal's endogenous kappa light chain immunoglobulin locus comprises a deletion of about or at least 500 kb, 600 kb, 700 kb, 800 kb, 900 kb, 1000 kb, 1500 kb, 2000 kb, 2500 kb, 3000 kb, or 3500 kb of endogenous sequence.

[0205] In some embodiments, the deleted sequence starts from IGKV2-137 to IGKJ4, starts from IGKV1-136 to IGKJ4, starts from IGKV1-135 to IGKJ4, starts from IGKV2-137 to IGKJ5, starts from IGKV1-136 to IGKJ5, or starts from IGKV1-135 to IGKJ5 (e.g., from IGKV2-137 to IGKJ5).

[0206] In some embodiments, the animal comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to sequences in a human light chain immunoglobulin locus. In some embodiments, the sequence has a length of about or at least 10 kb, 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb, 100 kb, 200 kb, 300 kb, 400 kb, 500 kb, 600 kb, 700 kb, 800 kb, 900 kb, 1000 kb, 1500 kb, 2000 kb, 2500 kb, 3000 kb, or 3500 kb.

[0207] In some embodiments, the animal may have one, two, three, four, five, six, seven, eight, nine, or ten unmodified human sequences. In some embodiments, the unmodified human sequence has a length of about or at least 10 kb, 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb, 100 kb, 200 kb, 300 kb, 400 kb, 500 kb, 600 kb, 700 kb, 800 kb, 900 kb, 1000 kb, 1500 kb, 2000 kb, 2500 kb, 3000 kb, or 3500 kb.

[0208] In some embodiments, the sequence starts from human IGKV3D-7 to IGKJ5. In some embodiments, the sequence starts from human IGKV3D-7 to IGKJ4. In some embodiments, the sequence starts from human IGKV1D-8 to IGKJ5. In some embodiments, the sequence starts from human IGKV1D-8 to IGKJ4.

[0209] Human IGKV gene and human IGKJ gene are operably connected together and can undergo VJ rearrangement. In some embodiments, the modified mouse has a complete human IGKV and IGKJ gene library (for example, including all non-pseudo-human IGKV genes and IGKJ genes). Therefore, the modified mouse can produce a complete human antibody library. In some embodiments, after VJ recombination, an IGKV gene (for example, IGKV1D-43, IGKV1D-13, IGKV1D-16 or IGKV1D-12) constitutes a sequence encoding an antibody light chain variable region. A human IGKJ gene constitutes a sequence encoding an antibody light chain variable region. In some embodiments, the IGKV gene is IGKV1D-43, IGKV1D-13, IGKV1D-16 or IGKV1D-12. Furthermore, in some cases, the entire mouse IGKV gene and IGKJ gene (all non-pseudogenes) are knocked out and the light chain variable region will not have any sequence encoded by mouse-derived sequences, thereby minimizing immunogenicity in humans.

[0210] In some embodiments, the human proximal Vκ cluster IGKV gene is included in the modified chromosome. In some embodiments, the human distal Vκ cluster IGKV gene is included in the modified chromosome. In some embodiments, the human proximal Vκ cluster IGKV gene and the human distal Vκ cluster IGKV gene are both included in the modified chromosome.

[0211] Genetically modified lambda light chain immunoglobulin locus

[0212] The lambda chain immunoglobulin locus (also referred to as IGL or immunoglobulin lambda locus) is a region on a chromosome (e.g., human chromosome 22) containing human antibody (or immunoglobulin) light chain genes. Similarly, immunoglobulin light chain genes can also undergo a series of rearrangements, resulting in the production of mature immunoglobulin light chain nucleic acids (e.g., lambda chains). In healthy human individuals, the ratio of total κ ​​to λ in serum is approximately 2:1 (measurement of intact whole antibodies), or 1:1.5 if free light chains are measured. In mice, the ratio of total κ ​​to λ is approximately 9:1.

[0213] In some embodiments, the animal comprises a human lambda chain immunoglobulin locus.

[0214] In some embodiments, the animal comprises a disruption of an endogenous lambda light chain immunoglobulin locus in the animal. In some embodiments, the disruption of the endogenous light chain immunoglobulin locus of the animal comprises a deletion of one or more endogenous IGLV genes, one or more endogenous IGLJ genes, and / or one or more immunoglobulin lambda constant (IGLC) genes (e.g., IGLC1, IGLC2, IGLC3, and IGLC4).

[0215] The mouse lambda light chain immunoglobulin locus (IGL locus) is located on mouse chromosome 16. Table 11 lists the IGLV gene, IGLJ gene and IGLC gene in this locus and their relative order.

[0216] Table 11. List of genes at the mouse IGL locus

[0217]

[0218] The destruction of the endogenous lambda light chain immunoglobulin locus of the animal comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mouse IGLV genes, IGLJ genes and IGLC genes (e.g., genes as shown in Table 11). In some embodiments, the deletion comprises about or at least 1, 2, 3 or 4 mouse IGKC genes selected from IGLC1, IGLC2, IGLC3 and IGLC4. In some embodiments, the destruction comprises about or at least 1, 2 or 3 mouse IGLV genes selected from IGLV1, IGLV2 and IGLV3. In some embodiments, the destruction comprises about or at least 1, 2, 3, 4 or 5 mouse IGLJ genes selected from IGLJ1, IGLJ2, IGLJ3, IGLJ3P and IGLJ4.

[0219] In some embodiments, the disruption of the animal's endogenous lambda light chain immunoglobulin locus comprises a deletion of about or at least 10 kb, 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 70 kb, 80 kb, 90 kb, 100 kb, 110 kb, 120 kb, 130 kb, 140 kb, 150 kb, 160 kb, 170 kb, 180 kb, 190 kb, 200 kb, 210 kb, 220 kb, 230 kb, 240 kb, 250 kb, 260 kb, 270 kb, 280 kb, 290 kb, 300 kb, 350 kb, 400 kb, 450 kb, 500 kb, or 1000 kb of nucleotides. In some embodiments, there is no disruption in the animal's endogenous lambda light chain immunoglobulin gene.

[0220] In some embodiments, the deleted sequence starts from IGLV2 to IGLC1, starts from IGLV3 to IGLC1, or starts from IGLJ2 ​​to IGLC1.

[0221] Major histocompatibility complex

[0222] The major histocompatibility complex (MHC) plays a key role in the body's defense mechanism induced by T cell immune response by presenting antigenic peptides of cancer or virus origin. MHC is divided into class I or class II. Class I is expressed in all somatic cells except germ cells and erythrocytes. The MHC class I protein complex consists of an alpha chain (alpha chain or heavy chain) and a smaller chain called beta 2 microglobulin (B2M). The alpha chain consists of the alpha1 and alpha2 domains associated with the formation of the antigen peptide-holding groove and the alpha3 domain associated with binding to the co-receptor CD8 molecule expressed on the surface of cytotoxic T cells (CTLs). Like MHC class I molecules, class II molecules are also heterodimers and have two peptide chains, alpha and beta.

[0223] Both humans and mice have MHC class I and class II genes. In humans, the classical class I genes are called HLA-A, HLA-B and HLA-C, while in mice they are H-2K, H-2D and H-2L. In class I molecules, the α chain (also referred to as the heavy chain) has polymorphism, and the smaller chain B2M (also referred to as the light chain) is usually not polymorphic. The α chain contains three domains (α1, α2 and α3). Typically, exon 1 of the α chain gene encodes a leader sequence, exons 2 and 3 encode α1 and α2 domains, exon 4 encodes α3 domains, exon 5 encodes a transmembrane domain, and exons 6 and 7 encode a cytoplasmic tail region. The α chain forms a peptide binding groove that involves α1 and α2 domains (which are similar to Ig-like domains), followed by an α3 domain, which is similar to β2-microglobulin.

[0224] Class I MHC is expressed on all nucleated cells (including tumor cells). They are specifically expressed on cells such as T and B lymphocytes, macrophages, dendritic cells and neutrophils, and function to display peptide fragments (usually 8-10 amino acids in length) on the surface of CD8+ cytotoxic T lymphocytes (CTL). CTL is specialized to kill any cell with MHC I binding peptides recognized by its own membrane-bound TCR. When cells display peptides derived from cell proteins that do not normally exist (e.g., viruses, tumors or other non-self sources), such peptides are recognized by CTL, and CTL is activated and kills the cells displaying the peptides.

[0225] The present disclosure relates to genetically modified animals expressing human or chimeric (e.g., humanized) MHC protein complexes, MHC class I polypeptides, or B2Ms. As used herein, the term "MHC I complex" or "MHC class I complex" refers to a complex formed by an MHC I α chain polypeptide and a B2M polypeptide. In some embodiments, the MHC I α chain polypeptide and the B2M polypeptide are fused together. As used herein, the term "MHC I polypeptide" or "MHC class I polypeptide" refers to a single MHC I α chain polypeptide.

[0226] β2 microglobulin (B2M)

[0227] As mentioned above, the wild-type MHC class I molecule is a heterodimer composed of two polypeptide chains, α and β2-microglobulin (B2M). The two chains are non-covalently linked by the interaction of the B2M and α3 domains. Only the α chain is polymorphic and is encoded by the HLA gene. The B2M subunit is not polymorphic and is encoded by the B2M gene. The α3 domain spans the plasma membrane and interacts with the CD8 co-receptor of T cells. The α3-CD8 interaction holds the MHC I molecule in place, while the T cell receptor (TCR) on the surface of the cytotoxic T cell binds its α1-α2 heterodimer ligand and checks the antigenicity of the coupled peptide. The α1 and α2 domains fold to form a groove for peptide binding. MHC class I molecules bind peptides that are mainly 8-10 amino acids in length.

[0228] B2M (also known as β2M, β2 microglobulin, or beta-2 microglobulin) is a small protein (approximately 11,800 daltons) present in almost all nucleated cells and in most biological fluids, including serum, urine, and synovial fluid. Human β2M shows 70% amino acid sequence similarity to the murine protein, and both are located on syntenic chromosomes. The secondary structure of B2M consists of seven β strands organized into two β sheets connected by a single disulfide bond, presenting the classic β-sandwich typical of immunoglobulin (Ig) domains. B2M has no transmembrane region and contains a unique molecular structure known as the constant-1 Ig superfamily domain, shared with other adaptive immune molecules, including major histocompatibility complex (MHC) class I and class II. Two evolutionarily conserved tryptophan (Trp) residues are important for the correct structural folding and function of B2M. Trp60 is exposed to the solvent at the apex of the protein loop and is essential for promoting the binding of B2M in MHC I.

[0229] Typically, B2M is non-covalently linked to other polypeptide chains (α chains) to form MHC I or similar structures, including MHC I, neonatal Fc receptor (FcRn), differentiation cluster 1 (CD1), human hemochromatin (HFE), Qa, etc. B2M contacts all three domains of the α chain extensively. Therefore, the conformation of the α chain is highly dependent on the presence of B2M. Although the α1 domain and the α2 domain are different between molecules, the α3 domain and B2M are relatively conservative, where intermolecular interactions occur. Many residues at the B2M contact points are common to MHC I or similar molecules. In addition, in the presence of natural antigens, interactions with the α1 domain and the α2 domain are important for the pairing of the α3 domain and B2M. B2M can be separated from such molecules and shed into the serum, where it is transported to the kidneys for degradation and excretion. The 88kD protein (calnexin) rapidly and quantitatively binds to newly synthesized mouse MHC I molecules in the endoplasmic reticulum. Both B2M and peptide are required for efficient calnexin dissociation and subsequent MHC I transport.

[0230] B2M can stabilize the tertiary structure of MHC I or similar molecules. It is also widely involved in the functional regulation of cancer cell survival, proliferation, apoptosis and even metastasis.

[0231] A detailed description of B2M and its functions can be found in, for example, Li et al., "The implication and significance of beta2microglobulin: A conservative multifunctional regulator.", Chinese Medical Journal 129.4 (2016): 448; and Wang et al., "Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells," Stem Cells Translational Medicine 4.10 (2015): 1234-1245; each of these documents is incorporated herein by reference in its entirety.

[0232] In the human genome, the B2M gene (gene ID: 567) locus has four exons, namely exon 1, exon 2, exon 3 and exon 4. The B2M protein also has a signal peptide. The nucleotide sequence of human B2M mRNA is NM_004048.4, and the amino acid sequence of human B2M is NP_004039.1 (SEQ ID NO: 56). The position of each exon and each region in the human B2M nucleotide sequence and amino acid sequence is listed below.

[0233] Table 12

[0234]

[0235] The human B2M gene (Gene ID: 567) is located at 44,711,487 to 44,718,877 (GRCh38.p13 (GCF_000001405.39)) in chromosome 15 of the human genome. Based on transcript NM_004048.3, the 5'-UTR is 44,711,517 to 44,711,546, exon 1 is 44,711,614 to 44,711,613, the first intron is 44,711,614 to 44,715,422, exon 2 is 44,715,423 to 44,715,701, and the second intron is 44,715,702 to 44,715,703. 44,716,328, exon 3 is 44,716,329 to 44,716,356, the third intron is 44,716,357 to 44,717,606, exon 4 is 44,717,607 to 44,718,145, and the 3'-UTR is 44,716,343 to 44,716,356 and 44,717,607 to 44,718,145. All relevant information on the human B2M locus can be found on the NCBI website with gene ID: 567, which is incorporated herein by reference in its entirety.

[0236] In mice, the B2M locus has four exons, namely exon 1, exon 2, exon 3 and exon 4. The mouse B2M protein also has a signal peptide. The nucleotide sequence of mouse B2M mRNA is NM_009735.3, and the amino acid sequence of mouse B2M is NP_033865.2 (SEQ ID NO: 57). The position of each exon and each region in the mouse B2M nucleotide sequence and amino acid sequence is listed as follows:

[0237] Table 13

[0238]

[0239] The mouse B2M gene (Gene ID: 12010) is located at 122,147,686 to 122,153,083 of NC_000068.7 on chromosome 2 of the mouse genome (GRCm38.p6 (GCF_000001635.26)). Based on transcript NM_009735.3, the 5'-UTR is 122,147,686 to 122,147,736, exon 1 is 122,147,686 to 122,147,804, the first intron is 122,147,805 to 122,150,872, exon 2 is 122,150,873 to 122,151,151, and the second intron is 122,151,152 to 122,151,646, exon 3 is 122,151,647 to 122,151,675, the third intron is 122,151,676 to 122,152,650, exon 4 is 122,152,651 to 122,153,083, and the 3'-UTR is 122,151,661 to 122,153,083. All relevant information of the mouse B2M locus can be found on the NCBI website with gene ID: 12010, which is incorporated herein by reference in its entirety.

[0240] B2M genes, proteins and loci of other species are also known in the art. For example, the gene ID of B2M in Rattus norvegicus (rat) is 24223, the gene ID of B2M in Macaca mulatta (rhesus monkey) is 712428, the gene ID of B2M in Equus caballus (horse) is 100034203, and the gene ID of B2M in Sus scrofa (pig) is 397033. The relevant information of these genes (e.g., intron sequences, exon sequences, amino acid residues of these proteins) can be found in, for example, the NCBI database, which is incorporated herein by reference in its entirety.

[0241] The present disclosure provides people or chimeric (e.g., humanized) B2M nucleotide sequences and / or amino acid sequences. In some embodiments, the entire sequence of mouse exon 1, exon 2, exon 3, exon 4 and / or signal peptide is replaced by a corresponding human sequence. In some embodiments, a "region" or "part" of mouse exon 1, exon 2, exon 3, exon 4 and / or signal peptide is replaced by a corresponding human sequence. The term "region" or "portion" may refer to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 500, or 600 nucleotides, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 110 amino acid residues. In some embodiments, a "region" or "portion" may be at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to exon 1, exon 2, exon 3, exon 4 or a signal peptide. In some embodiments, a region, portion or the entire sequence of mouse exon 1, exon 2, exon 3 and / or exon 4 (e.g., a portion of exon 1, exon 2, and a portion of exon 3) is replaced by a region, portion or the entire sequence of a human exon 1, exon 2, exon 3 and / or exon 4 (e.g., a portion of exon 1, exon 2, and a portion of exon 3).

[0242] In some embodiments, the disclosure relates to a genetically modified non-human animal, whose genome comprises a chimeric (e.g., humanized) B2M nucleotide sequence. In some embodiments, a chimeric (e.g., humanized) B2M nucleotide sequence encodes a B2M protein comprising a signal peptide. In some embodiments, the signal peptide described herein is at least 80%, 85%, 90%, 95% or 100% identical to the amino acid 1-22 of SEQ ID NO:56. In some embodiments, the signal peptide described herein is at least 80%, 85%, 90%, 95% or 100% identical to the amino acid 1-22 of SEQ ID NO:57. In some embodiments, the humanized protein has a sequence at least 80%, 85%, 90%, 95% or 100% identical to the amino acid 1-119 or 23-119 of SEQ ID NO:56. In some embodiments, the humanized protein has a sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to amino acids 1-119, 23-119, or 21-119 of SEQ ID NO:57.

[0243] In some embodiments, the present disclosure also provides chimeric (e.g., humanized) B2M nucleotide sequences and / or amino acid sequences, wherein in some embodiments, at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% of the sequence is identical to a mouse B2M mRNA sequence, a mouse B2M amino acid sequence (e.g., SEQ ID NO:57) or a portion thereof (e.g., a portion of exon 1, exon 2, and a portion of exon 3) is identical or derived from them; and in some embodiments, at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% of the sequence is identical or derived from human B2M mRNA sequence, human B2M amino acid sequence (e.g., SEQ ID NO:56) or a portion thereof (e.g., a portion of exon 1, exon 2, and a portion of exon 3).

[0244] In some embodiments, the sequence encoding the mouse B2M region (e.g., amino acids 1-119 of SEQ ID NO: 57) is replaced. In some embodiments, the sequence is replaced by a sequence encoding the corresponding region of human B2M (e.g., amino acids 1-119 of human B2M (SEQ ID NO: 56)).

[0245] In some embodiments, a nucleic acid as described herein is operably linked to a promoter or regulatory element, for example, an endogenous mouse B2M promoter, an inducible promoter, an enhancer, and / or mouse or human regulatory elements.

[0246] In some embodiments, the nucleic acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides, e.g., consecutive or non-consecutive nucleotides) that is different from part or all of a mouse B2M nucleotide sequence (e.g., exon 1, exon 2, exon 3, exon 4, or NM_009735.3).

[0247] In some embodiments, the nucleic acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides, e.g., consecutive or non-consecutive nucleotides) that is identical to part or all of a mouse B2M nucleotide sequence (e.g., exon 1, exon 2, exon 3, exon 4, or NM_009735.3).

[0248] In some embodiments, the nucleic acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides, e.g., consecutive or non-consecutive nucleotides) that is different from part or all of the human B2M nucleotide sequence (e.g., exon 1, exon 2, exon 3, exon 4, or NM_004048.4).

[0249] In some embodiments, the nucleic acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides, e.g., consecutive or non-consecutive nucleotides) that is identical to part or all of a human B2M nucleotide sequence (e.g., exon 1, exon 2, exon 3, exon 4, or NM_004048.4).

[0250] In some embodiments, the amino acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, e.g., consecutive or non-consecutive amino acid residues) that is different from part or all of the mouse B2M amino acid sequence (e.g., amino acids encoded by exon 1, exon 2, exon 3 and / or exon 4 of NM_009735.3 or NP_033865.2 (SEQ ID NO: 57)).

[0251] In some embodiments, the amino acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, e.g., consecutive or non-consecutive amino acid residues) that is identical to part or all of a mouse B2M amino acid sequence (e.g., amino acids encoded by exon 1, exon 2, exon 3 and / or exon 4 of NM_009735.3 or NP_033865.2 (SEQ ID NO: 57)).

[0252] In some embodiments, the amino acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, e.g., consecutive or non-consecutive amino acid residues) that is different from part or all of the human B2M amino acid sequence (e.g., amino acids encoded by exon 1, exon 2, exon 3 and / or exon 4 of NM_004048.4 or NP_004039.1 (SEQ ID NO: 56)).

[0253] In some embodiments, the amino acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, e.g., consecutive or non-consecutive amino acid residues) that is identical to part or all of the human B2M amino acid sequence (e.g., amino acids encoded by exon 1, exon 2, exon 3 and / or exon 4 of NM_004048.4 or NP_004039.1 (SEQ ID NO: 56)).

[0254] Human Leukocyte Antigen (HLA)

[0255] Human leukocyte antigens (HLA) corresponding to MHC class I molecules include, for example, HLA-A, HLA-B, and HLA-C. Human HLA corresponding to MHC class II molecules include, for example, HLA-DP, HLA-DM, HLA-DO, HLA-DQ, and HLA-DR.

[0256] Human HLA-A can have many serotype groups, such as HLA-A1 and HLA-A*02. For HLA-A1 (A1), the serotype is determined by antibody recognition of the α1 subtype of the HLA-A α chain. For A1, the α chain is encoded by the HLA-A*01 allele group, and the β chain is encoded by the B2M locus. This group is currently dominated by A*0101 (A*01:01:01:01). For HLA-A*02 (HLA-A2), the serotype is determined by antibody recognition of the α2 domain of the HLA-A α chain. For A*02, the α chain is encoded by the HLA-A*02 gene, and the β chain is encoded by the B2M locus. The subtype of HLA-A2 is HLA-A2.1. Details of HLA nomenclature can be found in, e.g., Marsh, SG et al., “Nomenclature for factors of the HLA system, 2010.”, Tissue antigens 75.4 (2010): 291, which is incorporated herein by reference in its entirety.

[0257] In the human genome, a typical HLA-A locus has eight exons, namely exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7 and exon 8. The HLA protein also has a signal peptide, an extracellular region, a transmembrane region and a cytoplasmic region. In addition, the extracellular region includes an α1 domain, an α2 domain, an α3 domain and a connecting peptide. The nucleotide sequence of human HLA-A*0101 mRNA is NM_001242758.1, and the amino acid sequence of human HLA-A*0101 is NP_001229687.1 (SEQID NO: 58). In addition, the nucleotide sequence of human HLA-A is nucleic acid 95493-99436 of AF055066.1, and the amino acid sequence of human HLA-A is AAC24825.1 (SEQ ID NO: 59). The position of each exon and each region in the human HLA-A nucleotide sequence and amino acid sequence are listed below.

[0258] Table 14

[0259]

[0260] The human MHC class I region (GenBank ID: AF055066.1) is located in chromosome 6 of the human genome. The human HLA-A gene is located at 95493 to 99436 of AF055066.1. Based on AF055066.1, exon 1 is 99566 to 99629, the first intron is 99436 to 99565, exon 2 is 99166 to 99435, the second intron is 98925 to 99165, exon 3 is 98649 to 98924, the third intron is 98049 to 98648, exon 4 is 97773 to 98048, and the fourth intron is 97674 to 98924. 97772, exon 5 is 97557 to 97673, the fifth intron is 97119 to 97556, exon 6 is 97086 to 97118, the sixth intron is 97085 to 96944, exon 7 is 96896 to 96943, the seventh intron is 96727 to 96895, exon 8 is 96726 to 96322, and the 3'-UTR is 96721 to 96322. All relevant information of the human HLA-A locus can be found on the NCBI website with GenBank ID: AF055066.1, which is incorporated herein by reference in its entirety.

[0261] In some embodiments, the HLA described herein is HLA-A (e.g., HLA-A*0101, HLA-A*0201, HLA-A*0301, HLA-A*0302, HLA-A*1101, HLA-A*2402, HLA-A*2901, HLA-A*3101, HLA-A*3201, HLA-A*3301, or HLA-A*3303), HLA-B (e.g., HLA-B*4402 or HLA-B*0702), or HLA-C (e.g., HLA-C*0702, HLA-C*0102, HLA-C*0701, HLA-C*0401, HLA-C*0801, or HLA-C*0802).

[0262] HLA-A*0101 has an amino acid sequence as shown in SEQ ID NO: 58. Specifically, the signal peptide of HLA-A*0101 corresponds to position 1 to position 24 of SEQ ID NO: 58, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 58, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 58, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 58, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 58, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 58, and the cytoplasmic region corresponds to position 333 to position 365 of SEQ ID NO: 58.

[0263] HLA-A*0201 has an amino acid sequence as shown in SEQ ID NO: 6. Specifically, the signal peptide of HLA-A*0201 corresponds to position 1 to position 24 of SEQ ID NO: 6, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 6, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 6, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 6, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 6, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 6, and the cytoplasmic region corresponds to position 333 to position 365 of SEQ ID NO: 6.

[0264] HLA-A*0301 has an amino acid sequence as shown in SEQ ID NO: 7. Specifically, the signal peptide of HLA-A*0301 corresponds to position 1 to position 24 of SEQ ID NO: 7, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 7, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 7, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 7, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 7, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 7, and the cytoplasmic region corresponds to position 333 to position 365 of SEQ ID NO: 7.

[0265] HLA-A*0302 has an amino acid sequence as shown in SEQ ID NO: 8. Specifically, the signal peptide of HLA-A*0302 corresponds to position 1 to position 24 of SEQ ID NO: 8, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 8, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 8, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 8, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 8, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 8, and the cytoplasmic region corresponds to position 333 to position 365 of SEQ ID NO: 8.

[0266] HLA-A*1101 has an amino acid sequence as shown in SEQ ID NO: 9. Specifically, the signal peptide of HLA-A*1101 corresponds to position 1 to position 24 of SEQ ID NO: 9, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 9, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 9, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 9, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 9, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 9, and the cytoplasmic region corresponds to position 333 to position 365 of SEQ ID NO: 9.

[0267] HLA-A*2402 has an amino acid sequence as shown in SEQ ID NO: 10. Specifically, the signal peptide of HLA-A*2402 corresponds to position 1 to position 24 of SEQ ID NO: 10, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 10, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 10, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 10, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 10, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 10, and the cytoplasmic region corresponds to position 333 to position 365 of SEQ ID NO: 10.

[0268] HLA-A*2901 has an amino acid sequence as shown in SEQ ID NO: 11. Specifically, the signal peptide of HLA-A*2901 corresponds to position 1 to position 24 of SEQ ID NO: 11, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 11, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 11, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 11, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 11, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 11, and the cytoplasmic region corresponds to position 333 to position 365 of SEQ ID NO: 11.

[0269] HLA-A*3101 has an amino acid sequence as shown in SEQ ID NO: 12. Specifically, the signal peptide of HLA-A*3101 corresponds to position 1 to position 24 of SEQ ID NO: 12, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 12, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 12, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 12, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 12, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 12, and the cytoplasmic region corresponds to position 333 to position 365 of SEQ ID NO: 12.

[0270] HLA-A*3201 has an amino acid sequence as shown in SEQ ID NO: 13. Specifically, the signal peptide of HLA-A*3201 corresponds to position 1 to position 24 of SEQ ID NO: 13, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 13, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 13, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 13, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 13, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 13, and the cytoplasmic region corresponds to position 333 to position 365 of SEQ ID NO: 13.

[0271] HLA-A*3301 has an amino acid sequence as shown in SEQ ID NO: 14. Specifically, the signal peptide of HLA-A*3301 corresponds to position 1 to position 24 of SEQ ID NO: 14, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 14, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 14, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 14, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 14, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 14, and the cytoplasmic region corresponds to position 333 to position 365 of SEQ ID NO: 14.

[0272] HLA-C*0802 has an amino acid sequence as shown in SEQ ID NO: 15. Specifically, the signal peptide of HLA-C*0802 corresponds to position 1 to position 24 of SEQ ID NO: 15, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 15, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 15, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 15, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 15, the transmembrane region corresponds to position 309 to position 333 of SEQ ID NO: 15, and the cytoplasmic region corresponds to position 334 to position 366 of SEQ ID NO: 15.

[0273] HLA-A*3303 has an amino acid sequence as shown in SEQ ID NO: 92. Specifically, the signal peptide of HLA-A*3303 corresponds to position 1 to position 24 of SEQ ID NO: 92, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 92, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 92, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 92, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 92, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 92, and the cytoplasmic region corresponds to position 333 to position 365 of SEQ ID NO: 92.

[0274] HLA-B*4402 has an amino acid sequence as shown in SEQ ID NO: 93. Specifically, the signal peptide of HLA-B*4402 corresponds to position 1 to position 24 of SEQ ID NO: 93, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 93, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 93, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 93, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 93, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 93, and the cytoplasmic region corresponds to position 333 to position 362 of SEQ ID NO: 93.

[0275] HLA-B*0702 has an amino acid sequence as shown in SEQ ID NO: 94. Specifically, the signal peptide of HLA-B*0702 corresponds to position 1 to position 24 of SEQ ID NO: 94, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 94, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 94, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 94, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 94, the transmembrane region corresponds to position 309 to position 332 of SEQ ID NO: 94, and the cytoplasmic region corresponds to position 333 to position 362 of SEQ ID NO: 94.

[0276] HLA-C*0702 has an amino acid sequence as shown in SEQ ID NO: 95. Specifically, the signal peptide of HLA-C*0702 corresponds to position 1 to position 24 of SEQ ID NO: 95, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 95, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 95, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 95, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 95, the transmembrane region corresponds to position 309 to position 333 of SEQ ID NO: 95, and the cytoplasmic region corresponds to position 334 to position 366 of SEQ ID NO: 95.

[0277] HLA-C*0102 has an amino acid sequence as shown in SEQ ID NO: 96. Specifically, the signal peptide of HLA-C*0102 corresponds to position 1 to position 24 of SEQ ID NO: 96, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 96, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 96, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 96, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 96, the transmembrane region corresponds to position 309 to position 333 of SEQ ID NO: 96, and the cytoplasmic region corresponds to position 334 to position 366 of SEQ ID NO: 96.

[0278] HLA-C*0701 has an amino acid sequence as shown in SEQ ID NO: 97. Specifically, the signal peptide of HLA-C*0701 corresponds to position 1 to position 24 of SEQ ID NO: 97, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 97, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 97, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 97, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 97, the transmembrane region corresponds to position 309 to position 333 of SEQ ID NO: 97, and the cytoplasmic region corresponds to position 334 to position 366 of SEQ ID NO: 97.

[0279] HLA-C*0401 has an amino acid sequence as shown in SEQ ID NO: 98. Specifically, the signal peptide of HLA-C*0401 corresponds to position 1 to position 24 of SEQ ID NO: 98, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 98, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 98, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 98, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 98, the transmembrane region corresponds to position 309 to position 333 of SEQ ID NO: 98, and the cytoplasmic region corresponds to position 334 to position 366 of SEQ ID NO: 98.

[0280] HLA-C*0801 has an amino acid sequence as shown in SEQ ID NO: 99. Specifically, the signal peptide of HLA-C*0801 corresponds to position 1 to position 24 of SEQ ID NO: 99, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 99, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 99, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 99, the connecting peptide corresponds to position 299 to position 308 of SEQ ID NO: 99, the transmembrane region corresponds to position 309 to position 333 of SEQ ID NO: 99, and the cytoplasmic region corresponds to position 334 to position 366 of SEQ ID NO: 99.

[0281] In mice, H-2K, H-2D and H-2L are MHC class I genes. Specifically, the H2-D1 locus has eight exons, namely exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7 and exon 8. The mouse H2-D1 protein (encoding MHC class I α chain) also has a signal peptide, an extracellular region, a transmembrane region and a cytoplasmic region. Specifically, the extracellular region includes an α1 domain, an α2 domain, an α3 domain and a connecting peptide. The nucleotide sequence of mouse H2-D1 mRNA is NM_010380.3, and the amino acid sequence of mouse H2-D1 is NP_034510.3 (SEQ ID NO: 60). The position of each exon and each region in the mouse H2-D1 nucleotide sequence and amino acid sequence is listed as follows:

[0282] Table 15

[0283]

[0284]

[0285] The mouse H2-D1 gene (Gene ID: 14964; MGI: 95896) is located at 35482070 to 35486473 of NC_000083.7 on chromosome 17 of the mouse genome (GRCm39 (GCF_000001635.27)). Based on transcript NM_010380.3, the 5′-UTR is 35,262,730 to 35,263,113, exon 1 is 35,262,730 to 35,263,186, the first intron is 35,263,187 to 35,263,378, exon 2 is 35,263,379 to 35,263,648, the second intron is 35,263,649 to 35,263,838, exon 3 is 35,263,839 to 35,264,114, the third intron is 35,264,115 to 35,265,783, exon 4 is 35,265,784 to 35,266,059, and the fourth intron is The sequences are 35,266,060 to 35,266,186, exon 5 is 35,266,187 to 35,266,303, the fifth intron is 35,266,304 to 35,266,481, exon 6 is 35,266,482 to 35,266,514, the sixth intron is 35,266,515 to 35,266,687, exon 7 is 35,266,688 to 35,266,726, the seventh intron is 35,266,727 to 35,266,865, exon 8 is 35,266,866 to 35,267,499, and the 3'-UTR is 35,266,871 to 35,267,499. All relevant information for the mouse H2-D1 locus can be found at the NCBI website with Gene ID: 14964, which is incorporated herein by reference in its entirety.

[0286] Mouse H2-D1 has an amino acid sequence as shown in SEQ ID NO: 60. Specifically, the signal peptide of mouse H2-D1 corresponds to position 1 to position 24 of SEQ ID NO: 60, the α1 domain corresponds to position 25 to position 114 of SEQ ID NO: 60, the α2 domain corresponds to position 115 to position 206 of SEQ ID NO: 60, the α3 domain corresponds to position 207 to position 298 of SEQ ID NO: 60, the connecting peptide corresponds to position 299 to position 309 of SEQ ID NO: 60, the transmembrane region corresponds to position 310 to position 331 of SEQ ID NO: 60, and the cytoplasmic region corresponds to position 332 to position 362 of SEQ ID NO: 60.

[0287] MHC molecule genes, proteins and loci of other species are also known in the art. For example, gene IDs of these genes and related information (e.g., intron sequences, exon sequences, amino acid residues of these proteins) can be found in, for example, the NCBI database, which is incorporated herein by reference in its entirety.

[0288] The present disclosure provides human or chimeric (e.g., humanized) MHC molecules (e.g., MHC class I alpha chain) nucleotide sequences and / or amino acid sequences. The present disclosure also relates to genetically modified animals expressing human or chimeric (e.g., humanized) HLA protein complexes and / or HLA polypeptides. As used herein, the term "HLA complex" or "HLA protein complex" refers to a complex formed by an HLA alpha chain polypeptide and a B2M polypeptide. In some embodiments, the HLA alpha chain polypeptide and the B2M polypeptide are fused together. As used herein, the term "HLA" or "HLA polypeptide" refers to an HLA alpha chain polypeptide.

[0289] In some embodiments, the entire sequence of mouse H2-D1 exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, signal peptide, extracellular region (e.g., α1 domain, α2 domain, α3 domain and / or connecting peptide), transmembrane region and / or cytoplasmic region is replaced by the corresponding human sequence. In some embodiments, a "region" or "part" of mouse H2-D1 exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, signal peptide, extracellular region (e.g., α1 domain, α2 domain, α3 domain and / or connecting peptide), transmembrane region and / or cytoplasmic region is replaced by the corresponding human sequence. The term "region" or "portion" may refer to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 500, or 600 nucleotides, or at least 1, 2, 3, 4, 5, 6, 300, 310, 320, 330, 340, 350 or 360 amino acid residues. In some embodiments, a "region" or "portion" may be at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, a signal peptide, an extracellular region (e.g., an α1 domain, an α2 domain, an α3 domain and / or a connecting peptide), a transmembrane region and / or a cytoplasmic region. In some embodiments, a region, portion, or the entire sequence of mouse H2-D1 exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, and / or exon 8 (e.g., exon 1, exon 2, and exon 3) is replaced by a region, portion, or the entire sequence of human HLA (e.g., HLA-A, HLA-B, or HLA-C) exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, and / or exon 8 (e.g., exon 1, exon 2, exon 3) sequences.In some embodiments, the HLA described herein comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to SEQ ID NO:58, 59, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 92, 93, 94, 95, 96, 97, 98, or 99.

[0290] In some embodiments, the present disclosure relates to a genetically modified non-human animal whose genome comprises a chimeric (e.g., humanized) MHC molecule (e.g., human HLA / mouse H2-D1) nucleotide sequence. In some embodiments, the chimeric (e.g., humanized) MHC molecule nucleotide sequence encodes an MHC molecule protein including an extracellular region, a transmembrane region, a cytoplasmic region, and a signal peptide. In some embodiments, the extracellular region includes all or part of the extracellular region of a human HLA (e.g., HLA-A*0101, HLA-A, or any HLA molecule described herein). For example, the extracellular region described herein comprises an amino acid sequence that is at least 80%, 85%, 90%, 95% or 100% identical to the extracellular region of a human HLA (e.g., amino acids 25-308 of SEQ ID NO:58, or amino acids 22-305 of SEQ ID NO:59). In some embodiments, the transmembrane region includes all or part of the transmembrane region of human HLA (e.g., HLA-A*0101, HLA-A, or any HLA molecule described herein). For example, the transmembrane region is at least 80%, 85%, 90%, 95%, or 100% identical to the transmembrane region of human HLA (e.g., amino acids 309-332 of SEQ ID NO: 58, or amino acids 306-329 of SEQ ID NO: 59). In some embodiments, the cytoplasmic region includes all or part of the cytoplasmic region of human HLA (e.g., HLA-A*0101, HLA-A, or any HLA molecule described herein). For example, the cytoplasmic region is at least 80%, 85%, 90%, 95%, or 100% identical to the cytoplasmic region of human HLA (e.g., amino acids 333-365 of SEQ ID NO: 58, or amino acids 330-362 of SEQ ID NO: 59).

[0291] In some embodiments, the chimeric (e.g., humanized) MHC molecule nucleotide sequence encodes an MHC molecule protein comprising a signal peptide. In some embodiments, the signal peptide described herein is at least 80%, 85%, 90%, 95% or 100% identical to amino acids 1-24 of SEQ ID NO: 60. In some embodiments, the signal peptide described herein is at least 80%, 85%, 90%, 95% or 100% identical to amino acids 1-24 of SEQ ID NO: 58 or amino acids 1-21 of SEQ ID NO: 59. In some embodiments, the signal peptide described herein is at least 80%, 85%, 90%, 95% or 100% identical to the signal peptide of any HLA molecule described herein.

[0292] In some embodiments, the present disclosure also provides chimeric (e.g., humanized) MHC molecule nucleotide sequences and / or amino acid sequences, wherein in some embodiments, at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% of the sequence is identical to a mouse H2-D1 mRNA sequence, a mouse H2-D1 amino acid sequence (e.g., SEQ ID NO:60) or a portion thereof (e.g., exon 4, exon 5, exon 6, exon 7, and a portion of exon 8); and in some embodiments, at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% of the sequence is identical to or derived from a human HLA molecule mRNA sequence, a human HLA amino acid sequence (e.g., SEQ ID NO:58, SEQ ID NO:59 or SEQ ID NO: 6-15 and 92-99) or a portion thereof (e.g., a portion of exon 1, exon 2, and exon 3) is identical to or derived from them.

[0293] In some embodiments, the sequence encoding the region of mouse H2-D1 (e.g., amino acids 1-206 or 25-206 of SEQ ID NO: 60) is replaced. In some embodiments, the sequence is replaced by a sequence encoding the corresponding region of human HLA (e.g., amino acids 1-206 or 25-206 of human HLA-A*0101 (SEQ ID NO: 58); or amino acids 1-203 or 22-203 of human HLA-A (SEQ ID NO: 59)).

[0294] In some embodiments, a nucleic acid as described herein is operably linked to a promoter or regulatory element, for example, an endogenous mouse H2-D1 promoter, an inducible promoter, an enhancer, and / or mouse or human regulatory elements.

[0295] In some embodiments, the nucleic acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides, e.g., consecutive or non-consecutive nucleotides) that is different from part or all of a mouse H2-D1 nucleotide sequence (e.g., exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, or NM_010380.3).

[0296] In some embodiments, the nucleic acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides, e.g., consecutive or non-consecutive nucleotides) that is identical to part or all of a mouse H2-D1 nucleotide sequence (e.g., exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, or NM_010380.3).

[0297] In some embodiments, the nucleic acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides, e.g., consecutive or non-consecutive nucleotides) that is different from part or all of a human HLA nucleotide sequence (e.g., exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, or NM_001242758.1).

[0298] In some embodiments, the nucleic acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides, e.g., consecutive or non-consecutive nucleotides) that is identical to part or all of a human HLA nucleotide sequence (e.g., exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, or NM_001242758.1).

[0299] In some embodiments, the amino acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, e.g., consecutive or non-consecutive amino acid residues) that is different from part or all of the mouse H2-D1 amino acid sequence (e.g., amino acids encoded by exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7 and / or exon 8 of NM_010380.3 or NP_034510.3 (SEQ ID NO: 60)).

[0300] In some embodiments, the amino acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, e.g., consecutive or non-consecutive amino acid residues) that is identical to part or all of a mouse H2-D1 amino acid sequence (e.g., amino acids encoded by exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7 and / or exon 8 of NM_010380.3 or NP_034510.3 (SEQ ID NO: 60)).

[0301] In some embodiments, the amino acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, e.g., consecutive or non-consecutive amino acid residues) that is different from part or all of a human HLA amino acid sequence (e.g., amino acids encoded by exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7 and / or exon 8 of NM_001242758.1, NP_001229687.1 (SEQ ID NO: 58) or AAC24825.1 (SEQ ID NO: 59)).

[0302] In some embodiments, the amino acid sequence has at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, e.g., consecutive or non-consecutive amino acid residues) that is identical to part or all of a human HLA amino acid sequence (e.g., amino acids encoded by exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7 and / or exon 8 of NM_001242758.1, NP_001229687.1 (SEQ ID NO: 58) or AAC24825.1 (SEQ ID NO: 59)).

[0303] The present disclosure also relates to the genomic DNA sequence of B2M or MHC molecules of humanized mice. The DNA sequence is obtained by reverse transcription of mRNA obtained by transcription thereof, and the mRNA is consistent with or complementary to a DNA sequence homologous to the sequence described herein.

[0304] The present disclosure also provides an amino acid sequence having at least 90% homology, or at least 90% identity, to the sequence shown in any one of SEQ ID NOs: 61-80 and 100-117 and having protein activity. In some embodiments, the homology to the sequence shown in any one of SEQ ID NOs: 61-80 and 100-117 is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99%. In some embodiments, the aforementioned homology is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 80% or 85%.

[0305] In some embodiments, the percent identity to the sequence shown in any one of SEQ ID NOs: 61-80 and 100-117 is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99%. In some embodiments, the aforementioned percent identity is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 80% or 85%.

[0306] The present disclosure also provides nucleic acid sequences that are at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 240%, 241%, 242%, 243%, 244%, 245%, 246%, 247%, 248%, 249%, 250%, 97%, 98%, 99% identical to any of the amino acid sequences described herein. In some embodiments, the disclosure relates to nucleotide sequences encoding any of the peptides described herein or any amino acid sequences encoded by any of the nucleotide sequences described herein. In some embodiments, the nucleic acid sequence is less than 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 150, 200, 250, 300, 350, 400, 500, or 600 nucleotides. In some embodiments, the amino acid sequence is less than 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 amino acid residues.

[0307] In some embodiments, the amino acid sequence (i) comprises an amino acid sequence; or (ii) consists of an amino acid sequence, wherein the amino acid sequence is any one of the sequences described herein.

[0308] In some embodiments, the nucleic acid sequence (i) comprises a nucleic acid sequence; or (ii) consists of a nucleic acid sequence, wherein the nucleic acid sequence is any one of the sequences described herein.

[0309] In order to determine the percent identity of two amino acid sequences or two nucleic acid sequences, these sequences are compared for the best comparison purpose (for example, a gap can be introduced in one or both of the first and second amino acid or nucleic acid sequences for the best comparison, and non-homologous sequences can be ignored for the purpose of comparison). The amino acid residues or nucleotides at the corresponding amino acid positions or nucleotide positions are then compared. When the position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, these molecules are identical at that position. Considering the number of gaps and the length of each gap that need to be introduced to achieve the best comparison of the two sequences, the percent identity between the two sequences is a function of the number of identical positions shared by the sequences. For example, the comparison of the sequence and the determination of the percent identity between the two sequences can be completed using the Blossum 62 scoring matrix, wherein the gap penalty is 12, the gap extension penalty is 4, and the frameshift gap penalty is 5.

[0310] The percentage (homology percentage) of conservative residues with similar physicochemical properties, such as leucine and isoleucine, can also be used to measure sequence similarity. Families of amino acid residues with similar physicochemical properties have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids with beta-branched side chains (e.g., threonine, valine, isoleucine) and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In many cases, the homology percentage is higher than the identity percentage.

[0311] Also provided are cells, tissues, and animals (eg, mice) comprising the nucleotide sequences described herein, as well as cells, tissues, and animals (eg, mice) expressing human or chimeric (eg, humanized) MHC from endogenous non-human B2M or MHC loci.

[0312] Genetically modified animals

[0313] As used herein, the term "genetically modified non-human animal" refers to a non-human animal having a modified sequence in at least one chromosome of the animal genome. In some embodiments, at least one or more cells (e.g., at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50% of cells) of a genetically modified non-human animal have a modified sequence in its genome. The cells with the modified sequence can be various types of cells, such as endogenous cells, somatic cells, immune cells, T cells, B cells, germ cells, embryos or endogenous tumor cells. In some embodiments, a genetically modified non-human animal is provided, which comprises a human or humanized B2M and / or a human or humanized MHC molecule gene (e.g., MHC class I α chain) at an endogenous B2M or MHC locus. Animals are generally able to pass the modification to offspring, i.e., through germline transmission.

[0314] As used herein, the term "humanization" and the like refer to molecules (e.g., nucleic acids, proteins, etc.) of non-human origin, and portions of the molecules have been replaced by corresponding portions of corresponding human molecules in such a manner that the modified (e.g., humanized) molecules retain their biological functions and / or retain structures that perform the retained biological functions. Humanized molecules can be considered to be derived from human molecules, wherein the humanized molecules are encoded by nucleotides comprising a nucleic acid sequence encoding a human molecule (or a portion thereof).

[0315] In some embodiments, the genetically modified non-human animal does not express endogenous B2M (e.g., mouse B2M). In some embodiments, the genetically modified non-human animal does not express functional endogenous B2M (e.g., mouse B2M). In some embodiments, the genetically modified non-human animal does not express endogenous MHC molecules (e.g., mouse H2-D1). In some embodiments, the genetically modified non-human animal does not express functional endogenous MHC molecules (e.g., mouse H2-D1) or functional endogenous MHC protein complexes.

[0316] In some embodiments, the genetically modified non-human animals described herein are immunodeficient. In some embodiments, the animals have NOD-Prkdc scid IL-2rγ nul 、NOD-Rag 1 - / - -IL2rg - / - (NRG), Rag 2 - / - -IL2rg - / - (RG) or NOD / SCID (NOD-Prkdc scid )background.

[0317] In some embodiments, the genetically modified non-human animals described herein (e.g., mice) have a disrupted endogenous B2M gene. In some embodiments, the genetically modified non-human animals described herein (e.g., mice) express dysfunctional endogenous B2M proteins (e.g., mouse B2M). In some embodiments, the genetically modified non-human animals described herein (e.g., mice) have disrupted endogenous MHC genes. In some embodiments, the genetically modified non-human animals described herein (e.g., mice) express dysfunctional endogenous MHC molecules (e.g., mouse H2-D1) or dysfunctional endogenous MHC protein complexes.

[0318] In some embodiments, the genetically modified non-human animal is a RenMab TM Mice (hVH / hVL mice) that have both a humanized immunoglobulin heavy chain locus and a humanized immunoglobulin kappa chain locus. RenMab TM A detailed description of mice can be found in, for example, PCT / CN2020 / 075698 and US20200390073A1, the entire texts of which are incorporated herein by reference.

[0319] In some embodiments, the genetically modified non-human animal is a RenLite TM Mice (or hVH / hcVL mice) having a humanized immunoglobulin heavy chain locus and a humanized common light chain locus. RenLite TM A detailed description of mice can be found in, for example, PCT / CN2021 / 097652, which is incorporated herein by reference in its entirety.

[0320] In some embodiments, the genetically modified non-human animal is a mouse. In some embodiments, the genetically modified non-human animal is a B-NDG mouse. The details of the B-NDG mouse can be found in, for example, PCT / CN2018 / 079365, US10820580B2, each of which is incorporated herein by reference in its entirety. In some embodiments, the genetically modified animal is an NSG mouse or a NOG mouse. A detailed description of NSG mice and NOD mice can be found in, for example, Ishikawa et al., "Development of functional human blood and immune systems in NOD / SCID / IL2receptorγchainnull mice.", Blood 106.5 (2005): 1565-1573; Katano et al., "NOD-Rag2null IL-2Rγnull mice: an alternative to NOG mice for generation of humanized mice.", Experimental animals 63.3 (2014): 321-330, both of which are incorporated herein by reference in their entirety.

[0321] Genetically modified non-human animals can also be various other animals, such as rats, rabbits, pigs, cattle (e.g., cows, bulls, buffaloes), deer, sheep, goats, chickens, cats, dogs, ferrets, primates (e.g., marmosets, rhesus monkeys). For non-human animals, in the case of suitable genetically modified ES cells that are not easily available, other methods can be used to prepare non-human animals comprising genetic modification. Such methods include, for example, modifying non-ES cell genomes (e.g., fibroblasts or induced pluripotent cells) and using nuclear transfer to transfer the modified genome to suitable cells (e.g., oocytes), and incubating modified cells (e.g., modified oocytes) in non-human animals under suitable conditions to form embryos. These methods are known in the art, and are described in, for example, A. Nagy et al., "Manipulating the Mouse Embryo: A Laboratory Manual (Third Edition)", Cold Spring Harbor Laboratory Press, 2003, which is incorporated herein by reference in its entirety.

[0322] In one aspect, the animal is a mammal, such as a mammal of the superfamily Dipodoidea or Muroidea. In some embodiments, the genetically modified animal is a rodent. The rodent can be selected from mice, rats, and hamsters. In some embodiments, the rodent is selected from the superfamily Muroidea. In some embodiments, the genetically modified animal is from a family selected from the group consisting of Calomyscidae (e.g., mouse-like hamster), Cricetidae (e.g., hamsters, New World rats and mice, voles), Muridae (true mice and rats, gerbils, spiny mice, crested rats), Nesomyidae (climbing mice, rock mice, with-tailed rats, Malagasy rats and mice), Platacanthomyidae (e.g., spiny dormouse), and Spalacidae (e.g., molerate, bamboo rat, and zokor). In some embodiments, the genetically modified rodent is selected from true mice or rats (Murine family), gerbils, spiny mice, and crested rats. In one embodiment, the non-human animal is a mouse.

[0323] In some embodiments, the animal is a mouse of a strain selected from BALB / c, A, A / He, A / J, A / WySN, AKR, AKR / A, AKR / J, AKR / N, TA1, TA2, RF, SWR, C3H, C57BR, SJL, C57L, DBA / 2, KM, NIH, ICR, CFW, FACA, C57BL / A, C57BL / An, C57BL / GrFa, C57BL / KaLwN, C57BL / 6, C57BL / 6J, C57BL / 6ByJ, C57BL / 6NJ, C57BL / 10, C57BL / 10ScSn, C57BL / 10Cr, C57BL / Ola, C57BL, C58, CBA / Br, CBA / Ca, CBA / J, CBA / st, and CBA / H. In some embodiments, the mouse is a 129 strain selected from 129P1, 129P2, 129P3, 129X1, 129S1 (e.g., 129S1 / SV, 129S1 / SvIm), 129S2, 129S4, 129S5, 129S9 / SvEvH, 129S6 (129 / SvEvTac), 129S7, 129S8, 129T1, 129T2 strains. These mice are described in, for example, Festing et al., Revised nomenclature for strain 129 mice, Mammalian Genome 10: 836 (1999); Auerbach et al., Establishment and Chimera Analysis of 129 / SvEv-and C57BL / 6-Derived Mouse Embryonic Stem Cell Lines (2000), both of which are incorporated herein by reference. In some embodiments, the genetically modified mouse is a mixture of the 129 strain and the C57BL / 6 strain. In some embodiments, the mouse is a mixture of the 129 strain, or a mixture of the BL / 6 strain. In some embodiments, the mouse is a BALB strain, such as a BALB / c strain. In some embodiments, the mouse is a mixture of the BALB strain and another strain. In some embodiments, the mouse is from a heterozygous strain (eg, 50% BALB / c-50% 12954 / Sv; or 50% C57BL / 6-50% 129).

[0324] In some embodiments, the animal is a rat. The rat can be selected from Wistar rats, LEA strains, Sprague Dawley strains, Fischer strains, F344, F6 and Dark Agouti. In some embodiments, the rat strain is a mixture of two or more strains selected from Wistar, LEA, Sprague Dawley, Fischer, F344, F6 and Dark Agouti.

[0325] The animal may have one or more other genetic modifications and / or other modifications suitable for the specific purpose of preparing an animal expressing human or humanized B2M and / or MHC molecules (e.g., MHC class I alpha chain). For example, a suitable mouse for maintaining a xenograft (e.g., a human cancer or tumor) may have one or more modifications that damage, inactivate, or destroy all or part of the immune system of a non-human animal. Damaging, inactivating, or destroying the immune system of a non-human animal may include, for example, destroying hematopoietic cells and / or immune cells by chemical methods (e.g., administering a toxin), physical methods (e.g., irradiating the animal), and / or genetic modifications (e.g., knocking out one or more genes).

[0326] Non-limiting examples of such mice include, for example, NOD mice, SCID mice, NOD / SCID mice, nude mice, NOD / SCID nude mice, NOD-Rag 1 mice, and NOD / SCID mice. - / - -IL2rg - / - (NRG) mouse, Rag 2 - / - -IL2rg - / - (RG) mice, B-NDG (NOD-Prkdc scid IL-2rγ null ) mice and Rag1 and / or Rag2 knockout mice. In some embodiments, these mice may optionally be irradiated or otherwise treated to destroy one or more immune cell types. Therefore, in various embodiments, genetically modified mice are provided that may comprise one or more mutations at endogenous non-human B2M or MHC loci and further comprise modifications that impair, inactivate or destroy all or part of the immune system (or one or more cell types of the immune system) of the non-human animal. In some embodiments, the modifications are, for example, selected from the group consisting of leading to NOD mice, SCID mice, NOD / SCID mice, B-NDG (NOD-Prkdc scid IL-2rγ null ) mice, nude mice, Rag1 and / or Rag2 knockout mice, and combinations thereof. These genetically modified animals are described in, for example, US10820580B2 and PCT / CN2018 / 079365; each of these patents is incorporated herein by reference in its entirety.

[0327] Although genetically modified cells (e.g., ES cells, somatic cells) that can comprise the modifications (e.g., disruptions, mutations) described herein are also provided, in many embodiments, the genetically modified non-human animal comprises modifications to endogenous B2M and / or MHC loci in the animal's germline.

[0328] In addition, the genetically modified animal can be homozygous for the modification (e.g., replacement) of endogenous B2M and / or MHC genes. In some embodiments, the animal can be heterozygous for the modification (e.g., replacement) of endogenous B2M and / or MHC genes.

[0329] The present disclosure also relates to non-human mammals produced by the methods described herein. In some embodiments, their genome contains human genes.

[0330] In addition, the present disclosure also relates to a tumor-bearing non-human mammal model, characterized in that the non-human mammal model is obtained by the method as described herein. In some embodiments, the non-human mammal is a rodent (eg, a mouse).

[0331] The present disclosure also relates to cells or cell lines or primary cell cultures thereof derived from non-human mammals or their progeny or tumor-bearing non-human mammals; tissues, organs or cultures thereof derived from non-human mammals or their progeny or tumor-bearing non-human mammals; and tumor tissues derived from non-human mammals or their progeny (when suffering from tumors) or tumor-bearing non-human mammals.

[0332] The present disclosure also provides a non-human mammal produced by any of the methods described herein. In some embodiments, a non-human mammal is provided; and the genetically modified animal contains a modification (eg, replacement) of a B2M and / or MHC gene in the genome of the animal.

[0333] In some embodiments, the expression of human or humanized MHC protein complexes, human or humanized B2M, human or humanized MHC genes (e.g., MHC class I α chain) and / or fusion proteins in genetically modified animals is controllable, such as by adding specific inducers or repressors. In some embodiments, the specific inducer is selected from the Tet-Off system / Tet-On system or the Tamoxifen system.

[0334] In some embodiments, the genetically modified non-human animal comprises a humanized heavy chain immunoglobulin locus and / or a humanized light chain immunoglobulin locus. In some embodiments, the animal comprises one or more human IGHV genes, one or more human IGHD genes, one or more human IGHJ genes, one or more human IGKV genes, and / or one or more human IGKJ genes. In some embodiments, these genes are located at the endogenous immunoglobulin locus.

[0335] In some embodiments, the animal comprises a human lambda chain immunoglobulin locus. In some embodiments, the animal comprises a disruption of an endogenous lambda light chain immunoglobulin locus in the animal. In some embodiments, the animal does not have a disruption of an endogenous lambda light chain immunoglobulin locus in the animal.

[0336] The animal may have one or more additional genetic modifications and / or other modifications as appropriate for the particular purpose of making the humanized animal.

[0337] A genetically modified non-human animal comprising a modification of an endogenous non-human immunoglobulin locus. In some embodiments, the modification may comprise a human nucleic acid sequence encoding at least a portion of a human protein (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to a human heavy chain variable domain or light chain variable domain sequence). Although genetically modified cells (e.g., ES cells, somatic cells) that may comprise the modifications described herein are also provided, in many embodiments, a genetically modified non-human animal comprises a modification of an endogenous locus in the animal germline.

[0338] Genetically modified animals can express humanized antibodies and / or chimeric antibodies from endogenous mouse loci, wherein one or more endogenous mouse immunoglobulin genes have been replaced with human immunoglobulin genes and / or nucleotide sequences that are at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to human immunoglobulin gene sequences (e.g., IGHV genes, IGHD genes, IGHJ genes, IGKV genes and / or IGKJ genes). In various embodiments, endogenous non-human immunoglobulin loci are modified in whole or in part to contain human nucleic acid sequences.

[0339] The above-mentioned non-human mammals can be subjected to genetic, molecular and behavioral analysis. The present disclosure also relates to offspring produced by mating the non-human mammals provided by the present disclosure with the same or other genotypes. The non-human mammal can be any non-human animal known in the art, and it can be used in the methods as described herein. Preferred non-human mammals are mammals (e.g., rodents). In some embodiments, the non-human mammal is a mouse.

[0340] The disclosure also provides cell lines or primary cell cultures derived from non-human mammals or their progeny. For example, cell culture-based models can be prepared by the following methods. Cell cultures can be obtained by separation from non-human mammals, alternatively, cells can be obtained from cell cultures established using the same construct and standard cell transfection techniques. The integration of genetic constructs containing DNA sequences encoding human or humanized immunoglobulins can be detected by a variety of methods.

[0341] There are many analytical methods that can be used to detect modifications on exogenous DNA or genomic DNA, including methods at the nucleic acid level (including mRNA quantitative methods using reverse transcriptase polymerase chain reaction (RT-PCR) or Southern blots, and in situ hybridization) and protein levels (including histochemistry, immunoblotting analysis, and in vitro binding studies). In addition, the expression level of the gene of interest can be quantified by ELISA technology well known to those skilled in the art. Many standard analytical methods can be used to complete quantitative measurements. For example, transcription levels can be measured using RT-PCR and hybridization methods (including RNA enzyme protection, Southern blot analysis, RNA dot analysis (RNAdot) analysis). Immunohistochemical staining, flow cytometry, Western blot analysis can also be used to assess the presence of people or humanized proteins.

[0342] The non-human mammals described above can be subjected to genetic, molecular and behavioral analyses. The present disclosure also relates to offspring produced by mating the non-human mammals provided by the present disclosure with the same or other genotypes.

[0343] In some embodiments, the genome of the genetically modified non-human animal described herein comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to any one of SEQ ID NO:81, 82, 83, 84, 85, 86, 87, 88, 89, 90 and / or 91.

[0344] Antibodies and antigen-binding fragments

[0345] The present disclosure provides antibodies and antigen-binding fragments thereof (eg, humanized antibodies or chimeric antibodies) produced by the methods described herein.

[0346] Typically, antibodies (also known as immunoglobulins) are composed of two types of polypeptide chains, namely light chains and heavy chains. The non-limiting antibodies of the present disclosure may be complete tetraimmunoglobulin chain antibodies comprising two heavy chains and two light chains. The heavy chain of the antibody may be of any isotype (including IgM, IgG, IgE, IgA or IgD) or subclass (including IgG1, IgG2, IgG2a, IgG2b, IgG3, IgG4, IgE1, IgE2, etc.). The light chain may be a kappa light chain or a lambda light chain. The antibody may include two identical copies of a light chain and two identical copies of a heavy chain. Each contains a variable domain (or variable region, V H ) and multiple constant domains (or constant regions) are bound to each other through disulfide bonds within their constant domains to form the "backbone" of the antibody. L ) and a light chain of a constant domain (or constant region) each bind to a heavy chain through a disulfide bond. The variable region of each light chain is aligned with the variable region of the heavy chain to which it binds. The variable regions of both the light and heavy chains contain three hypervariable regions, which are sandwiched between more conserved framework regions (FR).

[0347] These hypervariable regions, called complementarity determining regions (CDRs), form loops that comprise the major antigen-binding surface of the antibody. The four framework regions largely adopt a beta-sheet conformation, while the CDRs form loops that connect and in some cases form part of the beta-sheet structure. The CDRs in each chain are held tightly together by the framework regions and, together with the CDRs from the other chain, contribute to the formation of the antigen-binding region.

[0348] Methods for identifying the CDR regions of an antibody by analyzing its amino acid sequence are well known, and a number of definitions of CDRs are commonly used. The Kabat definition is based on sequence variability, and the Chothia definition is based on the location of structural loop regions. These methods and definitions are described, for example, in Martin, "Protein sequence and structure analysis of antibody variable domains", Antibody engineering, Springer Berlin Heidelberg, 2001. 422-439; Abhinandan et al., "Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains", Molecular immunology 45.14 (2008): 3832-3839; Wu, TT and Kabat, EA (1970) J. Exp. Med. 132: 211-250; Martin et al., Methods Enzymol. 203: 121-53 (1991); Morea et al., Biophys Chem. 68 (1-3): 9-16 (Oct. 1997); Morea et al., J Mol Biol. 275 (2): 269-94 (Jan. 1998); Chothia et al., Nature 342(6252):877-83 (Dec. 1989); Ponomarenko and Bourne, BMC Structural Biology 7:64 (2007), each of which is incorporated herein by reference in its entirety.

[0349] CDR is very important for recognizing the epitope of an antigen. As used herein, an "epitope" is the smallest part of a target molecule that can be specifically bound by the antigen-binding domain of an antibody. The minimum size of an epitope can be about three, four, five, six or seven amino acids, but these amino acids do not have to be in a continuous linear sequence of the primary structure of the antigen, because the epitope can depend on the three-dimensional configuration of the antigen based on the secondary and tertiary structures of the antigen.

[0350] In some embodiments, the antibody is a complete immunoglobulin molecule (e.g., IgG1, IgG2a, IgG2b, IgG3, IgG4, IgM, IgD, IgE, IgA). The IgG subclasses (IgG1, IgG2, IgG3, and IgG4) are highly conserved, but their constant regions differ, particularly the hinge and upper CH2 domains. The sequences and differences of IgG subclasses are known in the art and are described, for example, in Vidarsson et al., "IgG subclasses and allotypes: from structure to effector functions.", Frontiers in immunology 5 (2014); Irani et al., "Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases.", Molecular immunology 67.2 (2015): 171-182; Shakib, Farouk, ed., "The human IgG subclasses: molecular analysis of structure, function and regulation.", Elsevier, 2016, each of which is incorporated herein by reference in its entirety.

[0351] Antibodies can also be immunoglobulin molecules derived from any species (e.g., humans, rodents, mice, rats, camelids). Antibodies disclosed herein also include, but are not limited to, polyclonal antibodies, monoclonal antibodies, monospecific antibodies, multispecific antibodies, and chimeric antibodies comprising immunoglobulin binding domains fused to another polypeptide. The term "antigen binding domain" or "antigen binding fragment" is a part of the specific binding activity of an antibody that retains a complete antibody, that is, any part of an antibody that can specifically bind to an epitope on a target molecule of a complete antibody. It includes, for example, Fab, Fab', F(ab')2 and variants of these fragments. Therefore, in some embodiments, an antibody or its antigen binding fragment can be, for example, scFv, Fv, Fd, dAb, bispecific antibodies, bispecific scFv, double antibodies, linear antibodies, single-chain antibody molecules, multispecific antibodies formed by antibody fragments, and any polypeptide comprising an antibody binding domain or a binding domain homologous thereto. Non-limiting examples of antigen binding domains include, e.g., heavy and / or light chain CDRs of an intact antibody, heavy and / or light chain variable regions of an intact antibody, the full length heavy or light chain of an intact antibody, or a single CDR from a heavy or light chain of an intact antibody.

[0352] In some embodiments, the antigen binding fragment may form a part of a chimeric antigen receptor (CAR). In some embodiments, the chimeric antigen receptor is a fusion of a single chain variable fragment (scFv) as described herein with a CD3-ζ transmembrane domain and an intracellular domain.

[0353] In some embodiments, the scFV has one heavy chain variable domain and one light chain variable domain. In some embodiments, the scFV has two heavy chain variable domains and two light chain variable domains. In some embodiments, the scFV has two antigen binding regions, and the two antigen binding regions can bind to respective target antigens.

[0354] Antibodies and antigen-binding fragments thereof (e.g., humanized antibodies or chimeric antibodies) produced by the methods described herein have a variety of advantages. In some embodiments, desired properties (e.g., binding affinity, thermal stability and / or limited aggregation) can be obtained without further optimization.

[0355] In some embodiments, the antibody (or antigen-binding fragment thereof) is activated in less than 0.1 s -1 Less than 0.01s -1 , less than 0.001s -1 , less than 0.0001s -1 or less than 0.00001s -1 The dissociation rate (koff) of the antibody specifically binds to the target. In some embodiments, the dissociation rate (koff) is greater than 0.01s -1, greater than 0.001s -1 , greater than 0.0001s -1 , greater than 0.00001s -1 or greater than 0.000001s -1 .

[0356] In some embodiments, the kinetic binding rate (kon) is greater than 1×10 2 / Ms, greater than 1×10 3 / Ms, greater than 1×10 4 / Ms, greater than 1×10 5 / Ms or greater than 1×10 6 / Ms. In some embodiments, the kinetic binding rate (kon) is less than 1×10 5 / Ms, less than 1×10 6 / Ms or less than 1×10 7 / Ms.

[0357] Affinity can be derived from the quotient of the kinetic rate constants (KD = koff / kon). In some embodiments, KD is less than 1×10 -6 M, less than 1×10 -7 M, less than 1×10 -8 M, less than 1×10 -9 M or less than 1×10 -10 In some embodiments, the KD is less than 50 nM, 40 nM, 30 nM, 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM. In some embodiments, the KD is greater than 1×10 -7 M, greater than 1×10 -8 M, greater than 1×10 -9 M, greater than 1×10 -10 , greater than 1×10 -11 M or greater than 1×10 -12 M. In some embodiments, the antibody binds to the target with a KD of less than or equal to about 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, or 0.1 nM.

[0358] In some embodiments, thermal stability is determined.Antibodies or antigen-binding fragments as described herein may have a Tm greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, or 95°C.

[0359] Since IgG can be described as a multi-domain protein, the melting curve is sometimes shown to have two or three transitions, with the first denaturation temperature being Tm D1, the second denaturation temperature being Tm D2, and optionally the third denaturation temperature being Tm D3.

[0360] In some embodiments, the antibodies or antigen-binding fragments as described herein have a Tm D1 of greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C or 95°C. In some embodiments, the antibodies or antigen-binding fragments as described herein have a Tm D2 of greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C or 95°C. In some embodiments, the antibodies or antigen-binding fragments as described herein have a Tm D3 of greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C or 95°C.

[0361] In some embodiments, Tm, Tm D1, Tm D2, Tm D3 is less than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C or 95°C.

[0362] In some embodiments, the antibodies or antigen-binding fragments as described herein do not form aggregates when the temperature is below 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C or 95°C.

[0363] In some embodiments, antibodies and antigen-binding fragments thereof (e.g., TCR-like antibodies) specifically recognize peptide epitopes in the context of MHC molecules (such as MHC class I molecules). In some cases, the MHC class I molecule is an HLA-A2 molecule, e.g., HLA-A2*01. In some embodiments, the MHC class I molecule is any of the HLA molecules described herein, or any of the fusion proteins described herein.

[0364] In some embodiments, antibodies and antigen-binding fragments thereof can specifically recognize peptide epitopes in an MHC molecule-dependent manner. In some embodiments, antibodies and antigen-binding fragments thereof can specifically recognize peptide epitopes in an MHC molecule-independent manner.

[0365] Methods for preparing genetically modified animals

[0366] Genetically modified animals can be prepared by several techniques known in the art, including, for example, non-homologous end joining (NHEJ), homologous recombination (HR), zinc finger nucleases (ZFN), nucleases (TALEN) based on transcription activator-like effectors, and clustered regularly spaced short palindromic repeats (CRISPR)-Cas systems. In some embodiments, homologous recombination is used. In some embodiments, CRISPR-Cas9 genome editing is used to produce genetically modified animals. Many of these genome editing techniques are known in the art and are described in, for example, Yin et al., "Delivery technologies for genome editing", Nature Reviews Drug Discovery 16.6 (2017): 387-399, which is incorporated herein by reference in its entirety. Many other methods that can be used for genome editing are also provided, for example, microinjection of genetically modified nuclei into enucleated oocytes, and fusion of enucleated oocytes with another genetically modified cell.

[0367] In some embodiments, genetically modified animals can be prepared by introducing human or humanized genes into the genome of non-human animals. In some embodiments, these methods first involve modifying the human immunoglobulin loci on human chromosomes. The modified human chromosomes are then introduced into mouse recipient cells. The human immunoglobulin variable regions are then introduced into the corresponding regions of the mouse genome by direct replacement. Then, the recipient cells are screened. In some embodiments, these cells do not contain human chromosomes. These cells are then injected into blastocysts to prepare chimeric mice. Subsequent breeding can be performed to obtain mice containing complete humanized immunoglobulin loci.

[0368] In some embodiments, the method for preparing a genetically modified humanized animal may include a step of replacing a nucleic acid (e.g., V, D, J region or V, J region) with a corresponding region of a human sequence at an endogenous locus (or site). The sequence may include a region (e.g., part or the entire region) of an IGHV gene, an IGHD gene, an IGHJ gene, an IGKV gene, and / or an IGKJ gene. In some embodiments, the replacement is mediated by homologous recombination. In some embodiments, the replacement is mediated by Cre recombinase.

[0369] In some embodiments, the present disclosure provides that in at least one cell of an animal, a sequence encoding a fusion protein described herein is substituted for a sequence encoding an endogenous B2M or MHC alpha chain region at an endogenous B2M or MHC locus. In some embodiments, the substitution occurs in a germ cell, a somatic cell, a blastocyst, or a fibroblast, etc. The nucleus of a somatic cell or a fibroblast can be inserted into an enucleated oocyte.

[0370] Figure 1 , Figure 2B and Figure 3B The strategy for humanizing the MHC protein complex at the mouse B2M locus is shown. Figure 2B and Figure 3B In the present invention, the targeting strategy involves a vector comprising a 5' homology arm, a sequence encoding a fusion protein, and a 3' homology arm. The method may involve replacing the endogenous B2M gene sequence with a sequence encoding a fusion protein by homologous recombination. In some embodiments, cutting upstream and downstream of the target site (e.g., by zinc finger nucleases, TALENs, or CRISPR) may cause DNA double-strand breaks, and homologous recombination is used to replace the endogenous B2M gene sequence with a sequence encoding a fusion protein.

[0371] In some embodiments, Figure 2B The targeting strategy in can be used to produce a genetically modified non-human animal expressing a fusion protein (or chimeric fusion protein). In some embodiments, the expressed fusion protein comprises from N-terminus to C-terminus: (a) a signal peptide of human HLA (e.g., any of the HLA molecules described herein), (b) human B2M, (c) a linker peptide, (d) the α1 and α2 domains of human HLA, (e) the α3 domain, connecting peptide, transmembrane region, and cytoplasmic region of mouse H2-D1. In some embodiments, the fusion protein comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to SEQ ID NO:61, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116 or 117.

[0372] In some embodiments, Figure 3B The targeting strategy in can be used to produce genetically modified non-human animals expressing fusion proteins. In some embodiments, the expressed fusion protein comprises from N-terminus to C-terminus: (a) a signal peptide of human HLA (e.g., any of the HLA molecules described herein), (b) human B2M, (c) a linker peptide, and (d) the α1 domain, α2 domain, α3 domain, connecting peptide, transmembrane region, and cytoplasmic region of human HLA. In some embodiments, the fusion protein comprises or consists of an amino acid sequence identical to SEQ ID NO: 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99%.

[0373] In some embodiments, the linker peptide described herein comprises at least 1, 2, 3, 4, 5, 6, 7 or 8 repeats of GGGGS (SEQ ID NO: 5). In some embodiments, the linker peptide is a flexible linker. The details of the flexible linker can be found in, for example, Chen, X. et al., "Fusion protein linkers: property, design and functionality.", Advanced Drug Delivery Reviews 65.10 (2013): 1357-1369, which is incorporated herein by reference in its entirety. In some embodiments, the linker peptide comprises or consists of an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 4.

[0374] In some embodiments, the sequence between the 5' end targeting site and the 3' end targeting site is knocked out. In some embodiments, the sequence between the 5' end targeting site and the 3' end targeting site is replaced. In some embodiments, the replaced sequence starts from exon 1 or intron 1 of the mouse B2M gene. In some embodiments, the replaced sequence ends in exon 3 or intron 3 of the mouse B2M gene.

[0375] Therefore, in some embodiments, the method for preparing a genetically modified humanized animal may include a step of replacing a nucleic acid encoding a sequence (which encodes an endogenous B2M region) with a sequence encoding a fusion protein described herein at an endogenous B2M locus (or site). The sequence may include regions (e.g., part or the entire region) of exon 1, exon 2, exon 3, and exon 4 of an endogenous B2M gene. In some embodiments, the sequence encoding the fusion protein includes regions (e.g., part or the entire region) of exon 1, exon 2, exon 3, and exon 4 of a human B2M gene, as well as regions (e.g., part or the entire region) of exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, and exon 8 of an endogenous or human MHC α chain gene. In some embodiments, the endogenous B2M locus is a portion of exon 1, exon 2, and exon 3 of a mouse B2M gene.

[0376] In some embodiments, the method of modifying the B2M locus of a mouse to express a fusion protein described herein may include the following steps: replacing the nucleotide sequence encoding mouse B2M at the endogenous mouse B2M locus with a nucleotide sequence encoding the fusion protein, thereby generating a sequence encoding a fusion protein comprising human B2M and a human or chimeric MHC α chain.

[0377] In some embodiments, the nucleotide sequences described herein do not overlap with each other (eg, the 5' homology arm, the A fragment (or the BNDG-A fragment), and / or the 3' homology arm do not overlap). In some embodiments, the amino acid sequences described herein do not overlap with each other.

[0378] The zinc finger protein, TAL effector domain, or single guide RNA (sgRNA) DNA binding domain can be designed to target an endogenous (e.g., mouse) B2M locus within exon 1, exon 2, exon 3, exon 4, intron 1, intron 2, and / or intron 3. After the zinc finger protein, TAL effector domain, or single guide RNA (sgRNA) DNA binding domain binds to the target sequence, the nuclease cleaves the genomic DNA. In some embodiments, the nuclease is CRISPR-associated protein 9 (Cas9).

[0379] Thus, methods for producing mice expressing human or humanized MHC protein complexes, human or humanized B2M and / or human or humanized MHC molecules may involve one or more of the following steps: transforming mouse embryonic stem cells with a gene editing system targeting endogenous B2M or MHC genes, thereby producing transformed embryonic stem cells; introducing the transformed embryonic stem cells into mouse embryos; implanting the mouse embryos into pseudopregnant female mice; and allowing the embryos to undergo fetal development to term.

[0380] In some embodiments, transformed embryonic cells are instead implanted directly into pseudopregnant female mice and the embryonic cells are allowed to undergo fetal development.

[0381] In some embodiments, the gene editing system may involve zinc finger proteins, TAL effector domains, or single guide RNA (sgRNA) DNA binding domains.

[0382] The present disclosure also provides a method for establishing an animal model expressing a human or humanized MHC protein complex, a human or humanized B2M and / or a human or humanized MHC molecule, the method involving the following steps:

[0383] (a) providing a genetic modification to a cell (e.g., a fertilized egg cell) based on the methods described herein;

[0384] (b) culturing the cell in a liquid culture medium;

[0385] (c) transplanting the cultured cells into the oviduct or uterus of a recipient female non-human mammal to allow the cells to develop in the uterus of the female non-human mammal;

[0386] (d) identifying germline transmission in the offspring (i.e., the genetically modified humanized non-human mammal) of the pregnant female in step (c).

[0387] In some embodiments, the non-human mammal in the foregoing methods is a mouse (e.g., a RenMab mouse, a C57BL / 6 mouse, a NOD / scid mouse, a NOD / scid nude mouse, or a B-NDG mouse). In some embodiments, the non-human mammal is a B-NDG (NOD-Prkdc scid IL-2rγ null ) mouse. In some embodiments, the non-human mammal is a NOD / scid mouse.

[0388] In some embodiments, the fertilized egg used in the above method is RenMab TM Mouse fertilized eggs, RenLite TM Mouse fertilized eggs, NOD / scid fertilized eggs, NOD / scid naked fertilized eggs or B-NDG fertilized eggs. Other fertilized eggs that can also be used for the method as described herein include but are not limited to C57BL / 6 fertilized eggs, FVB / N fertilized eggs, BALB / c fertilized eggs, DBA / 1 fertilized eggs and DBA / 2 fertilized eggs.

[0389] The fertilized egg can be from any non-human animal, for example, any non-human animal as described herein. In some embodiments, the fertilized egg cell is derived from a rodent. By microinjection of DNA, the genetic construct can be introduced into the fertilized egg. For example, by culturing the fertilized egg after microinjection, the cultivated fertilized egg can be transferred to a pseudo-pregnant non-human animal, and then the non-human mammal is born, thereby producing the non-human mammal mentioned in the above method.

[0390] The present disclosure also provides a method for establishing a humanized animal model, the method involving the following steps:

[0391] (a) providing a cell (e.g., a fertilized egg cell) according to the methods described herein;

[0392] (b) culturing the cell in a liquid culture medium;

[0393] (c) transplanting the cultured cells into the oviduct or uterus of a recipient female non-human mammal to allow the cells to develop in the uterus of the female non-human mammal;

[0394] (d) identifying germline transmission in the offspring (i.e., the genetically modified humanized non-human mammal) of the pregnant female in step (c).

[0395] In some embodiments, the non-human mammal in the foregoing methods is a mouse (eg, a C57 mouse, a BALB / c mouse, or a C57BL / 6 mouse).

[0396] In some embodiments, the non-human mammal in step (c) is a pseudopregnant (or pseudo-pregnant) female.

[0397] In some embodiments, the fertilized eggs used in the above methods are C57BL / 6 fertilized eggs. Other fertilized eggs that can also be used in the methods described herein include, but are not limited to, FVB / N fertilized eggs, BALB / c fertilized eggs, DBA / 1 fertilized eggs, and DBA / 2 fertilized eggs.

[0398] The fertilized egg can be from any non-human animal, for example, any non-human animal as described herein. In some embodiments, the fertilized egg cell is derived from a rodent. By microinjection of DNA, the genetic construct can be introduced into the fertilized egg. For example, by culturing the fertilized egg after microinjection, the cultivated fertilized egg can be transferred to a pseudo-pregnant non-human animal, and then the non-human mammal is born, thereby producing the non-human mammal mentioned in the above method.

[0399] Also provided are cells, tissues, and animals (eg, mice) comprising the nucleotide sequences described herein, as well as cells, tissues, and animals (eg, mice) expressing humanized or chimeric antibodies from endogenous non-human loci.

[0400] The present disclosure also relates to a method for producing a genetically modified animal model with two or more people or chimeric genes. The animal may include one or more people or humanized immunoglobulin loci and sequences encoding other people or chimeric proteins. In some embodiments, the other people or chimeric proteins may be programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), B and T lymphocyte-associated protein (BTLA), programmed cell death 1 ligand 1 (PD-L1), CD27, CD28, CD47, CD137, CD154, T cell immune receptor with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-3 (TIM-3), glucocorticoid-induced TNFR-related protein (GITR) or TNF receptor superfamily member 4 (TNFRSF4 or OX40).

[0401] A method of generating a genetically modified animal model with additional human or chimeric genes (e.g., humanized genes) may comprise the following steps:

[0402] (a) using the methods described herein to obtain a genetically modified non-human animal;

[0403] (b) mating a genetically modified non-human animal with another genetically modified non-human animal and then screening the offspring to obtain a genetically modified non-human animal having two or more human genes or chimeric genes.

[0404] In some embodiments, in step (b) of the method, the genetically modified animal can be mated with a genetically modified non-human animal having human or chimeric PD-1, CTLA-4, LAG-3, BTLA, PD-L1, CD27, CD28, CD47, CD137, CD154, TIGIT, TIM-3, GITR, SIRPa or OX40. Some of these genetically modified non-human animals are described in, for example, PCT / CN2017 / 090320, PCT / CN2017 / 099577, PCT / CN2017 / 099575, PCT / CN2017 / 099576, PCT / CN2017 / 099574, PCT / CN2017 / 106024, PCT / CN2017 / 110494, PCT / CN2017 / 110435, PCT / CN2017 / 120388, PCT / CN2018 / 081628, and PCT / CN2018 / 081629; the entire text of each of these patents is incorporated herein by reference.

[0405] Methods of using genetically modified animals

[0406] Genetically modified animals can be used to produce humanized or chimeric antibodies that can specifically bind to a target. In some embodiments, the target (e.g., a protein or a fragment of a protein) can be used as an immunogen to produce antibodies in these animals using standard techniques for preparing polyclonal and monoclonal antibodies. In some embodiments, the genetically modified animal is exposed to a selected antigen for a period of time under conditions that allow the animal to produce antibodies specific for the antigen.

[0407] Polyclonal antibodies can be produced in animals by multiple injections (e.g., subcutaneous or intraperitoneal injections) of antigenic peptides or proteins. In some embodiments, the antigenic peptides or proteins are injected together with at least one adjuvant. In some embodiments, the antigenic peptides or proteins can be conjugated to an agent that is immunogenic in the species to be immunized. Animals can be injected with more than one (e.g., two, three, or four) antigenic peptides or proteins.

[0408] Full-length polypeptides or proteins, or alternatively antigenic peptide fragments thereof, can be used as immunogens. The antigenic peptide of a protein comprises at least 8 (e.g., at least 10, 15, 20, or 30) amino acid residues of an amino acid sequence and encompasses an epitope of the protein such that antibodies generated against the peptide form specific immune complexes with the protein.

[0409] Immunogens are generally used to prepare antibodies by immunizing a suitable subject (e.g., a genetically modified animal as described herein). Suitable immunogenic preparations may contain, for example, recombinantly expressed or chemically synthesized polypeptides (e.g., fragments of proteins). The preparations may also include adjuvants (such as Freund's complete or incomplete adjuvant) or similar immunostimulants.

[0410] Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a polypeptide or its antigenic peptide (e.g., a portion of a protein) as an immunogen. Antibody titers in immunized subjects can be monitored over time using immobilized polypeptides or peptides by standard techniques, such as enzyme-linked immunosorbent assay (ELISA). If necessary, antibody molecules can be isolated from mammals (e.g., from blood) and further purified by well-known techniques (such as protein A or protein G chromatography) to obtain IgG fractions. At an appropriate time after immunization, for example, when specific antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as hybridoma techniques initially described by Kohler et al. (Nature 256: 495-497, 1975), human B cell hybridoma techniques (Kozbor et al., Immunol. Today 4: 72, 1983), EBV-hybridoma techniques (Cole et al., "Monoclonal Antibodies and Cancer Therapy", Alan R. Liss, Inc., pp. 77-96, 1985) or trioma techniques. Techniques for producing hybridomas are well known (see generally "Current Protocols in Immunology", 1994, Coligan et al., (Eds.), John Wiley & Sons, Inc., New York, NY). Hybridoma cells producing monoclonal antibodies are detected by screening hybridoma culture supernatants for antibodies that bind the polypeptide or epitope of interest, for example, using a standard ELISA assay.

[0411] In one aspect, the disclosure provides a mouse comprising a modification of an endogenous immunoglobulin heavy chain locus, wherein the mouse produces a B cell comprising a rearranged immunoglobulin sequence operably linked to a heavy chain constant region gene sequence. In some embodiments, the rearranged immunoglobulin sequence operably linked to a heavy chain constant region gene sequence comprises a human heavy chain V, D and / or J sequence. In some embodiments, the heavy chain constant region gene sequence comprises a human or mouse heavy chain sequence selected from CH1, hinge, CH2, CH3 and a combination thereof.

[0412] In one aspect, the disclosure provides a mouse comprising a modification of an endogenous immunoglobulin light chain (e.g., κ or λ) locus, wherein the mouse produces a B cell comprising a rearranged immunoglobulin sequence operably connected to a light chain constant region gene sequence. In some embodiments, the rearranged immunoglobulin sequence operably connected to a light chain constant region gene sequence comprises a human light chain V and / or J sequence. In some embodiments, the light chain constant region gene sequence comprises a human or mouse light chain constant region.

[0413] Mouse B cells or splenocytes may contain rearranged non-mouse immunoglobulin variable gene sequences, for example, operably linked to mouse immunoglobulin constant region genes. The sequences encoding human heavy chain variable regions and human light chain variable regions have been determined. These sequences can be determined, for example, by sequencing the hybridoma or B cell of interest. In some embodiments, single B cell screening is used. It can screen natural antibody repertoires without the need for hybridoma fusion and combined display. For example, B cells can be mixed with a set of DNA barcode antigens so that the antigen barcodes and B cell receptor (BCR) sequences of each B cell are recovered by a single cell sequencing scheme.

[0414] The antibody can be further modified to obtain a humanized antibody or a human antibody, for example, by operably linking a sequence encoding a human heavy chain variable region to a sequence encoding a human heavy chain constant region and / or operably linking a sequence encoding a human light chain variable region to a sequence encoding a human light chain constant region.

[0415] In some embodiments, if the mouse expresses a protein that is very similar to the antigen of interest, it may be difficult to induce an immune response in the mouse. This is because during the development of immune cells, B cells and T cells that recognize MHC molecules bound to peptides of self-origin are deleted from the immune cell pool. In those cases, humanized mice can be further modified. The corresponding gene in the mouse can be knocked out, and then the mouse is exposed to the antigen of interest. Since the mouse does not experience negative selection for the gene product, the mouse can produce antibodies that can easily bind specifically to the target.

[0416] The present disclosure also provides methods for preparing antibodies, nucleic acids, cells, tissues (e.g., spleen tissue). In some embodiments, these methods involve exposing an animal as described herein to an antigen. Antibodies (e.g., hybrid antibodies), nucleic acids encoding antibodies, cells and / or tissues (e.g., spleen tissue) can be obtained from the animal. In some embodiments, nucleic acids encoding human heavy chain and light chain immunoglobulin variable regions are determined, for example, by sequencing. In some embodiments, nucleic acids encoding human heavy chain immunoglobulin variable regions can be operably connected to nucleic acids encoding human heavy chain immunoglobulin constant regions. In some embodiments, nucleic acids encoding human light chain immunoglobulin variable regions can be operably connected to nucleic acids encoding human light chain immunoglobulin constant regions. In some embodiments, cells containing nucleic acids as described herein are cultured and antibodies are collected.

[0417] In some embodiments, there is no mouse immunoglobulin V gene, D gene, J gene (e.g., no mouse IGHV, IGHD, IGHJ, IGKV or IGKJ gene) to constitute the heavy chain and / or light chain variable region sequence. In some embodiments, the heavy chain and / or light chain variable region sequence produced by the animal is fully humanized and is completely composed of human immunoglobulin V genes, D genes, J genes (e.g., human IGHV genes, IGHD genes, IGHJ genes, IGKV genes and IGKJ genes).

[0418] Variants of antibodies or antigen-binding fragments described herein can be prepared by introducing appropriate nucleotide changes into DNA encoding people, humanized or chimeric antibodies or their antigen-binding fragments described herein, or by peptide synthesis. Such variants include, for example, deletions, insertions or substitutions of residues in the amino acid sequence constituting the antigen-binding site of the antibody or antigen-binding domain. In a population of such variants, some antibodies or antigen-binding fragments will have increased affinity for the target protein. Any combination of deletions, insertions and / or combinations can be performed to obtain antibodies or their antigen-binding fragments with increased binding affinity for the target. Amino acid changes introduced into antibodies or antigen-binding fragments can also change or introduce new post-translational modifications to antibodies or antigen-binding fragments, such as changing (e.g., increasing or decreasing) the number of glycosylation sites, changing the type of glycosylation sites (e.g., changing the amino acid sequence so that different sugars are connected by enzymes present in the cell), or introducing new glycosylation sites.

[0419] The antibodies disclosed herein can be derived from animals of any species, including mammals. Non-limiting examples of natural antibodies include antibodies derived from humans, primates (e.g., monkeys and apes), cattle, pigs, horses, sheep, camelids (e.g., camels and llamas), chickens, goats, and rodents (e.g., rats, mice, hamsters, and rabbits, including transgenic rodents genetically engineered to produce human antibodies).

[0420] Human and humanized antibodies include antibodies having variable and constant regions derived from human germline immunoglobulin sequences (or having the same amino acid sequence as antibodies derived from human germline immunoglobulin sequences). Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or somatic mutations in vivo), such as in CDRs.

[0421] The antibody or antigen binding fragment may be further modified. For example, cysteine ​​residues may be introduced into the Fc region, thereby allowing the formation of interchain disulfide bonds in this region. The homodimeric antibodies thus produced may have any increased in vitro and / or in vivo half-life. Homodimeric antibodies with increased in vitro and / or in vivo half-life may also be prepared using heterologous bifunctional cross-linking agents, as described in, for example, Wolff et al. (Cancer Res. 53: 2560-2565, 1993). Alternatively, the antibody may be engineered to have dual Fc regions (see, for example, Stevenson et al., Anti-Cancer Drug Design 3: 219-230, 1989).

[0422] In one aspect, the MHC-I VH / VL mice described herein can be immunized with one or more antigen-MHC complexes. For a specific antigen, a mouse with MHC tolerance to the corresponding antigen (i.e., a mouse expressing the corresponding HLA) can be selected for immunization. Antigenic peptides that can be used for immunization are shown in the table below. In some embodiments, the antigen of the antigen-MHC complex described herein includes a peptide comprising an amino acid sequence as shown in SEQ ID NO: 23-55.

[0423] Table 16.

[0424]

[0425]

[0426] In some embodiments, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, or at least 60% of the antibodies produced in any genetically modified non-human animal comprise a VH CDR3 having an amino acid sequence longer than 15, 16, 17, 18, 19, or 20 amino acids.

[0427] Antibodies or their antigen-binding portions can be expressed on cells as part of recombinant receptors such as antigen receptors. There are functional non-TCR antigen receptors in antigen receptors, such as chimeric antigen receptors (CAR). Generally, CARs containing antibodies or antigen-binding fragments that exhibit TCR-like specificity for peptides in the context of MHC molecules may also be referred to as TCR-like CARs. Therefore, there are antigen receptors in the binding molecules provided, such as those including one of the antibodies provided (e.g., TCR-like antibodies). In some embodiments, antigen receptors and other chimeric receptors specifically bind to regions or epitopes (e.g., TCR-like antibodies). There are functional non-TCR antigen receptors in antigen receptors, such as chimeric antigen receptors (CAR). Cells expressing CAR and their use in adoptive cell therapy are also provided, such as treating diseases and disorders associated with antigen expression.

[0428] TCR-like CAR contains non-TCR molecules that exhibit T cell receptor specificity when displayed or presented in the context of MHC molecules, such as specificity for T cell epitopes or peptide epitopes. In some embodiments, TCR-like CAR may contain antibodies or antigen-binding portions thereof, such as TCR-like antibodies, such as described herein. In some embodiments, antibodies or their antibody-binding portions may react with specific peptide epitopes in the context of MHC molecules, wherein antibodies or antibody fragments may distinguish specific peptides in the context of MHC molecules from separate MHC molecules, separate specific peptides, and non-related peptides in the context of MHC molecules in some cases. In some embodiments, antibodies or their antigen-binding portions may exhibit higher binding affinity than T cell receptors.

[0429] In some embodiments, the antibody, or antigen binding portion thereof, can be expressed on a cell as part of a T cell receptor.

[0430] The present disclosure also provides methods for determining antibodies that can specifically bind to antigenic peptide-MHC complexes. These methods involve incubating the antibody with cells presenting the antigenic peptide of interest, cells presenting control antigenic peptides, and / or cells that do not present any antigenic peptides; and determining that the antibody can specifically bind to cells presenting the antigenic peptide of interest, and optionally determining that the antibody does not bind to cells presenting the control antigenic peptide or cells that do not present any antigenic peptides. MHC can be any MHC as described herein.

[0431] The present disclosure also provides methods for determining the VH and VL sequences of antibodies that can specifically bind to an antigen of interest (e.g., a peptide-MHC complex). In some embodiments, these methods involve exposing an animal as described herein to an antigen of interest (e.g., a peptide-MHC complex comprising an antigenic peptide of interest); and assaying cells from an animal tissue (e.g., spleen tissue, lymphoid tissue) that expresses an antibody that binds to the antigen of interest; and sequencing nucleic acids encoding human heavy and light chain immunoglobulin variable regions in cells expressing the antibody. In some embodiments, these sequences are obtained by System determination.

[0432] The present disclosure provides a genetically engineered animal that expresses a limited light chain library that can be associated with a variety of heavy chains. In various embodiments, the endogenous κ light chain variable region gene is deleted and replaced by a single, two, three, four or five human light chain variable region genes operably linked to the endogenous κ constant region gene. In various embodiments, the animal also comprises a non-functional λ light chain locus or its deletion or a deletion that makes the locus unable to form a λ light chain.

[0433] In some embodiments, the animal comprises a light chain variable region locus that lacks an endogenous light chain variable region gene and comprises a rearranged human V / J sequence operably linked to an endogenous constant region, and wherein the locus expresses light chains comprising the human V / J sequence linked to the endogenous constant region.

[0434] In some embodiments, the methods described herein are designed to prepare bispecific antibodies, eg, bispecific antibodies that bind to two antigen-MHC complexes.

[0435] In some embodiments, the animal comprises a rearranged light chain variable region locus. In some embodiments, the bispecific antibody may have a common light chain. In some embodiments, the methods involve immunizing a first animal comprising a rearranged light chain variable region locus, and obtaining the VH and VL sequences of the antibody. Then, the methods involve immunizing a second animal comprising the rearranged light chain variable region locus, and obtaining the VH and VL sequences of the antibody.

[0436] Bispecific antibodies can be prepared by engineering the interface between a pair of antibody molecules so that the percentage of the heterodimer recovered from recombinant cell culture is maximized. For example, the interface can include at least a portion of the CH3 domain of the antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced by larger side chains (for example, tyrosine or tryptophan). By replacing the large amino acid side chains with smaller amino acid side chains (for example, alanine or threonine), a compensation "cavity" identical or similar to the large side chain size is produced on the interface of the second antibody molecule. This provides a mechanism that can make the yield of heterodimers higher than other unwanted end products (such as homodimers). The method is described in, for example, WO 96 / 27011, which is incorporated herein by reference in its entirety.

[0437] In some embodiments, the knob-into-hole (KIH) technology can be used, which includes engineering the CH3 domain to produce a "knob" or "hole" in each heavy chain to promote heterodimerization. The KIH technology is described in, for example, Xu, Yiren et al., "Production of bispecific antibodies in'knobs-into-holes'using a cell-free expression system.", MAbs. Vol. 7. No. 1. Taylor & Francis, 2015, which is incorporated herein by reference in its entirety. In some embodiments, one heavy chain has T366W and / or S354C (knob) substitutions (EU numbering), while the other heavy chain has Y349C, T366S, L368A and / or Y407V (hole) substitutions (EU numbering). In some embodiments, one heavy chain has one or more of the following substitutions: Y349C and T366W (EU numbering). The other heavy chain may have one or more of the following substitutions: E356C, T366S, L368A, and Y407V (EU numbering). In some embodiments, one heavy chain has a T366Y (knob) substitution and the other heavy chain has one, two, or three of these substitutions T366S, L368A, Y407V (hole).

[0438] Example

[0439] The present invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

[0440] Example 1: Generation of MHC humanized mice

[0441] The nucleotide sequences encoding human B2M and HLA class I proteins are introduced into non-human animals comprising rearranged or unrearranged human or humanized immunoglobulin heavy and / or light chain loci to obtain genetically modified non-human animals (MHC-I VH / VL background) that can express and tolerate human MHC protein molecules in vivo. The non-human animal can be RenMab TM Mice (hVH / hVL mice) that have both a humanized immunoglobulin heavy chain locus and a humanized immunoglobulin kappa chain locus. RenMab TM A detailed description of mice can be found in, for example, PCT / CN2020 / 075698 and US20200390073A1, which are incorporated herein by reference in their entirety. Alternatively, the non-human animal can be a RenLite TM Mice (or hVH / hcVL mice) having a humanized immunoglobulin heavy chain locus and a humanized common light chain locus. RenLite TM A detailed description of mice can be found, for example, in PCT / CN2021 / 097652, which is incorporated herein by reference in its entirety. One or more gene edits can be directly performed in a non-human animal containing human immunoglobulin sequences to introduce gene sequences that can express human B2M and MHC class I proteins. Such animals can also be obtained by breeding non-human animals containing human immunoglobulin sequences with MHC humanized non-human animals. Figure 1 As shown, a non-limiting MHC humanization strategy includes inserting an artificial MHC I class gene encoding B2M and MHC class I α chain fusion protein into the endogenous B2M locus. Optionally, the coding sequence of endogenous B2M can also be inactivated (e.g., knocked out). Specific schemes for MHC humanization can be found in, for example, PCT / CN2021 / 070967, which is incorporated herein by reference in its entirety.

[0442] Figure 1The targeting vector shown may include the following main features, in 5' to 3' order: a homology arm sequence (SEQ ID NO: 1) upstream of the insertion site, a sequence of the first part of the MHC class I α chain, a human B2M coding sequence, a sequence of the second part of the MHC class I α chain, and a homology arm sequence (SEQ ID NO: 2) downstream of the insertion site. Specifically, the sequence of the first part of the MHC class I α chain may include a sequence encoding a signal peptide sequence of a human MHC class I α chain; the sequence of the second part of the MHC class I α chain may include a sequence other than a sequence encoding a signal peptide, such as a coding sequence of the MHC class I α chain (e.g., sequences encoding α1, α2, α3, transmembrane and intracellular domains of human HLA proteins; or sequences encoding α1 and α2 domains of human HLA proteins, followed by sequences encoding α3, transmembrane and intracellular domains of mouse H2-D1 protein). Optionally, a linker sequence, such as a flexible linker sequence of 5'-GGAGGTGGCGGATCCGGCGG AGGCGGCTCGGGTGGCGGCGGCTCT-3' (SEQ ID NO: 3), can be inserted between the human B2M coding sequence and the MHC class I α chain part 2 sequence, and the flexible linker sequence encodes the amino acid sequence (GGGGS) 3 (SEQ ID NO: 4). In order to promote the expression of the fusion protein, the MHC class I α chain part 3 sequence can also include the downstream of the MHC class I α chain part 2 sequence. The MHC class I α chain part 3 sequence can include the 3'UTR sequence of the MHC class I α chain gene and the downstream part of the regulatory sequence (for example, the 3'UTR sequence and the downstream part of the regulatory sequence of the human HLA gene or the mouse H2-D1 gene).

[0443] Considering the high polymorphism of human HLA class I gene sequences, the existence of a large number of different alleles, and their similar structure and function, the targeting strategy described herein can be applied to all HLA class I genes. Some HLA gene information is shown in the table below. For example, the mouse B2M locus can be modified by inserting a sequence from the human HLA-A gene (NCBI gene ID: 3105, original source: HGNC: 4931, UniProt ID: P04439) to obtain Figure 2A or Figure 3A The humanized mouse B2M locus is shown in Figure 2. The corresponding targeting strategies are shown in Figure 2. Figure 2B and Figure 3B The modified mice can express an MHC complex containing human B2M and human or humanized HLA-A.

[0444] Table 17

[0445]

[0446]

[0447]

[0448]

[0449]

[0450]

[0451] exist Figure 2B In , a targeting vector was designed, which contains homology arm sequences upstream and downstream of the mouse B2M gene, and an "A fragment" encoding the human B2M protein, a portion of the human HLA-A protein, and a portion of the mouse H2-D1 protein. The "A fragment" contains sequences encoding the following polypeptides from the 5' end to the 3' end: the signal peptide of human HLA-A; human B2M; a flexible linker polypeptide sequence; a portion of the human HLA-A protein; and a portion of the mouse H2-D1 protein. Due to the presence of the flexible linker polypeptide sequence, the protein can have the functional domains of human B2M and HLA-A proteins. Figure 3B In the Figure 2B The targeting vector used in is similar to that used in Figure 2B It does not contain any sequence encoding the mouse H2-D1 protein, but contains sequences encoding the α1, α2, α3, transmembrane and intracellular domains of the human HLA-A protein.

[0452] Preparation of mice expressing humanized MHC complexes containing HLA-A*0201

[0453] Based on the sequence information of HLA-A*0201 (SEQ ID NO: 6), a genetically modified mouse expressing a humanized MHC complex containing HLA-A*0201 was prepared by the above method. Figure 2B As shown in the targeting strategy in, the sequence of the mouse B2M locus (about 3.9 kb) is replaced by a sequence (about 3.5 kb) encoding the following items: the signal peptide sequence of the human HLA-A*0201 protein, human B2M, a flexible linker sequence, the α1 and α2 domains of the human HLA-A*0201 protein, and the α3, transmembrane and intracellular domains of the mouse H2-D1 protein, thereby humanizing the mouse MHC complex. The targeting vector contains homology arm sequences upstream and downstream of the mouse B2M gene, and an "A fragment" containing HLA-A*0201 and B2M gene (or cDNA) fragments. Specifically, the sequence of the upstream homology arm is shown in SEQ ID NO: 1, and the sequence of the downstream homology arm is shown in SEQ ID NO: 2. The connection between the human HLA-A*0201 sequence and the mouse H2-D1 sequence is designed as: The sequence " GATCT The last "T" in " is the last nucleotide of the human HLA-A*0201 sequence, and the sequence The first "G" in is the first nucleotide of the mouse H2-D1 sequence. The encoded fusion protein sequence is shown in SEQ ID NO:61.

[0454] Alternatively, if Figure 3B As shown in the schematic diagram of the targeting strategy in , the sequence of the mouse B2M locus (about 3.9kb) is replaced by a sequence (about 4.4kb) encoding the following items: the signal peptide sequence of the human HLA-A*0201 protein, human B2M, a flexible linker sequence, and the α1, α2, α3 domains, transmembrane and intracellular domains of the human HLA-A*0201 protein, thereby humanizing the mouse MHC complex. The targeting vector contains homology arm sequences upstream and downstream of the mouse B2M gene, as well as a "knock-in fragment" containing HLA-A*0201 and B2M gene (or cDNA) fragments. Specifically, the sequence of the upstream homology arm is shown in SEQ ID NO: 1, and the sequence of the downstream homology arm is shown in SEQ ID NO: 2. The connection between the downstream of the human HLA-A*0201 sequence and the mouse sequence is designed as:

[0455] The sequence " GCCGC The last "C" in " is the last nucleotide of the human HLA-A*0201 sequence, and the sequence The first "G" in is the first nucleotide of the mouse sequence. The encoded fusion protein sequence is shown in SEQ ID NO:62.

[0456] Preparation of mice expressing humanized MHC complexes containing HLA-A*2402

[0457] Based on the sequence information of HLA-A*2402 (SEQ ID NO: 10), a genetically modified mouse expressing a humanized MHC complex containing HLA-A*2402 was prepared by the above method. Figure 3BAs shown in the schematic diagram of the targeting strategy in , the sequence of the mouse B2M locus (about 3.9kb) is replaced by the sequence encoding the following items (about 3.7kb): the signal peptide sequence of the human HLA-A*2402 protein (Part 1), human B2M, a flexible linker sequence, and the α1, α2, α3 domains, transmembrane and intracellular domains (Part 2) of the human HLA-A*2402 protein, thereby humanizing the mouse MHC complex. The targeting vector contains homology arm sequences upstream and downstream of the mouse B2M gene, as well as a "knock-in fragment" containing HLA-A*2402 and B2M gene (or cDNA) fragments. Specifically, the sequence of the upstream homology arm is shown in SEQ ID NO: 1, and the sequence of the downstream homology arm is shown in SEQ ID NO: 2. The connection between the human HLA-A*2402 Part 1 sequence and the upstream of the human B2M coding sequence is designed as:

[0458]

[0459] The sequence " GGGCA "A" in " is the last nucleotide of the first part of the sequence of human HLA-A*2402, and the sequence The first "A" in is the first nucleotide of the human B2M coding sequence. The connection between the human B2M coding sequence, the flexible linker sequence and the human HLA-A*2402 part 2 sequence is designed as follows:

[0460]

[0461] The sequence " ACATG "G" in the sequence is the last nucleotide of the human B2M coding sequence, and the sequence The first "G" in is the first nucleotide of the human HLA-A*2402 part 2 sequence. The junction between the downstream of the human HLA-A*2402 part 2 sequence and the mouse sequence is designed as:

[0462]

[0463] The sequence " ATTAC "C" in " is the last nucleotide of the second part of the sequence of human HLA-A*2402, and the sequence The first "G" in is the first nucleotide of the mouse sequence. The encoded fusion protein sequence is shown in SEQ ID NO:65.

[0464] Preparation of mice expressing humanized MHC complexes containing HLA-A*1101

[0465] Based on the sequence information of HLA-A*1101 (SEQ ID NO: 9), a genetically modified mouse expressing a humanized MHC complex containing HLA-A*1101 was prepared by the above method. Figure 3B As shown in the schematic diagram of the targeting strategy in , the sequence of the mouse B2M locus (about 3.9kb) is replaced by the sequence encoding the following items (about 3.7kb): the signal peptide sequence of the human HLA-A*1101 protein (Part 1), human B2M, a flexible linker sequence, and the α1, α2, α3 domains, transmembrane and intracellular domains of the human HLA-A*1101 protein (Part 2), thereby humanizing the mouse MHC complex. The targeting vector contains homology arm sequences upstream and downstream of the mouse B2M gene, as well as a "knock-in fragment" containing HLA-A*1101 and B2M gene (or cDNA) fragments. Specifically, the sequence of the upstream homology arm is shown in SEQ ID NO: 1, and the sequence of the downstream homology arm is shown in SEQ ID NO: 2. The connection between the human HLA-A*1101 Part 1 sequence and the upstream of the human B2M coding sequence is designed as:

[0466]

[0467] The sequence " GGGCG The last "G" in " is the last nucleotide of the first part of the sequence of human HLA-A*1101, and the sequence The first "A" in is the first nucleotide of the human B2M coding sequence. The connection between the human B2M coding sequence, the flexible linker sequence and the human HLA-A*1101 part 2 sequence is designed as follows: The sequence " ACATG "G" in the sequence is the last nucleotide of the human B2M coding sequence, and the sequence The first "G" in is the first nucleotide of the human HLA-A*1101 part 2 sequence. The junction between the downstream of the human HLA-A*1101 part 2 sequence and the mouse sequence is designed as: The sequence " TCCAT The last "T" in " is the last nucleotide of the second part sequence of human HLA-A*1101, and the sequence The first "G" in is the first nucleotide of the mouse sequence. The encoded fusion protein sequence is shown in SEQ ID NO:64.

[0468] Preparation of mice expressing humanized MHC complexes containing HLA-A*0302

[0469] Based on the sequence information of HLA-A*0302 (SEQ ID NO: 8), a genetically modified mouse expressing a humanized MHC complex containing HLA-A*0302 was prepared by the above method. Figure 3B As shown in the schematic diagram of the targeting strategy in , the sequence of the mouse B2M locus (about 3.9kb) is replaced by the sequence encoding the following items (about 4.3kb): the signal peptide sequence of the human HLA-A*0302 protein (Part 1), human B2M, a flexible linker sequence, and the α1, α2, α3 domains, transmembrane and intracellular domains (Part 2) of the human HLA-A*0302 protein, thereby humanizing the mouse MHC complex. The targeting vector contains homology arm sequences upstream and downstream of the mouse B2M gene, as well as a "knock-in fragment" containing HLA-A*0302 and B2M gene (or cDNA) fragments. Specifically, the sequence of the upstream homology arm is shown in SEQ ID NO: 1, and the sequence of the downstream homology arm is shown in SEQ ID NO: 2. The connection between the human HLA-A*0302 Part 1 sequence and the upstream of the human B2M coding sequence is designed as: The sequence " GGGCG The last "G" in " is the last nucleotide of the sequence of part 1 of human HLA-A*0302, and the sequence The first "A" in is the first nucleotide of the human B2M coding sequence. The connection between the human B2M coding sequence, the flexible linker sequence and the human HLA-A*0302 part 2 sequence is designed as follows:

[0470]

[0471] The sequence " ACATG "G" in the sequence is the last nucleotide of the human B2M coding sequence, and the sequence The first "G" in is the first nucleotide of the human HLA-A*0302 part 2 sequence. The connection between the downstream of the human HLA-A*0302 part 2 sequence and the mouse sequence is designed as:

[0472]

[0473] The sequence " AGGGAThe last "A" in " is the last nucleotide of the second part sequence of human HLA-A*0302, and the sequence The first "G" in is the first nucleotide of the mouse sequence. The encoded fusion protein sequence is shown in SEQ ID NO:63.

[0474] Humanized mice with other HLA genes in Table 17 can also be prepared by a similar method as described above, and the fusion proteins expressed by these humanized mice are shown in SEQ ID NOs: 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 and 80 (by Figure 3B Targeting strategy in) or SEQ ID NO: 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116 and 117 (by Figure 2B Targeted strategies in .

[0475] Detection of human B2M and MHC class I expression in mice

[0476] The genotype of somatic cells of offspring mice was determined by PCR and Southern blotting (according to Figure 3B For example, HLA-A*2402 heterozygous hVH / hVL mice (HLA-A*2402 H / + The PCR identification results of hVH / hVL) are shown in Figure 4A to Figure 4B The results showed that all 16 mice numbered F1-01 to F1-16 were positive heterozygous mice. The primers used in PCR identification are listed in the table below.

[0477] Table 18

[0478]

[0479]

[0480] Specifically, WT-F is located upstream of the 5' homology arm; WT-R is located within intron 1 of the mouse B2M gene; and Mut-R is located within the human B2M coding sequence.

[0481] Positive mice were further tested by Southern blotting to verify the presence of random insertions. Genomic DNA was extracted from mouse tail blood and the restriction enzymes BclI or BglII were selected to digest the genomic DNA, followed by membrane transfer and hybridization. Both the 5' probe and the 3' probe were located within the HLA part 2 sequence. The sizes of the specific probes and target fragments are shown in the table below.

[0482] Table 19

[0483] Restriction enzymes Probe WT size Target size BclI 5' probe 5.5kb 7.2kb BglII 3' probe 4.0 kb 2.8kb

[0484] The Southern blot probes were synthesized using the following primers:

[0485] 5' probe-F: 5'-ATGAGGTCTTTTTGTGGGCAGAGCA-3' (SEQ ID NO: 19),

[0486] 5' probe-R: 5'-CTCCCTACGGCCACATCACCATTAC-3' (SEQ ID NO: 20);

[0487] 3' probe-F: 5'-TAACTTCATGTAAGGCACCGTCAC-3' (SEQ ID NO: 21),

[0488] 3' Probe-R: 5'-TCCAGACCTCACCATCAAATGAG-3' (SEQ ID NO: 22).

[0489] Example Southern blot results are shown below: Figure 5 As shown. Results were obtained using 5' and 3' probes, which were further verified by sequencing. Eight mice, numbered F1-01 to F1-08, were identified as positive clones without random insertions. The results show that MHC-I VH / VL mice can be generated using the methods described herein, and that the mice can be stably passaged without random insertions. MHC-I VH / VL homozygous mice can be obtained by breeding heterozygous mice identified as positive with each other.

[0490] Anti-mouse β2M antibody (BioLegend, catalog number: 154503), anti-human β2M antibody (BioLegend, catalog number: 395711), and anti-HLA-A3 antibody (Invitrogen, catalog number: 17-5754-42) were used to detect the expression of human B2M protein and HLA protein in wild-type C57BL / 6 mice and HLA-A*0302 humanized heterozygous mice (HLA-A*0302 H / + hVH / hVL) in vivo expression. The analysis results based on the flow cytometry detection results are shown in the table below. The results show that the HLA-A*0302hVH / hVL mice generated herein can successfully express human B2M protein and HLA protein in vivo.

[0491] Table 20

[0492]

[0493]

[0494] Similarly, APC anti-human β2-microglobulin antibody (BioLegend, catalog number: 395712), PE anti-mouse β2-microglobulin antibody (BioLegend, catalog number: 154504) and PE anti-human HLA-A, B, C antibodies (BioLegend, catalog number: 311406) were used to detect the expression of human B2M protein and HLA protein in wild-type C57BL / 6 mice and HLA-A*1101 humanized heterozygous mice (HLA-A*1101 H / + hVH / hVL) in vivo. The analysis results are shown in the table below. The results show that the HLA-A*1101hVH / hVL mice generated herein can successfully express human B2M protein and HLA protein in vivo.

[0495] Table 21

[0496] Positive cells C57BL / 6 <![CDATA[HLA-A*1101 H / + hVH / hVL]]> Mouse B2M positive cells (%) 91.4% 29.2% Human B2M positive cells (%) 0.65% 96.8% HLA positive cells (%) 0.94% 98.3%

[0497] Similarly, the protein expression of humanized mice with other HLA genes in Table 17 can be detected by the above method. The results show that the MHC-I VH / VL mice produced by the method described herein can successfully express human B2M protein and HLA protein in vivo.

[0498] Example 2: Generation of human antibodies

[0499] MHC-I VH / VL mice obtained as described herein are immunized with antigen-MHC complexes. For example, mice are immunized with antigen-MHC complexes multiple times (e.g., four times), and orbital blood is collected before immunization (as a negative control). Freund's complete adjuvant (CFA) is used for the first immunization, and Freund's incomplete adjuvant (IFA) is used for the second to fourth immunizations, with two weeks between each immunization. Orbital blood is collected 1 week after the third immunization, and the serum titer of antigen-specific antibodies is detected by ELISA.

[0500] In subsequent experiments, MHC-I VH / VL mice were immunized with antigen-MHC complexes including one of the following heterologous antigens: peptide A, peptide B, peptide C, peptide D, peptide E, and peptide F. These antigen peptides are compatible with HLA-A*0201, and the immunized mice can express HLA-A*0201 protein.

[0501] ELISA was performed as follows. His-tagged antigen was diluted to 0.5 μg / ml in 1×PBS and added to a 96-well plate at 0.1 ml / well, followed by incubation at 37°C for 2 hours. After incubation, each well was washed three times with 300 μl 1×PBS and then blocked with 250 μl 1×PBS supplemented with 5% skim milk at 37°C for 1 hour. Each well was then washed twice with 300 μl 1×PBS. Serum samples from MHC-I VH / VL mice were first diluted with 1×PBS at 1:100, 1:500, 1:2500, 1:12500, 1:62500, 1:312500, or 1:1562500, and then the samples were added to a 96-well plate. Serum samples from unimmunized mice were also diluted at 1:100 and added to the plate as a blank control. The diluted serum samples (120 μl / well) were incubated in a 96-well plate at 37°C for 1 hour. After incubation, the plate was washed five times with 300 μl / well of 1×PBST. The plate was then incubated with 0.1 ml / well of goat anti-mouse IgG Fc (HRP) diluted 1:20000 at 37°C for 1 hour. After incubation, the plate was washed five times with 300 μl / well of 1×PBST. Next, 0.1 ml of TMB (3,3',5,5'-tetramethylbenzidine) developer was added to each well, and the plate was placed in the dark at room temperature for 10 minutes, followed by the addition of 0.1 ml of stop solution to each well. OD450 was measured by a plate reader and the standard OD value was calculated. After mice were immunized three times with antigenic peptide A, peptide B, peptide C, peptide D, peptide E and peptide F, the antigen-specific antibody serum titers were shown in 6A to 6F The results showed that the antibody titer obtained by immunizing HLA heterozygous mice was higher than that of HLA homozygous mice.

[0502] Antigen-positive immune cells are isolated from immunized mice and fused with mouse myeloma cells to form hybridoma cells. Hybridoma cells that secrete antigen-specific monoclonal antibodies are screened to obtain antigen-specific antibodies. The heavy chain and light chain variable region sequences of antigen-specific antibodies can also be directly obtained by isolating antigen-positive B cells from immunized mice. For example, single cell technology (e.g., Optical fluid system, Berkeley Lights Inc.) can be used for screening and separating plasma cells that secrete antigen-specific monoclonal antibodies, and then reverse transcription and PCR sequencing are performed to obtain antibody variable region sequences. Then, these sequences can be used to express antibodies. Then, the specificity of expressed antibodies combined with antigen peptide-MHC complexes can be verified by FACS (fluorescence activated cell sorting).

[0503] Example 3: Diversity and Binding Affinity Distribution of Anti-Peptide A Antibodies

[0504] After immunizing mice with antigenic peptide A-MHC complexes, The optofluidic system separates plasma cells that produce antigen-specific monoclonal antibodies. Total RNA is extracted from plasma cells, reverse transcribed into cDNA, and then sequenced. A total of 171 pairs of antibody heavy chain variable region (VH) sequences and light chain variable region (VL) sequences were obtained. The sequences expressing the VH and VL of these antibodies were cloned into a vector expressing the constant region of human IgG1 to obtain human antibodies.

[0505] Antibodies bound to peptide A-MHC complexes were detected by FACS. Prior to FACS detection, T2 cells loaded with antigenic peptide A were prepared. Specifically, T2 cells (ATCC, catalog number: CRL-1992) were centrifuged at 25°C for 5 minutes, and the supernatant was discarded. The cells were resuspended to 2×10 cells / mL using a culture medium containing antigenic peptide A and human B2M protein (at a concentration of 20 μg / ml). 6 The cells were cultured at 37°C under 5% CO2 for more than 16 hours. An irrelevant peptide (control peptide) and human B2M protein were added to the control group. The cells were then collected by centrifugation and resuspended to an appropriate density (about 1×10 in 10 μl). 5 cells) to obtain T2 cells loaded with peptide A (T2 plus peptide A) and T2 cells loaded with irrelevant peptides (T2 plus control peptide). 50 μl of the test antibody was diluted to the specified concentration, and then 50 μl of the fluorescent antibody was added. The mixture was incubated at 4°C for 30 minutes and then washed once with PBS. The washed cells were resuspended and subjected to FACS analysis.

[0506] Using the above method, 115 antigen-specific antibodies (characterized by: T2 is negative; T2 plus peptide A is positive; and T2 plus control peptide is negative) were screened out from 171 antibodies. Some exemplary flow cytometry detection results are shown in the table below.

[0507] Table 22

[0508]

[0509]

[0510] Then use Biacore TM Purified anti-antigenic peptide A antibodies were diluted to 1 μg / ml and then injected into the Biacore system at 10 μl / min. TMThe chip was titrated in 8K biosensor for about 50 seconds to reach the desired protein density (e.g., about 50 response units (RU)). The His-tagged antigen peptide A-MHC complex at a concentration of 200 nM was then injected at 30 μl / min for 120 seconds. The dissociation was monitored for 600 seconds. After the last injection of each round of titration, the chip was regenerated with glycine solution (pH 2.0, 30 μl / min, 30 seconds).

[0511] By using Biacore TM 8K Evaluation Software 3.0 fits the data to a 1:1 Langmuir binding model (Karlsson, R. Roos, H. Fagerstam, L. Petersson, B., 1994. Methods Enzymology 6.99-110), thereby simultaneously obtaining the kinetic association rate (kon) and dissociation rate (koff). Affinity is derived from the quotient of the kinetic rate constant (KD = koff / kon).

[0512] As will be appreciated by one of ordinary skill in the art, the same approach with appropriate adjustment of parameters (e.g., antibody concentration) is employed for each antibody tested. Figure 7 As shown, the results showed that 55.6% of the tested antibodies had a -8 20% of the tested antibodies (23 out of 115) had a KD value of about 10 -10 33.9% of the tested antibodies (39 out of 115) had KD values ​​less than 10 -11 The KD value of M. The results show that the method described in this article can successfully produce antibodies with high binding affinity to antigens. At the same time, the VH and VL sequences of 171 antibodies obtained in the first screening were compared, and 16 pairs of antibody VH and VL sequences were obtained after deduplication.

[0513] The lengths of the VH and VL CDR3 sequences of these antibodies and the use of human germline genes were also determined. The length distribution of the VH CDR3 sequences is shown in Figure 8 As shown. The results show that 75% of the 16 antibodies have a VH CDR3 length of greater than 20 amino acids. After further analysis of the VH CDR3 sequences, 10 groups of sister antibodies (i.e., sequences with a VH CDR3 identity of not less than 85%) were found, of which Group 1 includes 6 sequences, Group 2 includes 2 sequences, and the other groups each include 1 sequence. The results show that a diverse collection of antibody sequences can be obtained using the methods described herein.

[0514] The human germline genes of 16 antibody heavy chain sequences were verified by molecular biology methods, and then the variable region genes were classified into corresponding subgroups according to the IMGT database for statistical analysis. The results of the human germline gene application of these antibodies are shown in FIG. 9A to FIG. 9B The results showed that these 16 antibodies involved 7 IGHV genes and 5 IGKV genes, indicating a diverse antibody collection.

[0515] Example 4: Diversity and Binding Affinity Distribution of Anti-Peptide B Antibodies

[0516] In the antigen peptide group B, a total of 269 pairs of VH and VL sequences were obtained. A similar method as described in Example 3 was used, including the preparation of cells loaded with high-throughput antigen peptides and flow cytometry detection. The results showed that 34 antigen-specific antibodies were screened out from 269 antibodies. TM The system measured the binding affinity of the antibodies. The percentage of positive cells and affinity of some antibodies are shown in the table below.

[0517] Table 23

[0518]

[0519] The VH, VL and CDR sequences of all antibodies were analyzed. After sequence alignment and deduplication, 19 antibodies were obtained. Fig.10 As shown in Figure 5, 57.8% of antibodies have a VH CDR3 length longer than 20 amino acids. Further analysis of the VH CDR3 sequences revealed 17 groups of sister antibodies. Except for Group 2 and Group 6, which both included 2 sequences, the other 15 groups each included only 1 sequence. The germline gene application is shown in Figure 5. FIG. 11A to FIG. 11B The results showed that these 19 antibodies involved 7 IGHV genes and 9 IGKV genes, indicating a diverse antibody collection.

[0520] Example 5: Diversity and Binding Affinity Distribution of Anti-Peptide C Antibodies

[0521] In the antigen peptide group C, a total of 126 pairs of VH and VL sequences were obtained. A similar method as described in Example 3 was used, including the preparation of cells loaded with high-throughput antigen peptides and flow cytometry detection. The results showed that 31 antigen-specific antibodies were screened out from the 126 antibodies. TM The system measured the binding affinity of the antibodies. Some exemplary flow cytometry detection and affinity results are shown in the table below.

[0522] Table 24

[0523]

[0524]

[0525] Similar to the method described in Example 3, the VH, VL and CDR sequences of all antibodies were analyzed. After sequence alignment, 18 antibodies were obtained after deduplication. Fig.12 As shown in Figure 1, 11 antibodies have VH CDR3 lengths longer than 20 amino acids. Further analysis of the VH CDR3 sequences revealed 12 groups of sister antibodies. Except for group 5, which included 6 sequences, the other 11 groups each included only 1 sequence. The germline gene application is shown in Figure 1. FIG. 13A to FIG. 13B The results showed that these 18 antibodies involved 10 IGHV genes and 8 IGKV genes, indicating a diverse antibody collection.

[0526] HLA homozygous or heterozygous hVH / hVL mice immunized with antigenic peptide B or antigenic peptide C (HLA H / + hVH / hVL and HLA H / H The percentage of antibody positive cells produced by immunizing HLA heterozygous mice was further analyzed, and the results are listed in the table below. The results show that the percentage of antigen-specific antibody positive cells obtained by immunizing HLA heterozygous mice is higher than that of antigen-specific antibody positive cells of homozygous mice.

[0527] Table 25

[0528]

[0529] Example 6: Diversity and Binding Affinity Distribution of Anti-Peptide D Antibodies

[0530] In the antigen peptide D group, a total of 207 pairs of VH and VL sequences were obtained. 31 antigen-specific antibodies were screened using a similar method as described in Example 3 (e.g., flow cytometry detection). TM The system measured the binding affinity of the antibodies to antigenic peptide D. Some exemplary results are shown in the table below. The results show that the antibodies have high affinity for antigenic peptide D, and the KD of some antibodies is even less than 10 -8 M.

[0531] Table 26

[0532]

[0533]

[0534] The VH, VL and CDR sequences of all antibodies were analyzed. After sequence alignment, 15 antibodies were obtained after deduplication. Among them, 8 antibodies had a VH CDR3 of 20 amino acids and 7 antibodies had a VH CDR3 of 19 amino acids. Further analysis of the VHCDR3 sequence revealed 10 groups of sister antibodies: Groups 1 and 2 had 3 sequences, Groups 3-5 each included 2 sequences, and the other groups each had 1 sequence. The results show that a diverse collection of antibodies can be generated using the method described herein.

[0535] Example 7: Diversity and Binding Affinity Distribution of Anti-Peptide F Antibodies

[0536] Similar to the method described in Example 2, HLA-A*0201hVH / hcVL heterozygous mice (HLA-A*0201 H / + hVH / hcVL v2). OD450 was measured by plate reader and the standard OD value was calculated. After mice were immunized four times with antigen peptide F, the titer of antigen-specific antibody serum was shown in Fig.18 middle.

[0537] After immunizing mice with antigenic peptide F-MHC complexes, The photofluidic system separates plasma cells that produce antigen-specific monoclonal antibodies. Total RNA is extracted from plasma cells, reverse transcribed into cDNA, and then sequenced. A total of 384 pairs of antibody heavy chain variable region (VH) sequences and light chain variable region (VL) sequences were obtained. The sequences expressing the VH and VL of these antibodies were cloned into a vector expressing the constant region of human IgG1 to obtain human antibodies.

[0538] The binding of the antibodies to the peptide F-MHC complex was detected by FACS using the method described in Example 3. 103 antigen-specific antibodies were screened from 384 antibodies. Some exemplary flow cytometry results are shown in the table below.

[0539] Table 27

[0540] Antibody T2 T2 plus peptide F T2 plus control peptide Antigen-specific antibodies F-001 1.4% 90.8% 3.3% have F-002 1.4% 89.1% 1.1% have F-003 1.1% 92.6% 1.2% have F-004 1.3% 93.9% 1.0% have F-005 1.4% 86.7% 96.8% none F-006 1.9% 93.8% 2.6% have F-007 1.4% 87.6% 1.2% have F-008 1.2% 87.2% 1.4% have

[0541] Using Biacore TM The antibody affinity was determined using the method described in Example 3, and the results are shown in Fig.19 In addition, the results of human germline gene applications of these antibodies are shown in Fig. 20 The results showed that these 29 antibodies involved 12 IGHV genes, indicating a diverse antibody collection.

[0542] Example 8: Diversity and Binding Affinity Distribution of Anti-Peptide G Antibodies

[0543] Similar to the method described in Example 2, HLA-A*0302hVH / hcVL homozygous mice (HLA-A*0302 H / H hVH / hcVL and HLA-A*0302hVH / hVL heterozygous mice (HLA-A*0302 H / + hVH / hVL). OD450 was measured by plate reader and the standard OD value was calculated. After mice were immunized four times with antigen peptide G, the titer of antigen-specific antibody serum was shown in Fig.21 The results showed that by immunizing HLA-A*0302hVH / hVL heterozygous mice (HLA-A*0302 H / + hVH / hVL) was higher than that of HLA-A*0302hVH / hVL homozygous mice (HLA-A*0302 H / H hVH / hVL) antibody titer.

[0544] Using a similar method as described above, HLA-A*1101hVH / hcVL homozygous mice (HLA-A*0101 H / H hVH / hcVL and HLA-A*1101hVH / hVL heterozygous mice (HLA-A*1101 H / + hVH / hVL). OD450 was measured by plate reader and the standard OD value was calculated. After mice were immunized four times with antigen peptide G, the titer of antigen-specific antibody serum was shown in Fig. 22 The results showed that by immunizing HLA-A*1101hVH / hVL heterozygous mice (HLA-A*1101 H / + hVH / hVL) was higher than that of HLA-A*1101hVH / hVL homozygous mice (HLA-A*1101 H / H hVH / hVL) antibody titer.

[0545] A total of 289 pairs of antibody heavy chain variable region (VH) sequences and light chain variable region (VL) sequences were obtained. The sequences expressing the VH and VL of these antibodies were cloned into a vector expressing the human IgG1 constant region to obtain human antibodies.

[0546] The binding of antibodies to peptide G-MHC complexes was detected by FACS using the method described in Example 3. 74 antigen-specific antibodies were screened from 289 antibodies. TM The antibody affinity was further measured by the system and the results are shown in Fig.23 middle.

[0547] Example 9: Diversity and Binding Affinity Distribution of Anti-Peptide H Antibodies

[0548] Similar to the method described in Example 2, HLA-A*2402hVH / hcVL heterozygous mice (HLA-A*2402 H / + hVH / hVL). OD450 was measured by plate reader and the standard OD value was calculated. After mice were immunized four times with antigen peptide G, the titer of antigen-specific antibody serum was shown in Fig.24 middle.

[0549] Using a similar method as described above, mice were immunized with peptide H-MHC complexes to produce antibodies. A total of 142 pairs of antibody heavy chain variable region (VH) sequences and light chain variable region (VL) sequences were obtained. The sequences of VH and VL expressing these antibodies were cloned into a vector expressing the constant region of human IgG1 to obtain human antibodies.

[0550] The binding of the antibody to the peptide H-MHC complex was detected by FACS using the method described in Example 3. Prior to this, COS7 cells loaded with peptide H (COS7 plus peptide H) and COS7 cells loaded with a control peptide (COS7 plus control peptide) were prepared. 24 antigen-specific antibodies were screened from 142 antibodies. Some exemplary flow cytometry detection results are shown in the table below.

[0551] Table 28

[0552]

[0553] The above results show that the MHC humanized mice prepared in this article can be used to produce antigen-specific fully human TCR-like antibodies. The TCR-like antibodies produced are highly diverse and have high affinity. Therefore, this mouse can be used as a useful mouse model for developing TCR-like antibodies. At the same time, by performing high-throughput screening on the obtained antibodies, antibody molecules with high affinity and specificity can be obtained quickly and efficiently, which speeds up the antibody discovery cycle.

[0554] Other Implementations

[0555] It should be understood that although the invention has been described in conjunction with the specific embodiments of the invention, the foregoing description is intended to illustrate rather than limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims.

Claims

1. A genetically modified non-human animal, comprising one or more human IGHV genes, one or more human IGHD genes and one or more human IGHJ genes at an endogenous heavy chain immunoglobulin locus, wherein the human IGHV genes, the human IGHD genes and the human IGHJ genes are operably linked and can undergo VDJ rearrangement, wherein the animal expresses a fusion protein comprising β2 microglobulin (B2M) and a human or humanized major histocompatibility complex (MHC) α chain.

2. The animal of claim 1, wherein the animal comprises at least 150 human IGHV genes selected from Table 1, at least 20 human IGHD genes selected from Table 2, and at least 5 human IGHJ genes selected from Table 3.

3. The animal of claim 1, wherein the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes in the endogenous heavy chain immunoglobulin locus of human chromosome 14 of a human subject.

4. The animal of claim 1, wherein the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes in the endogenous heavy chain immunoglobulin locus of human chromosome 14 of a human cell.

5. The animal of claim 1, wherein said animal comprises a disruption of an endogenous heavy chain immunoglobulin locus in said animal.

6. The animal of claim 5, wherein the animal is a mouse and the disruption of the animal's endogenous heavy chain immunoglobulin locus comprises a deletion of one or more mouse IGHV genes in Table 4, one or more mouse IGHD genes in Table 5, and / or one or more mouse IGHJ genes in Table 6.

7. The animal of claim 5, wherein the animal is a mouse and the disruption of the animal's endogenous heavy chain immunoglobulin locus comprises a deletion of a contiguous sequence starting from the mouse IGHV1-85 gene to the mouse IGHJ4 gene.

8. The animal of claim 1, wherein the animal comprises one or more endogenous IGHM genes, IGHδ genes, IGHG3 genes, IGHG1 genes, IGHG2b genes, IGHG2a genes, IGHE genes, and IGHA genes.

9. The animal of claim 1, wherein the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus, wherein the unmodified human sequence is at least 800 kb.

10. The animal of claim 1, wherein the animal comprises unmodified human sequences derived from the human heavy chain immunoglobulin locus starting from human IGHV(III)-82 to human IGHV1-2.

11. The animal of claim 1, wherein the animal comprises unmodified human sequences derived from the human heavy chain immunoglobulin locus starting from human IGHV(III)-82 to human IGHV6-1.

12. The animal of claim 1, wherein the animal comprises unmodified human sequences derived from the human heavy chain immunoglobulin locus starting from human IGHD1-1 to human IGHJ6.

13. The animal of claim 1, wherein the animal comprises unmodified human sequences derived from the human heavy chain immunoglobulin locus starting from human IGHV(III)-82 to human IGHJ6.

14. The animal of claim 1, wherein the animal is homozygous for the heavy chain immunoglobulin locus.

15. The animal of claim 1, wherein the animal is heterozygous for the heavy chain immunoglobulin locus.

16. The animal of claim 1, wherein the animal further comprises one or more human IGKV genes and one or more human IGKJ genes at the endogenous light chain immunoglobulin locus.

17. The animal of claim 1, wherein said animal comprises a disruption of an endogenous lambda light chain immunoglobulin locus in said animal.

18. The animal of claim 1, wherein the animal is a rodent (eg, a mouse).

19. A genetically modified non-human animal comprising one or more human IGKV genes and one or more human IGKJ genes at an endogenous light chain immunoglobulin locus, wherein the animal expresses a fusion protein comprising β2 microglobulin (B2M) and a human or humanized major histocompatibility complex (MHC) α chain.

20. The animal of claim 19, wherein the animal comprises all of the human IGKV genes in Table 7 and all of the human IGKJ genes in Table 8.

21. The animal of claim 19, wherein the animal comprises an unmodified sequence derived from the human light chain immunoglobulin locus starting from human IGKV3D-7 to human IGKJ5.

22. The animal of claim 19, wherein said animal comprises a disruption of an endogenous light chain immunoglobulin locus in said animal.

23. An animal according to claim 19, wherein the animal is a mouse and the disruption of the animal's endogenous light chain immunoglobulin locus comprises a deletion of one or more mouse IGKV genes in Table 9 and one or more mouse IGKJ genes in Table 10.

24. The animal of claim 22, wherein the animal is a mouse and the disruption of the animal's endogenous light chain immunoglobulin locus comprises a deletion of sequence starting from mouse IGKV2-137 to mouse IGKJ5.

25. The animal of claim 19, wherein the animal comprises endogenous IGKC.

26. The animal of claim 19, wherein the animal is homozygous for the light chain immunoglobulin locus.

27. The animal of claim 19, wherein the animal is heterozygous for the light chain immunoglobulin locus.

28. The animal of claim 19, wherein the animal further comprises one or more human IGHV genes, one or more human IGHD genes, and one or more human IGHJ genes at the endogenous heavy chain immunoglobulin locus.

29. The animal of claim 19, wherein the animal comprises a disruption of an endogenous lambda light chain immunoglobulin locus in the animal.

30. The animal of claim 19, wherein the animal is a rodent (eg, a mouse).

31. A genetically modified non-human animal, said non-human animal comprising an exogenous light chain variable region gene sequence at the endogenous light chain immunoglobulin locus, wherein said exogenous light chain variable region gene sequence comprises no more than three human IGKV genes and no more than two human IGKJ genes, wherein said no more than three human IGKV genes and said no more than two human IGKJ genes are operably linked to an endogenous light chain constant domain gene, wherein said animal expresses a fusion protein comprising β2 microglobulin (B2M) and a human or humanized major histocompatibility complex (MHC) α chain.

32. The animal of claim 31, wherein the no more than three human IGKV genes are selected from Table 7 and the no more than two human IGKJ genes are selected from Table 8.

33. The animal of claim 31 or 32, wherein the exogenous light chain variable region gene sequence comprises a human IGKV gene and a human IGKJ gene.

34. The animal of any one of claims 31 to 33, wherein the exogenous light chain variable region gene sequence further comprises a human IGKJ 3'-UTR sequence.

35. The animal of any one of claims 31 to 34, wherein the exogenous light chain variable region gene in one or more cells of the animal is somatically hypermutated.

36. The animal of claim 35, wherein the somatic hypermutation results in changes of up to one, two or three amino acids in the light chain variable region in the one or more cells of the animal.

37. An animal according to any one of claims 31 to 36, wherein the exogenous light chain variable region gene sequence comprises a human IGKV gene and a human IGKJ gene, wherein the human IGKV gene is selected from IGKV3-20, IGKV3-11 and IGKV1-39, wherein the human IGKV gene and the human IGKJ gene are operably linked.

38. The animal of claim 37, wherein the human IGKV gene is IGVK3-11.

39. The animal of any one of claims 31 to 38, wherein the human IGKJ gene is selected from IGKJ1 and IGKJ4.

40. The animal of any one of claims 31 to 39, wherein the human IGKV gene is IGKV1-39 and the human IGKJ gene is IGKJ4.

41. The animal of any one of claims 31 to 39, wherein the human IGKV gene is IGKV3-11 and the human IGKJ gene is IGKJ1.

42. The animal of any one of claims 31 to 39, wherein the human IGKV gene is IGKV3-20 and the human IGKJ gene is IGKJ1.

43. The animal of any one of claims 31 to 42, wherein the animal further comprises a promoter sequence operably linked to the human IGKV gene, wherein the promoter sequence is within 2500 bp or within 3000 bp of the human IGKV gene.

44. The animal of claim 43, wherein the promoter is an IGKV3-20 promoter, an IGKV3-11 promoter, or an IGKV1-39 promoter.

45. The animal of any one of claims 31 to 44, wherein the animal comprises a disruption of an endogenous light chain immunoglobulin locus in the animal.

46. ​​An animal according to claim 45, wherein the animal is a mouse and the disruption of the animal's endogenous light chain immunoglobulin locus comprises a deletion of one or more mouse IGKV genes in Table 9 and one or more mouse IGKJ genes in Table 10.

47. The animal of claim 46, wherein the animal is a mouse and the disruption of the animal's endogenous light chain immunoglobulin locus comprises a deletion of sequence starting from mouse IGKV2-137 to mouse IGKJ5.

48. The animal of any one of claims 31 to 47, wherein the animal comprises endogenous IGKC.

49. The animal of any one of claims 31 to 48, wherein the animal further comprises a kappa intronic enhancer 5' and / or a kappa 3' enhancer relative to the endogenous IGKC.

50. The animal of any one of claims 31 to 49, wherein the human light chain variable region is a rearranged sequence.

51. The animal of any one of claims 31 to 50, wherein the animal is homozygous for the light chain immunoglobulin locus.

52. The animal of any one of claims 31 to 50, wherein the animal is heterozygous for the light chain immunoglobulin locus.

53. The animal of any one of claims 31 to 52, wherein the animal comprises a disruption of an endogenous lambda light chain immunoglobulin locus in the animal.

54. The animal of any one of claims 31 to 53, wherein the animal is a rodent (e.g., a mouse).

55. An animal according to any one of claims 31 to 54, wherein the animal further comprises one or more human IGHV genes, one or more human IGHD genes, and one or more human IGHKJ genes at the endogenous heavy chain immunoglobulin locus, wherein the human IGHV genes, the human IGHD genes, and the human IGHJ genes are operably linked and can undergo VDJ rearrangement.

56. The animal of claim 55, wherein the animal comprises at least 150 human IGHV genes selected from Table 1, at least 20 human IGHD genes selected from Table 2, and at least 5 human IGHJ genes selected from Table 3.

57. The animal of claim 55, wherein the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes in the endogenous heavy chain immunoglobulin locus of human chromosome 14 of a human subject.

58. The animal of claim 55, wherein the animal comprises all human IGHV genes, all human IGHD genes, and all human IGHJ genes in the endogenous heavy chain immunoglobulin locus of human chromosome 14 of a human cell.

59. An animal according to any one of claims 55 to 58, wherein the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus, wherein the unmodified human sequence is at least 800 kb.

60. The animal of any one of claims 55 to 59, wherein the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus starting from human IGHV(III)-82 to human IGHV1-2.

61. The animal of any one of claims 55 to 59, wherein the animal comprises unmodified human sequences derived from a human heavy chain immunoglobulin locus starting from human IGHV(III)-82 to human IGHV6-1.

62. The animal of any one of claims 55 to 61, wherein the animal comprises unmodified human sequences derived from the human heavy chain immunoglobulin locus starting from human IGHD1-1 to human IGHJ6.

63. The animal of any one of claims 55 to 59, wherein the animal comprises an unmodified human sequence derived from a human heavy chain immunoglobulin locus starting from human IGHV(III)-82 to human IGHJ6.

64. An animal according to any one of claims 1 to 63, wherein the animal lacks an endogenous immunoglobulin heavy chain variable region locus that is capable of rearranging and forming a nucleic acid sequence encoding an endogenous heavy chain variable domain (e.g., a mouse heavy chain variable domain).

65. according to the animal described in any one of claims 1 to 63, wherein said animal lacks the endogenous immunoglobulin light chain variable region locus that can rearrange and form the nucleic acid sequence encoding endogenous light chain variable domain (for example, mouse light chain variable domain).

66. The animal of any one of claims 1 to 65, wherein the animal can produce humanized antibodies.

67. The animal of any one of claims 1 to 66, wherein the genome of the animal comprises at least one chromosome comprising a sequence encoding a fusion protein.

68. The animal of any one of claims 1 to 67, wherein the fusion protein comprises a human or humanized B2M protein.

69. The animal of any one of claims 1 to 68, wherein the MHC alpha chain is an MHC class I alpha chain.

70. The animal of any one of claims 1 to 69, wherein the MHC alpha chain is a chimeric MHC alpha chain.

71. The animal of any one of claims 1 to 69, wherein the MHC alpha chain is a human HLA protein (eg, HLA-A, HLA-B, or HLA-C).

72. An animal according to any one of claims 1 to 69, wherein the MHC α chain is a human HLA / mouse H-2 chimeric molecule, wherein the human HLA is selected from HLA-A, HLA-B, HLA-C, and wherein the mouse H-2 is selected from H-2K, H-2D and H-2L.

73. The animal of any one of claims 1 to 69, wherein the MHC alpha chain is a human HLA / mouse H2-D1 chimeric molecule.

74. The animal of any one of claims 1 to 69, wherein the fusion protein comprises a human B2M protein and a chimeric MHC α chain comprising human HLA α1 and α2 domains.

75. The animal of claim 74, wherein the chimeric MHC α chain further comprises a mouse H2-D1 α3 domain.

76. An animal according to any one of claims 67 to 75, wherein the sequence encoding the fusion protein is operably linked to an endogenous regulatory element (e.g., a promoter) at the endogenous β2 microglobulin (B2M) locus in at least one chromosome.

77. An animal according to any one of claims 71 to 76, wherein the human HLA is human HLA-A*0101, HLA-A*0201, HLA-A*0301, HLA-A*0302, HLA-A*1101, HLA-A*2402, HLA-A*2901, HLA-A*3101, HLA-A*3201, HLA-A*3301, HLA-A*3303, HLA-B*4402, HLA-B*0702, HLA-C*0702, HLA-C*0102, HLA-C*0701, HLA-C*0401, HLA-C*0801 or HLA-C*0802.

78. The animal of any one of claims 1 to 70, wherein the fusion protein comprises (a) Human B2M; and (b) Human HLA (eg, HLA-A, HLA-B or HLA-C).

79. The animal of claim 78, wherein the human B2M and the human HLA are linked by a linker peptide sequence.

80. The animal of any one of claims 1 to 70, wherein the fusion protein comprises (a) Human B2M; and (b) Chimeric MHC α chain.

81. The animal of claim 80, wherein the human B2M and the chimeric MHC α chain are connected via a linker peptide sequence.

82. The animal of claim 80 or 81, wherein the chimeric MHC α chain comprises human HLA α1 and α2 domains.

83. The animal of claim 82, wherein the chimeric MHC α chain further comprises a human HLA α3 domain.

84. The animal of claim 82, wherein the chimeric MHC alpha chain further comprises an MHC alpha 3 domain endogenous to the animal and / or an MHC cytoplasmic region endogenous to the animal.

85. The animal of any one of claims 80 to 84, wherein the chimeric MHC alpha chain comprises an alpha 3 domain, a connecting peptide, a transmembrane region, and a cytoplasmic region of an endogenous MHC.

86. The animal of any one of claims 80 to 84, wherein the animal is a mouse and the chimeric MHC α chain comprises the α3 domain, connecting peptide, transmembrane region, and cytoplasmic region of mouse H2-D1.

87. An animal according to any one of claims 71 to 86, wherein the fusion protein further comprises a signal peptide of the human HLA (e.g., at the N-terminus of the fusion protein).

88. The animal of any one of claims 1 to 87, wherein the animal is heterozygous for the sequence encoding the fusion protein.

89. The animal of any one of claims 1 to 87, wherein the animal is homozygous for the sequence encoding the fusion protein.

90. A cell obtained from the animal of any one of claims 1 to 89.

91. The cell of claim 90, wherein the cell is a B cell that expresses a chimeric immunoglobulin heavy chain comprising a rearranged immunoglobulin heavy chain variable domain derived from one or more human IGHV genes, one or more human IGHD genes, and one or more human IGHJ genes, wherein the immunoglobulin heavy chain variable domain is operably linked to a non-human heavy chain constant region.

92. The cell of claim 90, wherein the cell is a B cell expressing a chimeric immunoglobulin light chain comprising a rearranged immunoglobulin light chain variable domain derived from one or more human IGKV genes and one or more human IGKJ genes, and wherein the immunoglobulin light chain variable domain is operably linked to a non-human light chain constant region.

93. The cell of claim 90, wherein the cell is an embryonic stem (ES) cell.

94. A method for preparing an antibody that specifically binds to an antigen peptide-MHC complex, the method comprising The animal according to any one of claims 1 to 89 is exposed to the antigenic peptide-MHC complex comprising the antigenic peptide.

95. The method of claim 94, wherein the method further comprises producing hybridomas from cells collected from the animal; and The antibodies produced by the hybridomas are collected or analyzed.

96. The method of claim 94 or 95, wherein the method further comprises sequencing the genome of the hybridoma.

97. The method of any one of claims 94 to 96, wherein the antigenic peptide is an antigenic peptide (eg, any one of the antigenic peptides listed in Table 16).

98. A method for obtaining a nucleic acid encoding an antibody binding domain that specifically binds to an antigen peptide-MHC complex, the method comprising exposing the animal according to any one of claims 1 to 89 to the antigenic peptide-MHC complex comprising the antigenic peptide; as well as Nucleic acids encoding human heavy and light chain immunoglobulin variable regions are sequenced in cells that express hybrid antibodies that specifically bind to the antigenic peptide-MHC complex.

99. A method for obtaining a sample, the method comprising exposing the animal according to any one of claims 1 to 89 to an antigenic peptide-MHC complex; and The sample is collected from the animal.

100. The method of claim 99, wherein the sample is spleen tissue, lymphoid tissue, splenocytes, or B cells.

101. A method for screening an antibody that specifically binds to an antigen peptide-MHC complex, the method comprising exposing the animal according to any one of claims 1 to 89 to the antigenic peptide-MHC complex comprising the antigenic peptide of interest; producing hybridomas from cells collected from the animal; collecting or analyzing antibodies produced by the hybridoma; incubating the antibody with cells presenting the antigenic peptide of interest, cells presenting a control antigenic peptide, and / or cells not presenting any antigenic peptide; as well as It is determined that the antibody can specifically bind to the cell presenting the antigenic peptide of interest, and optionally it is determined that the antibody does not bind to the cell presenting the control antigenic peptide or the cell not presenting any antigenic peptide.

102. The method of claim 101, wherein the ability of the antibody to specifically bind to cells presenting the antigenic peptide of interest is determined by flow cytometry.

103. A method for screening an antibody that specifically binds to an antigen peptide-MHC complex, the method comprising exposing the animal according to any one of claims 1 to 89 to the antigenic peptide-MHC complex comprising the antigenic peptide of interest; and The nucleic acid encoding the human heavy chain and light chain immunoglobulin variable regions in the cell is sequenced, and the cell expresses antibodies that specifically bind to the antigen peptide-MHC complex.

104. The method according to claim 103, further comprising expressing antibodies comprising the encoded human heavy and light chain immunoglobulin variable regions; incubating the antibody with cells presenting the antigenic peptide of interest; and It is determined that the antibody can specifically bind to cells presenting the antigenic peptide of interest.

105. The method according to claim 103, further comprising incubating the antibody with cells presenting a control antigenic peptide and / or cells not presenting any antigenic peptide; and It is determined that the antibody does not bind to the cells presenting the control antigenic peptide or the cells not presenting any antigenic peptide.

Citation Information

Patent Citations

  • Non-human animals with modified immunoglobulin heavy chain sequences

    CN104994730A

  • Genetically modified non-human animals for generating therapeutic antibodies against peptide-MHC complexes, methods of making and uses thereof

    CN112040769A

  • Genetically modified non-human animals with humanized immunoglobulin locus

    CN112400022A

  • Method for preparing genetically modified major histocompatibility complex mice

    CN113564188A

  • Genetically modified non-human animals with humanized immunoglobulin locus

    WO2020169022A1

Cited By

  • Establishment method and application of transgenic mouse

    CN120485281A